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Abstract 
Predictors of mortality and survival in Type 1 diabetes: A retrospective cohort study of 
Type 1 Diabetes Mellitus (T1D) in the Wirral Peninsula 
Background: The prevalence of T1D is rising, despite improvements in the management of 
this condition. It presents a risk of premature and excess mortality, which impacts survival and 
life expectancy.  
Aim: The study aim was to assess mortality, identify predicting risk factors for mortality and 
survival in T1D in the Wirral. A systematic review was done to establish present current 
evidence of all-cause and cause-specific mortality amongst T1D patients.   
Methods: A retrospective cohort study design, 1786 patients diagnosed with T1D extracted 
from the Wirral Diabetes Register (WDR). The follow-up period was between 1st of January, 
2000 to 31st December, 2012. The primary outcome measured was all-cause mortality. 
Results: 1458 participants with T1D meet the inclusion criteria, after a follow-up period of 12 
years, 113(7.75%) deaths were recorded. While the incidence rate was steady over the study 
period, the prevalence rate continued to increase over the study period. 
Significant predictors of mortality in this cohort were age of diagnosis, duration of diabetes, 
HbA1c, systolic blood pressure (SBP), diastolic blood pressure (DBP), and triglyceride levels. 
The predicting risk gender, age at diagnosis, duration of T1D, BMI, serum creatinine levels, 
SBP, total cholesterol, LDL, HDL, TC\HDL, and LDL\HDL showed a linear increase in 
mortality risk. IMD and DBP followed a U-shaped relationship with relative and absolute 
mortality, while HbA1c levels reveal a sinusoidal pattern with the highest risk of mortality at 
the levels ≤ 5.9% (41 mmol/mol). The risk of mortality for the predicting risk factors for this 
study ranged between 5% and 9%. Maximal risk of mortality of 9% was recorded in the 
predicting risks of smoking, BMI, SBP, and DBP. The risk of mortality of 8% was recorded 
for IMD, serum creatinine, total cholesterol, TG, LDL\HDL ratio, and TSH.  The risk of 
mortality of 7% was recorded for the predicting variables of HbA1c, HDL, LDL, and TC\HDL 
ratio. The minimum risk of mortality of 5% was recorded for the predictor variable of the 
duration of diabetes. The significant predictors of mortality were the age at diagnosis, duration 
of diagnosis, systolic and diastolic blood pressure, HbA1c. The burden of mortality rest 
disproportionately with females who had higher relative risk of mortality of 4 times that of 
their male counterparts, however, the burden of premature mortality as recorded by the years 
of potential life lost was slightly higher in males (1797[53.6%]) as compare to females 
(1553[46.4%]). Of the 113 deaths recorded for the cohort that indicated a proportion of 7.75% 
of the total T1D patients, records for only 37 participants were retrieved. The principal cause 
of death in this cohort was malignancy-related 8 deaths (21.6%), this was followed by 
cardiovascular disease and sepsis, each having 6 deaths (16.2%) respectively. Cerebrovascular 
disease accounted for 5 deaths (13.5%). Death from diabetes complications (hypoglycaemia) 
was recorded in 1 patient (2.7%). There were marked reductions in life expectancy for this 
cohort. Life expectancy at 40 years for females was to an average age mortality of 66.2 years 
as compared to males 78.3 years. There has been improved survival for T1D in this cohort, 
77.185 years [95% CI: 75.191 – 79.179] in males and 76.011 years [95% CI: 73.169 – 78.000] 
in females.  
The systematic review highlighted increased mortality in those with T1D as compared to the 
general population, females showed greater risk of vascular complications as compared to the 
males with T1D. 35 studies were included. Results showed all-cause mortality RR 3.73 (95% 
CI 3.19, 4.36) compared to general population, with gender specific mortality RR 1.17 (95% 
CI 1.06, 1.29). For cause specific mortality risk (overall and gender specific): cardiovascular 
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disease RR 3.48 (95% CI 3.14, 3.86) and RR 1.41 (95% CI 0.92, 2.17); renal disease RR 1.06 
(95% CI 0.89, 1.26) and RR 0.63 (95% CI 0.38, 1.04); neoplasms RR 1.03 (95% CI 0.92, 1.16) 
and RR 1.18 (95% CI 0.75, 1.86); cerebrovascular disease according to gender RR 0.99 (95% 
CI 0.66, 1.48), and accidents and suicides according to gender RR 2.30 (95% CI 1.31, 4.06). 
Conclusion 
In conclusion, the study highlighted significant mortality risk in females as compared to their 
male counterparts; there has been progress in the survival of patients with T1D. However, life 
expectancy remains reduced as compared to those without the condition. Prevalence of T1D 
continues to increase, and the complex interplay of the predictor variables support the need for 
an individualised approach to care.  
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Chapter 1: Introduction and Literature review 
1.1 Background 
The World Health Organisation (WHO) defines diabetes mellitus as a group of chronic 
metabolic disorders of endocrine origin, characterised by chronic hyperglycaemia associated 
with alterations in the metabolism of carbohydrates, fats and proteins. This occurs as a resultant 
effect of defects in the action or production (relative or absolute deficiency) of insulin, a 
hormone that regulates glycaemic control (World Health Organisation [WHO], 1999; George, 
& Alberti, 2010; American Diabetes Association [ADA], 2014). Chronic hyperglycaemia is 
the main clinical feature of this condition and uncontrolled, predisposes an individual to acute 
and chronic complications. Diabetes has an estimated global prevalence of 8.8% and is 
expected to rise to 9.9% in 2045. It was estimated to affect 424.9 million people in 2017 with 
a projected rise to 628.6 million in 2045. The global healthcare expenditure on diabetes in 2017 
had an estimate of USD 727 billion with the projected increase to USD 776 billion by 2045 
(International Diabetes Federation [IDF], 2018). 
According to a broad aetiological classification based on glycaemic disorders, diabetes mellitus 
falls into specific groups. These are; type 1 diabetes (T1D), type 2 diabetes (T2D), gestational 
diabetes (GDM) and other specific types (Kuzuya & Matsuda, 1997; World Health 
Organisation [WHO], 1999; George & Alberti, 2010; American Diabetes Association [ADA], 
2014). T1D is further categorised based on aetiology into either being autoimmune or 
idiopathic in origin (American Diabetes Association [ADA], 2014). 
Type 1 diabetes (T1D) had previous phenotypic classifications of ‘Insulin-dependent diabetes’ 
(IDDM) and juvenile onset diabetes (Kaul et al. 2013). T1D is a long-term condition requiring 
lifelong treatment with insulin therapy. Although it accounts for between 5 – 10 % of the total 
number of people who have diabetes, it still contributes significantly to the overall burden of 
diabetes as a whole.   
The global prevalence of T1D is estimated to be over 1 million children and adolescents having 
the condition (International Diabetes Federation [IDF], 2017), with a yearly rate of increase in 
incidence ranging between 0.6 to 9.3% (Patterson et al. 2009). However, variations in incidence 
exist across regions, countries and ethnic backgrounds. The UK ranks fifth highest in incidence 
after Finland, Sweden, Saudi Arabia, and Norway. The incidence rate remains very high at 22.8 
per 100,000, with an increase of 4% annually (Diabetes UK, 2014, 2017). Prevalence estimate 
of T1D in the UK is 187.7 per 100,000. In the UK, current estimates of those living with this 
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condition are almost 400, 000 individuals. More than 90 % of all children with diabetes suffer 
from T1D (Juvenile Diabetes Research Foundation [JDRF], 2017). Previous estimates of the 
prevalence of the condition reveal that in 2013, the rate of children and young people (CYP) 
with T1D was between 1 per 430 to 1 per 53,012. For children who were younger than the age 
of 14 years, incidence rates were estimated to be 24.5 per 100,000 with an increase to 25.9 per 
100,000 in 2016 (Diabetes UK, 2013; 2017). 
Variations in the global incidence as noted in table 1.1 using an arbitrary system of 
classification into very low, low, intermediate, high and very high to highlight this trend. 
Observation of this trend reveals higher incidence rates in temperate regions with a gradual 
decline towards the hotter climates. In Asia, the incidence rates are very low (<1/100,000 per 
year) except Kuwait which has an incidence rate of 22/100,000/year. Countries in the African 
continent have incidence rates of very low to intermediate incidence rates (<1/100,000 per year 
- 5-9.99/100,000 per year). Populations from South America, Central America and the West 
Indies have different incidence rates from low to High (1-4.99/100,000 per year - 10-
19.9/100,000 per year). Many countries in Europe and North America were noted to have high 
to very high incidence rates (10-19.9/100,000 per year - ≥20/ 100,000 per year). 
In the UK, the peak age of diagnosis is in the age group 10 – 14 years with an observed 
increasing trend (Diabetes UK, 2014; Diabetes UK, 2017). This is comparable to what is 
observed globally with noted variations across populations, age and sex groups (The 
DIAMOND project group, 2006; Diabetes UK, 2013; Llenasa et al. 2015). Some studies 
suggest average increases of 5.4%, 4.3%, 2.9% for the 0-4 year, 5-9 year and 10-14 year age 
groups respectively, reflecting the strongest increase in incidence rates noted among the 
younger age group < 5 years (Pattterson et al. 2009; The DIAMOND project group, 2006). 
Table 1.1: Patterns in incidence rates of T1D across countries (adapted from IDF Diabetes 
Atlas 8th edition, 2017). 
Patterns of incidence variation Countries/regions represented 
Very low incidence (<1/100,000 per year) Venezuela, Peru, Pakistan,  
Low incidence (1-4.99/100,000 per year) Japan, Cuba, Chile 
Intermediate incidence (5-9.99/100,000 per year) Italy, France, Egypt 
High incidence (10-19.9/100,000 per year) USA, Australia, Germany, Spain, Italy. 
Very high incidence (≥20/ 100,000 per year) Finland, Sweden, UK, Kuwait, Saudi 
Arabia, China, Norway, Russia. 
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Estimating the real financial burden of T1D is difficult. However, a study by Hex et al. (2012) 
revealed a significant burden on the UK economy. This study estimated the direct cost and 
indirect cost of the burden of T1D to be £1bn and £0.9bn respectively with a projected rise to 
approximately £1.8bn and £2.4bn respectively in 2035/2036. Similar trends are also observed 
in other countries, for instance, a study by Tao et al. (2010), suggested the US spent 
approximately $14.4bn for T1D in direct medical cost and income lost. Another study in Spain, 
analysing the accrued expenses of 249 individuals with T1D, estimated the average direct 
healthcare cost to be €4070 per annum per individual and indirect (non-healthcare/informal) 
cost to be €23,204 per annum per individual (López-Bastida et al. 2017). The burden of T1D 
does not only accrue financially, but several other dimensions also contribute to its overall 
burden such as the health-related impact, social impact and economic impact (Murillo et al. 
2017; Rydén et al. 2016; Jacobson et al. 2013; Graue et al. 2003; Wu et al. 1998).  As such, 
this is evident on the effects on the health infrastructure as it pertains to health seeking, user 
satisfaction, quality of life and direct health cost implications. The health impact evolves from 
the diagnosis of T1D on morbidity and mortality, treatment and complication. The social 
impact relates to person hours lost due to illness episodes, impacts on family, caregivers and 
society at large. The economic impact relates to the direct and indirect cost of providing 
services, other associated financial implications, and indirect financial cost as it relates to loss 
of productivity (Rydén et al. 2016). 
The diagnosis of T1D heralds the development microvascular and macrovascular 
complications. Microvascular complications result from the sustained effect of hyperglycaemia 
on blood vessels, nerves and various organs. The resultant effects are varying degrees of 
retinopathy and neuropathy that may manifest with sexual dysfunction and reduced peripheral 
sensations predisposing to ulcers. Nephropathy occurs in patients who may present with 
microalbuminuria, and progressive chronic renal impairment leading to renal failure 
(Daneman, 2006; Pietrzak et al. 2013).  Macrovascular complications result from a cascade of 
biochemical abnormalities, with the principal contribution being hyperglycaemia that 
culminates in arteriosclerosis and its untoward effects. These complications constitute an 
elevated risk of cardiovascular conditions (myocardial infarction, ischaemic heart disease, and 
heart failure), cerebrovascular diseases (ischemic and haemorrhagic stroke), and hypertension. 
There is also increased risk of chronic infections of the skin, cognitive decline and autonomic 
impairment (diabetic foot). Other associated complications are a risk of psychiatric conditions, 
increased risk of morbidity and mortality, and reduced life expectancy. Pregnant women with 
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T1D have an increased risk of macrosomia and large for gestational age (LGA) babies. Other 
complications in pregnancy include polyhydramnios, pre-eclampsia, preterm delivery, early 
foetal loss, congenital malformations, perinatal and neonatal mortality (Evers, de Valk, & 
Visser, 2004; Jensen et al. 2004; Persson, Norman, & Hanson, 2009; Hod et al. 2008). The 
impact of these complications in T1D confers increased mortality risk as compared to the 
general population; research also suggests that mortality attributed to T1D and its 
complications vary according to regions, countries, sex and age groups (Soedamah-Muthu et 
al. 2006).  
Mortality in T1D attributed to the acute complications occur within the younger age groups 
(<30 years), while cardiovascular complications account for most of the deaths from chronic 
complications (Lind et al. 2015; Morgan et al. 2015; Huxley et al. 2015; Katz & Laffel, 2015; 
Snell-Bergeon, & Maahs, 2015; Tu et al. 2008). Research also links T1D to excess premature 
mortality which impacts gravely on survival and life expectancy (Livingstone et al. 2015; Katz 
& Laffel, 2015).  
Cardiovascular disease (CVD) complications are found to be the most common macrovascular 
complication in T1D especially above the age of 40 years. Below 40 years, the most common 
complications are from acute complications including Diabetic ketoacidosis and severe 
hypoglycaemia (Liang et al. 2009; Huxley et al. 2015). CVD accounts for a ten-fold increase 
in the risk of a cardiovascular event (Orchard et al. 2006). Livingstone et al. (2012), in their 
study considering CVD risk and all-cause mortality in T1D, found an increased risk as 
compared to the general population. In the UK, CVD accounts for 44% of deaths in T1D, while 
diabetic nephropathy (DN) contributes to 21% mortality from ESRD. Mortality from T1D is 
burdened disproportionately to females as they have a 40% increase in the risk of all-cause 
mortality as compared to males (Huxley et al. 2015). A systematic review and meta-analysis 
on mortality in T1D is discussed further in chapter three. 
Diabetic retinopathy (DR) is the most common ocular complication for T1D. It accounts for 
reduced vision and sometimes blindness among T1D patients between the ages of 20 and 79 
years.  A study by Esteves et al. (2009) found the prevalence of DR to be 44.4% in their study 
cohort. Another study highlighted the prevalence of DR to be 74.9% in blacks and 82.3% in 
whites’ population subset (Roy et al. 2004). A study in the UK using a national registry found 
the prevalence of DR to be 56% in the cohort studied (Thomas et al. 2015). DR that becomes 
a threat to vision rarely occurs within the first 3 – 5 years following diagnosis or before puberty. 
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Consequently, nearly all patients with T1D have some form of DR after 20 years post-diagnosis 
inferring that duration of diabetes remains a powerful predictor of diabetic retinopathy (Fong 
et al. 2004). However, a recent study suggests that other strong predictors of DR include higher 
levels of glycated haemoglobin (HbA1c) and low-density lipoproteins (LDL) levels (Romero-
Aroca et al. 2017). 
There remain considerable variations in the prevalence of diabetic neuropathy in T1D; they 
vary between 23 and 51% (Pop-Busui et al. 2009; Boulton et al. 2005; Young et al. 1993). The 
diagnosis of neuropathy is made difficult because of varying signs and symptoms which can 
be sensory, autonomic and/or motor. Neuropathy is a significant risk factor for the onset of foot 
ulcerations and the development of Charcot neuroarthropathy; it also increases the risk of non-
traumatic amputations of the lower extremities (Abbott et al. 2002; Alleman et al. 2015). 
Neuropathy also increases the risk of disability with a poor quality of life (Vileikyte et al., 
2005). The study by Abbott et al. (2011) found a weak correlation between increasing age and 
the painful symptoms of neuropathy; females were more likely to experience painful 
neuropathic symptoms than males. Ethnic variations were also highlighted in this study; the 
study found that the prevalence of clinical neuropathy was less in South Asians (14%) than 
Europeans (22%) and Afro-Caribbean (21%). 
Diabetic nephropathy (DN), a complication of T1D, is recognised as albuminuria.  It is 
recognised as the presence of increased urinary albumin excretion (UAE) without any other 
precipitating renal disease (Gross et al. 2005). Diabetic nephropathy can occur in stages: 
microalbuminuria (UAE >20 μg/min and ≤199 μg/min) and macroalbuminuria (UAE ≥200 
μg/min). The onset of albuminuria is noted to occur at the rate of 2 - 3 % annually (Bjornstad, 
Cherney, & Maahs, 2014). The natural evolution of this complication is its progression to end-
stage renal disease (ESRD). Despite therapeutic strategies in the control of DN, it remains one 
risk factor that contributes to the onset of coronary artery disease (CAD) and all-cause 
mortality.  In 2009, it was responsible for 44.5% of mortality related to end-stage renal disease 
(ESRD) in the USA (Collins et al. 2010). 
Glycaemic control remains one of the main predictors of cardiovascular disease complications 
and all-cause mortality (Sakurai et al. 2013; Zhao et al. 2014). The DCC/EDIC trial established 
that intensive glycaemic control was necessary to militate against the onset and progression of 
complications. The DCC/EDIC study established rates of retinopathy with a cumulative 
incidence of 50%, nephropathy rates where 25% and cardiovascular disease (CVD) rates were 
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14% in the conventional therapy population. Those in the intensive therapy arm experienced 
lesser rates of complications with incidence rates for retinopathy, nephropathy and CVD to be 
27%, 9%, and 9% respectively (Lachin et al. 2014; Lachin et al. 2016). Those in the intensive 
therapy group were managed using insulin pumps or a minimum of three daily insulin 
injections for a mean duration of 6.5 years during which they maintained a mean HbA1c of 
approximately 7%. Those in the conventional arm also received treatment for an average of 6.5 
years, they were managed with one or two doses of insulin, daily self-monitoring, received 
education on diet and exercises with minimal adjustments to daily insulin dosages with a target 
mean HbA1c of approximately 9%. Several other studies also support the concept of early 
commencement of intensive therapy a term referred to as ‘Metabolic Memory’. They argue 
that the early commencement of intensive therapy mitigates the long-term onset and 
progression of CVD complications (Agrawal et al. 2018; Diabetes Control and Complications 
Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study 
Research Group, 2016; Holman et al. 2016). An observational study with T2D population 
observed a U-shaped correlation with HbA1c and all-cause mortality, inferring increased 
mortality at the two polar ends of HbA1c levels (Currie et al., 2010). A similar finding was 
observed with T1D population subset in which the non-linearity of the relationship was 
highlighted between HbA1c levels and all-cause mortality. The study also found a U-shaped 
relationship between HbA1c levels and all-cause mortality, with increased mortality at HbA1c 
levels below 5.6% and above 11.8% (Schoenaker et al. 2014). 
The increased risk of mortality starts at the time of diagnosis and subsequently accumulates 
throughout life. Following the diagnosis of T1D, the individual endures lifelong exposure to 
increased morbidity and increased risk of mortality; these have an adverse effect on the quality 
of life. Considerably, life expectancy in T1D remains lower than those without the condition. 
An overall estimation of reduction in life expectancy varies between 7 – 15 years.  In a study 
by Livingstone et al. (2015), they found the expected life expectancy of males and females 
diagnosed with T1D at the age of 20 years was 66.2 years and 68.1 years respectively as 
compared to 77.3 years and 81 years for males and females without T1D. This indicated a 
reduced life expectancy of 11.1 years in males and 12.9 years in females. 
Specific predicting factors influence survival and mortality patterns in T1D. There is limited 
evidence on the predicting factors on mortality in T1D. While a few studies focus on all-cause 
mortality in T1D, most of the studies focus on the risk of Coronary artery disease (CAD) which 
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is a significant contributor to mortality in T1D. A study by Soedamah-Muthu et al. (2014) 
highlighted age and albumin/creatinine to be the strongest predicting factors for all-cause 
mortality in T1D. Another study by Soedamah-Muthu et al. (2008) identified the risk factors 
of age, waist-to-hip ratio (WHR), pulse pressure, and non-HDL cholesterol as significant risk 
factors for increased mortality in T1D. The study by Olson et al. (2002) identified smoking, 
overt nephropathy, non-HDL cholesterol, HbA1c and duration of diabetes as predictors of 
mortality. A study by Weis et al. (2001) suggests that some clinical and biochemical parameters 
were responsible for the onset of coronary artery disease and ultimately mortality. The 
parameters attributed to higher mortality rates were albuminuria (nephropathy), retinopathy, 
and lower apolipoprotein A1 levels. Participants who were more predisposed to the 
development of coronary artery disease were those with longer duration of diabetes, increasing 
age of onset of T1D, retinopathy and neuropathy. The study by Cusick et al. (2005) additionally 
identified amputation as a strong predictor of mortality. In the development of cardiovascular 
conditions, Stettle et al. (2007) found QT interval corrected for heart rate (QTc) was a strong 
predictor of long-term excess all-cause mortality owing to the increased risk of arrhythmia and 
death. Another study by Rewer et al. (2002) identified that in younger populations with T1D 
were at increased risk of mortality from DKA and hypoglycaemia, predictors of increased risk 
of severe hypoglycaemia were lower levels of HbA1c, increased duration of diabetes, and the 
presence of psychiatric disorders. Diabetic ketoacidosis (DKA) is a condition that results from 
persistent insulin deficit and subsequent rise in glucagon, epinephrine (adrenaline), 
norepinephrine (noradrenaline), cortisol, and growth hormone. These encourage the process of 
glycogenolysis, gluconeogenesis, ketogenesis, and other catabolic processes.  For increased 
risk of DKA, the study highlighted predictors as higher levels of HbA1c, higher doses of insulin 
doses, and the presence of psychiatric disorders. In patients on intensive insulin therapy, 
predictors of mortality included the onset of nephropathy, duration of diabetes, smoking status, 
systolic blood pressure, cholesterol level, hypertension, the presence of retinopathy and 
socioeconomic status (Mühlhauser et al., 2000). While some of these risk factors are 
modifiable, others are not. 
To understand all-cause mortality and cause-specific mortality among T1D patients, it is 
essential to get a better understanding of the predicting risk factors that influence survival and 
mortality in T1D. This would help to inform clinical practice in the management of T1D 
patients. 
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1.2 Clinical presentations of T1D 
T1D presents with a myriad of symptoms. The classic presentation of symptoms in children 
and young adults (CYP) are; hyperglycaemia (random plasma glucose more than 11 
mmol/litre), polyuria, polydipsia, polyphagia, weight loss and excessive tiredness (Roche, 
Menon, Gill, & Hoey, 2005). However, for some individuals, especially the very young 
(between 2-5 years), their initial presentation may be acute onset diabetic ketoacidosis (DKA). 
Almost a third of all patients have an acute presentation of DKA (Neu et al. 2003; Roche et al. 
2005).  
Polyuria (increase in the amount and frequency of urination) is often as a result of 
hyperglycaemia which causes osmotic diuresis. In some instances, polyuria also presents as 
nocturnal enuresis (increase excretion of urine at night). Another untoward effect of 
hyperglycaemia is the onset of dehydration, hypovolaemia and hyperosmolar state as such the 
affected individual remains in a state of excessive thirst. Insulin deficiency promotes a 
catabolic state that encourages the breakdown of muscles proteins, lipogenesis, and electrolyte 
imbalance. 
Persistent hyperglycaemia also influences the ability of the body to fight infections as the 
protective ability of phagocytes becomes impaired. Therefore, it is common for T1D patients 
to present with skin and muco-membranous conditions like Staphylococcal pustules, abscesses, 
carbuncles, vaginal candidiasis, balanitis, and in rare situations, necrotising fasciitis, Fournier 
gangrene, and mucormycosis of the maxillary sinus (Yanar et al. 2006, Dworkin et al. 2009). 
DKA usually presents with a triad of hyperglycaemia, acidosis and ketonuria (Pietrzak et al. 
2013). It reported incidence ranges from 0-56 per 1000 person-years while its prevalence is 
between 0-128 per 1000 persons (Fazeli Farsani et al. 2017; Rewers et al. 2015). The condition 
may present clinically with the classic signs of hyperglycaemia as well as complaints of 
malaise, muscle cramps, and gastrointestinal symptoms, which may mimic acute abdomen. 
Gastrointestinal symptoms include; nausea, vomiting, abdominal discomfort, acute fatty liver, 
right upper quadrant pain, and visceral autonomic neuropathy (Fazeli Farsani et al. 2017). 
Some clinical signs encountered in diagnosing this condition are dehydration, Kussmaul 
respiration (deep sighing respiration), ketone breath (sweet smell fetor), and altered 
consciousness, which can lead to death if untreated. 
T1D is associated with an increased risk of cardiovascular diseases (CVD) (de Ferranti et al. 
2014; Albers et al. 2010). Macrovascular presentations of T1D are acute myocardial infarction 
9 
 
(AMI) and acute stroke. Patients present with symptoms of acute chest pain, but sometimes 
with atypical chest pain. Patients with T1D also have an elevated risk of stroke with symptoms 
such as facial weakness, slurred speech and weakness of the limbs (Ståhl et al. 2017; Sundquist, 
& Li, 2006).  
Patients may also present with microvascular complications such as acute loss of vision from 
diabetic retinopathy. Some studies highlight that almost half of the patients (44.4%) with T1D 
may present with symptoms of diabetic retinopathy (Esteves et al. 2009). The sustained 
hyperglycaemic state encourages the osmotic engorgement of the eye lenses, altering its focal 
elasticity and resulting in blurred vision.  
Some patients with T1D may present with symptoms of neuropathic syndromes from 
peripheral neuropathy, mononeuropathy to amyotrophy (Sima, & Kamiya, 2006; Sima, Zhang, 
& Grunberger, 2004). Peripheral neuropathy presents in multiple ways relating to site; it may 
manifest as sensory, focal/multifocal, and autonomic neuropathies (Fowler, 2008). The 
presence of peripheral neuropathy in addition to complications of the peripheral vascular 
disease (PVD) may result in the onset of diabetic foot ulcers. These conditions expose the 
patient to an increased risk of amputation (Jain, 2016; McInnes, 2012; Clayton, & Elasy, 2009). 
Many individuals with T1D experience numerous episodes of hypoglycaemia that go 
undocumented but the mean incidence of symptomatic hypoglycaemia is around two episodes 
per week. However, documented evidence reveals that severe debilitating hypoglycaemia 
requiring intervention has a prevalence of between 30 and 40 per cent per year, and an annual 
incidence of 1.0-1.7 episodes per patient per year (McCrimmon, & Sherwin, 2010; Frier, 2009). 
1.3 Diagnosis of T1D 
The diagnosis of T1D presents a complex and challenging situation to the patient, families and 
caregivers and as such has a long-term impact on families and healthcare teams (Simms, & 
Monaghan, 2016; Jönsson, Lundqvist, Tiberg, & Hallström, 2015; Helgeson, Becker, Escobar, 
& Siminerio, 2012). Primary care is the first point of contact and usually the setting for 
diagnosis of most cases. However, some cases present to secondary care in the form of acute 
complications such as DKA and severe hypoglycaemia where the diagnosis is made. In the 
UK, NICE guidelines (NG17, NG18, and NG19), provide the basis for diagnosis and 
management.  
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1.3.1 Glycemic diagnostic criteria 
The diagnosis of T1D is obtained by the clinical presentation of diabetes and laboratory 
findings of hyperglycaemia as defined by the WHO (2017) and ADA (2011). The glycaemic 
criteria for glucose abnormalities are illustrated in Table 1.2 
Table 1.2 Diagnostic criteria for glycaemic abnormalities (adapted from WHO, 2011; ADA, 
2010). 
Diagnosis FPG≥8hours 2 hours post 
glucose load (75g 
oral glucose) 
Random test HbA1c(mmol/mol[%]) 
Normal <5.5mmol/l 
(<100mg/dl) 
<7.8mmol/l 
(<140mg/dl) 
- 20-40 
[4.0-5.9%] 
Impaired fasting 
glucose (IFG) 
6.1-6.9mmol/l 
100-125mg/dl 
<7.8mmol/l - 42-46 
[6.0-6.4%] 
Impaired glucose 
tolerance (IGT) 
<7.0mmol/l 
126mg/dl 
≥7.8mmol/l  
but <11.1mmol/l 
- 40-46 
[6.0-6.4%] 
Diabetes Mellitus ≥7.0mmol/l 
≥126mg/dl 
≥11.1mmol/l 
≥200mg/dl 
≥11.1mmol/l 
≥200mg/dl  
and clinical 
symptoms 
≥48 
≥6.5% 
 NB:  
Fasting plasma glucose (FPG):  This test is done after an overnight fast of a minimum of 8 
hours, a venous sample of blood is collected for laboratory estimation of blood glucose.  
Random plasma glucose (RPG): This is the estimation of venous plasma glucose from an 
individual not fasted with no regard to the time of last meal.  
 
 
 Table 1.3: Diagnostic criteria for Diabetes (adapted from WHO, 2011; ADA, 2010). 
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1. A) T1D symptoms (e.g. polyuria, polydipsia and unexplained weight loss for Type 1) plus:  
➢ A random venous plasma glucose concentration ≥ 11.1 mmol/l or  
➢ A fasting plasma glucose concentration of ≥ 7.0 mmol/l (whole blood ≥ 6.1 mmol/l) or 
➢ Two-hour plasma glucose concentration ≥  11.1 mmol/l two hours after 75g anhydrous 
glucose in an oral glucose tolerance test (OGTT). 
2. If at the time of diagnosis, there are no apparent clinical symptoms, the diagnosis should be 
confirmed with at least one additional glucose test result on another day of which a value in 
the diabetes range is essential, either fasting, from a random sample or the two-hour post 
glucose load. If the random fasting values are not diagnostic, then the two-hour value should 
be used. 
1.3.2 HbA1c estimation 
In 2010, an international expert committee comprising members appointed by the American 
Diabetes Association (ADA), the European Association for the Study of Diabetes (EASD), the 
International Diabetes Federation (IDF) and the WHO proposed the use of HbA1c estimation 
in the diagnosis and prognostication of diabetes (WHO, 2011; ADA, 2010; Kilpatrick, 
Bloomgarden, & Zimmet, 2009). Glycated haemoglobin (HbA1c) is formed from a ketoamine 
reaction involving the irreversible glycosylation of the N-terminal valine residue of one or two 
beta globin chains. It is an estimate of the beta-N-1-deoxy fructosyl component of 
haemoglobin.  The turnover rate is dependent on the lifespan of red blood cells (RBC) and 
correlates closely to a period of between 90-120 days (Gupta, Jain, Chauhan, 2017). This gives 
a diagnostic advantage of its use in diagnosis and prognosis in diabetes. Its fraction remains 
elevated in a state of persistent hyperglycaemia and its weighted average remains constant in 
fasting and non-fasting states (Leow, 2016; Bry, Chen, & Sack, 2001). Table 1.4 illustrates its 
use in the diagnosis of T1D. 
Table 1.4: HbA1c use in diagnosis (adapted from diabetes.co.uk) 
HbA1c mmol/mol % 
Normal Below 42 mmol/mol Below 6.0% 
Prediabetes 42 to 47 mmol/mol 6.0% to 6.4% 
Diabetes 48 mmol/mol or over 6.5% or over 
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1.3.3 Value of testing for pancreatic autoantibodies and genetic testing 
Before the clinical onset of T1D, autoantibodies produced to pancreatic islets cells indicate the 
prodromal phase. These autoantibodies can be assayed for diagnosis and prognosis of disease 
progression. Five pancreatic autoantibodies identified as necessary in the disease process of 
T1D are Islet Cell Cytoplasmic Autoantibodies (ICA), Glutamic Acid Decarboxylase 
Autoantibodies (GADA), Insulinoma-Associated-2 Autoantibodies (IA-2A), Insulin 
Autoantibodies (IAA) and zinc transporter 8 (ZnT8). The presence of three to four of these 
autoantibodies is highly suggestive of diagnosis or progression of T1D (Calderon, & Sacks, 
2014; Sacks et al. 2011). Their presence can be used to determine the autoimmune form of T1D 
and also differentiate T1D for T2D and MODY (Zeigler et al. 2013). However, critics for their 
use in diagnosis argue that there is no routine comprehensive use of these tests clinically, and 
they possess lower rates of positivity if measured long after diagnosis or in adulthood (Bingley, 
2010; Bingley et al. 1997). Table 1.5 below summarises the use of autoantibodies in the 
diagnosis of T1D. 
Table 1.5: Autoantibodies used in the diagnosis of T1D 
Test Description 
Islet Cell Cytoplasmic 
Autoantibodies (ICA) 
Autoantibody that usually is detected at the onset of T1D. 
Detection rates of 70-80% at the time of diagnosis. 
1.1 Glutamic Acid Decarboxylase 
Autoantibodies (GADA) 
Autoantibody that is usually detected at the onset of T1D. 
Detection rates of 70-80% at the time of diagnosis. 
Insulinoma-Associated-2 
Autoantibodies (IA-2A) 
Detection rates of almost 60% in T1D. 
Insulin Autoantibodies (IAA) 
Detected rates of almost 50% of T1D children; not 
commonly detected in adults 
Zinc transporter 8 (ZnT8) 
Detection rates of almost 30% in T1D with undetectable 
levels of other predictor autoantibodies (GAD65Ab, IA - 
2Ab and IAA) 
Although genetic screening is not routinely used in clinical practice, recent evidence suggests 
the clinical relevance of the use of Genetic risk scores (GRS) or polygenic score (Cooke Bailey, 
& Igo, 2016). It is a tool that can examine the cumulative risk of the genetic and intermediate 
traits or risk factors in the prediction of a disease condition. Factors to consider when creating 
GRS are contributions from genetic variations, weighting and comparability across ethnic 
groups. GRS are usually generated using genome-wide meta-analyses to accumulate 
information on a particular disease condition (Morrison et al. 2007). GRS has potential use of 
risk prediction in high-risk populations, gene-by-environment interaction studies, and 
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Mendelian randomisation studies (Cooke Bailey, & Igo, 2016). Its use is also relevant in a 
situation when there is diagnostic difficulty in accurately classifying patients with diabetes 
because of equivocal evidence from autoimmune markers and clinical features. Oram et al., 
(2016) used the GRS to precisely differentiate between the types of diabetes, and also made 
accurate predictions of those (adults) who in early diagnosis would require insulin treatment 
with disease progression. 
1.4 Management of T1D 
The management of T1D in the UK is governed by NICE guidelines (NG17, NG18, and 
NG19). The core of these guidelines is the delivery of services using a patient-centred 
approach. These guidelines are regularly updated every 2-4 years and are generated following 
extensive consultation with various stakeholders (NICE, 2017). These guidelines are set up 
with the overarching aims of reducing the burden of T1D by providing the necessary tools, 
services and information to adequately attain near to normal glycaemic levels, reducing and 
slowing down the onset and progression of complications, and reducing morbidity and 
mortality from this condition (NICE, 2015a). The NICE guidelines propose several 
management algorithms and clinical knowledge summaries (CKS) that provide advice on 
various aspects of management in T1D, these are but not restricted to the following; 
• Monitoring of blood glucose levels 
• Appropriate treatment modalities for glycaemic control 
• Monitoring of albuminuria, lipid profiles and blood pressure 
• Appropriate treatment guidelines to identify the onset and limit the progression of 
complications in T1D 
• Appropriate advice on patient centred management and care, including educational, 
lifestyle and dietary management 
• Identification of cardiovascular risk and interventions to control cardiovascular risk 
• Advice on inpatient care 
Routine care usually takes place in secondary care settings and backed up by primary care, 
hence the need for incorporation of a multidisciplinary team in patient care and optimisation of 
cost-effectiveness. 
For children and young people (CYP), and adults, the initial approach to management once the 
diagnosis is made is the provision of an integrated care package by a multidisciplinary team. 
14 
 
They undertake and provide detailed initial assessment, ongoing agreed plan of care and follow 
up, and details of the annual review process. 
Assessments include medical, environmental, cultural and educational assessments (NICE, 
2016b). The medical assessment considers the detailed history of the condition, evaluation 
vascular risk factors such as smoking status, Blood pressure, BMI, foot, and eye examination, 
biochemical parameters such as albumin:creatinine ratio, HbA1c levels, TSH. Other areas 
considered during the medical assessment include the psychological well-being of the patient, 
the patient’s attitude toward self-care and medication (NICE, 2016b). Environmental 
assessment involves ascertaining the impacts of home, social and work environments on the 
condition of the patient and influence of support structures such as family and friends. Also 
considered is the impact of lifestyle factors such as alcohol, smoking and substance abuse. The 
cultural and educational assessment considers the prior knowledge of the individual to enable 
measures to be designed to ensure appropriate treatment modalities, and incorporation into 
educational programmes (NICE, 2016b).  
Providing an integrated care package helps to optimise the level of care thereby reducing the 
risk of development or progression of complications. Home-based or inpatient care can be 
offered depending on the preference and clinical needs of the patient (NICE, 2015c).  It is 
essential that at this time initial contact details and the roles and responsibility of members of 
the diabetes care team are identified and explained to the patient and caregivers. A person 
should be identified as the primary contact whose responsibility is to provide information about 
access to services, especially at crucial points in management such as initial stage of diagnosis, 
change in treatment approach, referral to other services within the diabetes care team and 
transition services from paediatric to adult clinics. This role is sometimes best performed by 
the diabetes specialist nurse (DSN). Other possible functions of the DSN are to provide 
supportive services or direction in tackling problems, providing information on lifestyle, and 
telephone follow up appointments. Other members of the team, like the dietitians, provide 
dietary advice in line with treatment goals. Clinical psychologists can provide ongoing 
psychological support, and identify potential barriers to the uptake of treatment. If required, it 
is pertinent that an efficient system of communication is developed to ensure adequate 
communication between members of the diabetes team across disciplines and between primary, 
secondary, and community settings (Diabetes UK, 2005, 2009). Patients are encouraged to 
participate in continued education programmes that meet their individual needs. These 
programmes consider specific issues such as emotional well-being, age and maturity of the 
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patient, influence from culture, current diabetes knowledge, social circumstances, and life goals 
(NICE, 2015a). The educational programmes are designed to convey information on details of 
insulin therapy which encompasses its use, mode of delivery, its aims and dosage regulation. 
Approach to blood glucose control is taught with an emphasis on adequate self-monitoring of 
blood glucose or HbA1c levels according to agreed management targets (NICE, 2016a). 
Following an adequate understanding of the use of understanding of insulin use and blood 
glucose measurements, the focus is further understanding of the effects of diet, physical activity 
and intercurrent illness on glucose control (NICE, 2016a). Emphasis on what measures to take 
during intercurrent illness episodes are taught like the need to understand ‘sick-day’ rules, with 
measurement for ketones. They are also taught to understand the signs and symptoms of 
hypoglycaemia, hyperglycaemia and ketosis and measures to take during those periods (NICE, 
2016a). 
1.4.1 Blood glucose control 
NICE advocates that the treatment target is set considering individual capabilities and 
preferences. Other factors needed to determine treatment targets are activity levels, the 
presence of comorbidities, complications and the risk of developing hypoglycaemia. These 
targets should target close to normal glycaemic levels as possible. The NICE guidelines in 
2015, stipulate HbA1c targets should be levels of ≤ 48mmol/mol (6.5%). Prior to 2015, target 
levels for HbA1c were set at ≤ 58 mmol/mol (7.5%) for CYP (NICE, 2015a, 2015b). However, 
there was a need to further reduce to current levels to conform to levels obtainable in adult 
services, which ensured uniformity between adult and paediatric services, hence a smoother 
transition from children to adult services. This also had the added advantage of reducing the 
risk of long-term complications. Optimum levels of assessment for HbA1c are set at four times 
a year, but higher for sub-optimum glycaemic control (NICE, 2015a, 2015b). 
Routinely, to ensure optimum glycaemic control, it is essential that regular self-monitoring of 
glucose levels be done. CYP including their family and carers are recommended to ensure a 
minimum of five checks per day for glycaemic levels. In adults, it is recommended that a 
minimum of four checks per day be done for glycaemic levels. They should aim for; 
• Fasting plasma glucose level of 4–7 mmol/litre on waking. 
• A plasma glucose level of 4–7 mmol/L before meals (pre-prandial).   
• A plasma glucose level of 5–9 mmol/L at least 90 minutes after meals (post-prandial). 
• A plasma glucose level of at least 5 mmol/L while driving, if they are of driving age. 
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Several methods of glucose monitoring exist, and preference is made depending on clinical 
factors and individual preferences. These include self-monitoring using glucose meters and 
finger pricks. The subcutaneous flash glucose monitoring system, for example, the FreeStyle 
Libre Flash glucose monitoring system measures interstitial fluid glucose using a meter and a 
sensor placed subcutaneously. This eliminated the need for regular finger-prick measurements 
and performed at similar levels to continuous glucose monitoring (CGMs) systems (NICE, 
2015a, 2015b). 
Subcutaneous flash glucose monitoring systems do not have high or low alarms and are not as 
ideal in those with recurrent severe hypoglycaemia or hypoglycaemia unawareness. These 
CGMs adopts a system that employs the use of subcutaneous sensors which measure glucose 
levels every 1-5 minutes; they can be set up with integrated alarm systems which intimate the 
user of high and low glucose levels including rapidly rising and falling glycaemic levels. Flash 
glucose monitoring systems and CGMs have the main advantage of being less invasive, 
eliminating the need for multiple needle pricks during the day. Additionally, CGM intimate 
alarms of high and low glucose levels that are of great value at night time (Diabetes UK, 2015). 
1.4.2 Insulin use and hypoglycaemia  
Treatment in T1D involves the lifelong use of insulin. Insulin therapy should only be started 
and overseen by healthcare professionals with the requisite capability and training.  Several 
factors are considered with the administration of insulin, including the age of the individual, 
dexterity of handling cartridges, the presence of visual impairment, needle phobia, HbA1c 
targets and patients’ preferences (NICE, 2016a). Insulin therapy aims to closely mimic the 
physiological mechanisms of insulin function in the human body. There are three types of 
insulin offered as treatment options in the UK; these are human insulins, human insulin 
analogues, and animal insulins (which are now rarely used). Insulins are classified mainly 
based on their profile of time action. Short-acting insulin closely resembles the immediate 
physiologic release of insulin to a glucose meal, intermediate and long-acting insulins emulate 
continuous basal release of daily insulin.  
In practice, individuals with T1D undertake self-monitoring of blood glucose levels and 
adjustment of insulin doses based on glycaemic levels. Insulin replacement involves the use of 
basal insulin and pre-prandial (pre-meal) insulin. The basal insulin preparations are either long-
acting (glargine or detemir) or intermediate-acting (NPH). Pre-prandial insulin preparations are 
rapid acting (lispro, aspart, insulin inhaled, or glulisine) or short-acting (regular).  
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Insulins are classified based on their formulations or action profiles — classification based on 
human or animal insulin. The production of human insulin undergoes the manufacturing 
process that utilises recombinant DNA technology to produce similar variants having the same 
amino acid sequence as endogenous human insulin. Inputs can be made to alter and produce 
specific properties such as prolonged duration of action or faster absorption and action. Animal 
insulins are insulin preparations extracted from animal sources such as cows (bovine insulin) 
or pigs (porcine insulin).  
Regarding action profiles, insulin is classified into short-acting, intermediate-acting (Isophane 
or NPH [Neutral Protamine Hagedorn]), and Long-acting insulins (Dawoud et al. 2017; Muis 
et al. 2006; Hirch, 1999). Short-acting insulins are characterised by fast action of onset and 
short duration of action. Commonly, two types exist, soluble insulins which have an onset 
action time of 30-60 minutes and can remain active for approximately 8 hours (Human 
Actrapid® and Humulin S®). Also available are the rapid-acting insulin analogues with a more 
rapid onset of action (≤ 15 minutes) and approximate duration of action of 2 – 5 hours, they 
include Humalog® (insulin lispro) and Novorapid® (insulin aspart). Intermediate-acting 
insulins, examples of which include Humulin I®, Insuman basal®, and Human Insulatard®, 
act by emulating the effects of basal insulin with the onset time of approximately 2 hours, peak 
action of 4 – 12 hours and 16 – 35 hours in duration of action (Dawoud et al. 2017). Long-
acting insulins have longer durations of action than intermediate insulin, and attain optimum 
levels beyond 24 hours, hence providing steady-state insulin levels, examples are Lantus® 
(insulin glargine), Levemir® (insulin detemir), and Tresiba® (insulin degludec). 
Hypoglycaemia is the main side effect of insulin use; it is reported to have an incidence of 
almost 16% in T1D. However, this value is said to be underreported, as so many episodes of 
hypoglycaemia (≤ 3.9mmol/L [≤ 70mg/dl] are asymptomatic and go unreported. Symptomatic 
hypoglycaemia has an incidence of two (2) episodes per week in T1D, and severe 
hypoglycaemia requiring intervention has an incidence of 1.0 – 1.7 episodes per patient per 
year and yearly prevalence of 30 – 40% (McCrimmon, & Sherwin, 2010; Shafiee et al. 2012; 
Cryer, 2015). Recurrent episodes of severe hypoglycaemia subsequently blunt the body’s 
counter-regulatory mechanisms leading to autonomic dysfunction. This further result in 
reduced hypoglycemic awareness and the consequent hypoglycaemic-associated autonomic 
failure sometimes leading to unexpected death or “dead-in-bed” syndrome. “Dead-in-bed” is 
likely to account for approximately 5% mortality in T1D. A possible explanation of this 
phenomenon is nocturnal hypoglycaemia inducing cardiac dysrhythmia and elongation of QTc 
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with underlying subtle cardiac neuropathy and electrolyte abnormality (Weston, 2012). 
Predictors of severe hypoglycaemia include previous hypoglycemic episodes, long-term use of 
insulin. Other side effects from the use of insulin include dermatologic reactions like 
lipodystrophy, transient bilateral presbyopia, weight gain, transient gastrointestinal upset, 
possible atherogenic effects on the cardiovascular system and rarely immune and 
hypersensitivity reactions (Lebovitz, 2011; Reichard, Nilsson, & Rosenqvist, 1993). 
1.4.3 Use of Statins and Angiotensin-converting-enzyme inhibitor (ACE inhibitor) to 
the limit the progression of complications in T1D  
T1D conferred significantly increased risk of mortality from acute complications of diabetic 
ketoacidosis, or exhaustion from deficient nutrient state secondary to the inherent catabolic 
state. With the advent of insulin therapy, individuals with this condition were afforded the 
opportunity to live longer; as such, they were prone to the onset of long-term complications of 
T1D. These are microvascular complications affecting several organs (eyes, kidneys, heart, 
blood vessels, and nerves) resulting in retinopathy, nephropathy, and neuropathy. These further 
exacerbate macrovascular complications (cardiovascular disease, cerebrovascular disease, 
stroke), which are primarily a result of atherosclerotic changes in blood vessels. Several large 
scale studies have been conducted to shed more insight into the management of T1D, including 
the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and 
Complications Study (DCCT/EDIC), UK Prospective Diabetes Study (UKPDS), Framingham 
Heart Study (FHS), Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial, 
and the Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial [AdDIT] (Gubitosi-Klug, 
et al. 2014; Marcovecchio et al. 2017; Zoungas et al.2017; Mahmood et al. 2014; Rubins, 
Robins, & Collins, 1996). 
The DCC/EDIC trial advocated the central theme of tight glycaemic control to mitigate the 
onset and progression of T1D complications (neuropathy, nephropathy, and retinopathy). It 
also had the potential impact of reducing cognitive decline and improvement in health 
economics for healthcare systems (Martin et al. 2014; Aiello et al. 2014; Gubitosi-Klug et al. 
2014). The intensive treatment program of tight glycaemic control in the DCCT showed 
beneficial effects on limiting the onset and progression of atherosclerosis and cardiovascular 
diseases, hence mitigating the incidence of macrovascular complications such as myocardial 
infarctions [MI], coronary artery disease [CHD], and stroke (Lachin et al. 2014). It also 
demonstrated a reduction of microvascular complications (retinopathy, neuropathy and 
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nephropathy) by 35% as compared to 90% on those on conservative therapy (Nathan et al. 
2014; Kim et al. 2014). 
NICE guidelines advise on the management of cardiovascular risk factors such as adequate 
management of blood pressure and lipid profiles with the introduction of lifestyle changes 
and/or the use of medications. Studies show that there is an increased risk of cardiovascular 
diseases with T1D which are inclusive of coronary heart disease (CHD), heart failure, 
cardiomyopathy, cerebrovascular disease, and peripheral artery disease (PAD). Some studies 
indicate an increased relative risk of almost ten times that of the general population (Libby et 
al. 2005; de Ferranti et al. 2014). This is due to the association between elevated blood pressure 
and the development of coronary artery disease (CHD) and stroke (Rosendorff et al. 2015). 
Studies have established hypertension as a significant independent risk associated with CHD 
regardless of age, race, or sex. There is a two-fold increase in the risk of having a coronary 
event with every 20mmHg increase in systolic blood pressure (SBP) or 10mmHg increase in 
diastolic blood pressure (DBP). In middle age, a reduction of SBP by 10mmHg (5mmHg DBP) 
confers a 50-60% reduction in the risk of developing stroke and a 40-50% reduction in the risk 
of developing CHD (Lewington et al. 2002; Lackland et al. 2014, Rosendorff et al. 2016). 
NICE suggest that the ideal target blood pressure readings for those with T1D should be levels 
of ≤ 135/85mmHg. The threshold for the introduction of blood pressure management is the BP 
≥ 140/90mmHg for T1D patients with a target of ≤ 135/85mmHg in those without end organ 
damage and < 130/80mmHg in those with end organ damage (NICE, 2004, 2009, 2015). 
Several documented trials advocate the effects of angiotensin-converting enzyme inhibitors 
(ACE-I) as anti-hypertensive linked to reduction in cardiovascular disease (CVD) outcomes, 
and also the advantage of the reduction in onset and progression of albuminuria in T1D. This 
is achieved through the maintenance of the glomerular filtration rate by preserving the renal 
ultrastructure (Yusuf et al. 2000; Fox, 2003; Julius et al. 2006). The use of statins has also been 
found to provide beneficial effects by reducing levels of harmful lipids, hence providing cardio-
protection. A study by the Cholesterol Treatment Trialists' (CTT) Collaborators showed a risk 
reduction of 25% in cardiovascular disease events for every 1.0 mmol/l fall in low-density 
lipoprotein cholesterol (Shah, 2014; Minder, Blumenthal, & Blaha, 2013; Cholesterol 
Treatment Trialists' (CTT) Collaborators, 2012). Until recently, there remained the question of 
using ACE-I and statins in adolescent T1D patients, pregnant women, and women of child 
bearing age. However, a recent study by Marcovecchio et al. (2017) revealed that the 
introduction of ACE-I and/or statin therapy did not have any significant impact on albumin: 
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creatinine ratio. While the use of ACE-I was found to reduce the incidence of 
microalbuminuria, Statins use led to reductions in total, low-density lipoprotein, and non–high-
density lipoprotein cholesterol levels, and triglyceride levels.  
1.5 Screening for thyroid and coeliac conditions in T1D  
Coeliac disease and T1D share common genetic connotations. The prevalence of CD and T1D 
is between 1.6 -16.4%. There is a negative correlation between the age of onset of T1D and the 
risk of developing CD. Depending on the mode of onset for CD which can either be before the 
diagnosis of T1D (10-25%) or after the diagnosis of T1D (70-80%), it negatively influences 
the prognosis of T1D by predisposing the patient to further complications such as osteopenia. 
Autoimmune thyroid diseases (AITD) are also prevalent in T1D especially in those with 
multiple co-morbidities of T1D and coeliac disease (CD).  Although there is limited evidence 
of the direct link between T1D and AITD, research suggests a disproportionate genetic link 
between CD, T1D and AITD. Also, the other clinical effects of CD and AITD may negatively 
impact on complications, morbidity and quality of life hence the need for screening at the time 
of diagnosis of T1D and between 2 to 5 years after diagnosis in children (Kurien et al. 2016; 
Bakker et al. 2016; Pham-Short et al. 2015; Cohn, Sofia, & Kupfer, 2014; Gabriel et al. 2011; 
Djuric et al. 2010; Cerruti et al. 2004).  
1.6 Patient education and lifestyle modification 
The cornerstone to the delivery of diabetes services is patient empowerment. Patient 
empowerment is defined as the process of nurturing an individual with appropriate knowledge 
to enable them to develop the necessary skills, attitudes and beliefs, which influence 
behavioural changes tailored to enhance the quality of life (Funnell et al., 1991; Allgot, 2001). 
One method of facilitating patient empowerment is through patient education where the process 
aims to equip individuals with abilities and opportunities to preserve their autonomy. Education 
promotes shared decision making to optimise healthcare services (Bravo et al. 2015; NICE, 
2016b; ADA, 2016).  
Several education structured educational programmes have been validated through research to 
ensure patient empowerment. These include the diabetes education and self-management for 
ongoing and newly diagnosed (DESMOND), the Diabetes X-PERT Programme, and Dose 
Adjustment for Normal Eating (DAFNE) programme. The X-PERT Programme has been 
delivered to over 250,000 participants up to the year 2016, while the DAFNE programme has 
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been delivered to almost 44,000 participants in 2016. Following the implementation of these 
courses, there have been significant improvements in adherence to treatment regimens. Other 
parameters such as increased knowledge of diabetes have been enhanced leading to positive 
changes in illness beliefs, significant weight loss, decreased odds of smoking, lower depression 
rates, positive changes in personal responsibility, and better glycaemic control (Plank et al. 
2004; Davies et al. 2008; Deakin et al. 2006, 2011; Diabetes UK, 2015, X-PERT, 2017; NICE, 
2016a). 
Lifestyle choices such as dietary modification are still crucial in the management of diabetes. 
However, the NICE guideline (NG 17) encourages patients to access structured educational 
programmes that give them the requisite knowledge on carbohydrate counting. Advice on diet 
should tailor to individual needs and should target essential areas such as weight control and 
minimisation of cardiovascular risk factors (NICE, 2016a). Robust evidence exists on several 
associations between dietary modification and improvement in health quality, especially 
cardiovascular risk factors. For instance, there is the positive correlation between reduction in 
salt intake and reduction in blood pressure (Cappuccio et al. 2006; Zhao et al. 2009; Kyu Ha, 
2014; Graudal, Hubeck-Graudal, & Gesche Jurgens, 2017), avoidance of excessive caffeine 
intake and reduction in blood pressure (Geleijnse, 2008; Mesas et al. 2011), reduction in 
excessive alcohol consumption and improvement of blood pressure (Roerecke et al. 2017; 
Stewart et al. 2008; Miller et al. 2007; Xin et al. 2001; Ueshima et al. 1993), physical exercise 
and reduction in cardiovascular risk (American Heart Association (AHA), 2017; Eijsvogels et 
al. 2016; Agarwal, 2012;  Buttar, Li, & Ravi,  2005). 
A meta-analysis by Kennedy et al. (2013) on the glycaemic benefit of exercise in type 1 
diabetes was inconclusive, and other researchers reached similar findings (Lukács & Barkai, 
2015; Colberg et al. 2015). However, specific individual factors are contributory to this 
conclusion such as dosing and timing of insulin doses, calorific intake before, during or after 
exercise, and increased risk of hypoglycaemia (Lukács & Barkai, 2015). There is still value in 
exercise with a reduction of cardiovascular risk, reduction in blood pressure, weight reduction, 
and improved well-being, hence its essential place in the management of T1D (Chimen et al. 
2012). Recent evidence from Tikkanen-Dolenc et al. (2017) found that exercise ensures a 
reduction in the associated risk of early mortality and cardiovascular mortality in T1D patients. 
Some authors have argued that the burden of lifestyle modification may predispose some 
patients to negative psychological and behavioural implications, for instance, the burden of 
repeated self-monitoring and regulation of food intake with multiple insulin doses may impact 
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on the quality of life in particular when severe hypoglycaemic or hyperglycaemic episodes 
occur (Gonder-Frederick, 2014; Larrañaga, Docet, & García-Mayor, 2011). An initial episode 
of severe hypoglycaemia can be a debilitating and disruptive experience. Recurrent episodes 
of hypoglycaemia also increase susceptibility to decreased hypoglycemic awareness that can 
result in loss of consciousness, or death (Kalra et al. 2013; Abdelhafiz et al. 2015). As CYP 
develop into adulthood, they are prone to the pressures of keeping the ideal body weight or 
body image. As a result, studies have found that they are at an increased risk of developing 
eating disorders. For weight loss they may engage in behaviours such as deliberate missing of 
insulin doses, splitting of insulin doses, or restriction of food, binging and purging, improper 
use of laxatives, and strict exercise regimens (Colton et al. 2015; Wilson et al. 2015; Grylli et 
al. 2003; Neumark-Sztainer et al. 1998). Following a review of the Diabetes Attitudes, Wishes 
and Needs (DAWN) study, it highlighted the need for individuals with T1D to have emotional 
support, family support and social support networks for the management of their condition 
(Funnell, 2006). 
The diagnosis of T1D can be challenging in childhood for patients, parents and their caregivers 
who have to perform the daily management requirements some of which include multiple daily 
checks of glycaemic levels, administering appropriate insulin doses, ensuring appropriate 
dietary intake, monitoring physical activity and ensuring tight glycaemic control (Streisand, & 
Monaghan, 2014). A delicate balance of achieving the right glycaemic control is trying, as 
several factors are in play, some of which include the demands from the physical and 
neurological development of the child and the varying demands from unplanned outbursts of 
physical activities (Wood et al. 2013). Several other socio-emotional factors are contributory 
as the child develops, for instance, some parents perform the responsibility of educating support 
givers such as teachers and friends with the responsibility of being able to recognise early signs 
of hypo/hyperglycaemia. They also must be able to alter their schedule to respond to the needs 
of their child such as play dates and school activities. The child’s emotional well-being may 
also impact on management. Some children view interventions from parents as an overbearing 
impingement on their autonomy. The resultant effect arising from multiple blood glucose 
checks can lead to needle phobia, and phobia for medical personnel or environments (Streisand, 
& Monaghan, 2014; Desrocher, & Rovet, 2004). For parents, drawing a balance between 
performing the normal daily routines, childcare and the additional routine of ensuring the right 
glycaemic control can lead to elevated stress levels (Williams, Laffel, & Hood, 2009). As the 
child attains adolescence, increasing autonomy is given to them in the management of their 
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condition, sometimes this period may be plagued with poor metabolic control because of the 
influence of family conflicts. Sometimes, the impact of increased autonomy of care may 
predispose them to increased pressures especially when they are introduced to self-
management at an early stage without the requisite psychological maturity (Jaser, 2010; Palmer 
et al. 2004). Due to the peculiarity of the adolescence, and the resultant effects from the 
transition to early adulthood, they are at increased risk of disorders such as anxiety disorders, 
depressive disorders, eating disorders, and alcohol and substance abuse which impacts on 
metabolic control (Hood et al. 2006; Goebel-Fabbri, 2009). Crucial to successful psychosocial 
outcomes in management are strong family cohesion and support (Spencer, Cooper, & Milton, 
2012).  
The occurrence of psychiatric disorders in T1D may exist independent of T1D, as a 
complication of the condition, or as an independent risk of developing T1D. When these 
disorders are present, they predispose individuals to poor adherence to regimented treatment, 
inadequate metabolic control, increased complications, hospitalisations, and increased costs of 
care (Balhara, 2011; Butwicka et al. 2015). Evidence suggests an increased risk of developing 
mental health disorders in T1D (Almeida et al. 2018; Butwicka et al. 2015; Sivertsen et al. 
2014). 
Recent evidence suggests that the use of alcohol, smoking and substance abuse correlates 
closely with patterns and prevalence seen in the general population (Pastor et al. 2017; 
Hogendorf et al. 2016; Weitzman, Ziemnik, Huang, & Levy, 2015; Palladino et al. 2013; Cavoy 
et al. 2005).  The pattern of alcohol, smoking and substance abuse use starts in teenage years 
and most times intensifies into young adulthood. Several factors may influence patterns of use 
in T1D; these include the increased stress of daily management of their condition, the possible 
influence of other mental health conditions, peer pressure, and possible effects of familiarity 
with injection techniques (Feltbower et al. 2008). The use of alcohol can initiate and potentiate 
conditions like anxiety disorders and depression. Substance abuse also correlates closely with 
the onset or potentiation of disorders like aggressive behaviour or violent outburst, self-harm, 
schizo-affective disorders and psychosis (Rehm et al. 2009). The resultant effect of excessive 
alcohol use and substance abuse is its ability to impair strict adherence to the treatment regime, 
thereby contributing to worsening metabolic, glycaemic control and onset of secondary 
complications (Pator et al. 2017; Sacco, & Bykowski, 2010). Smoking is seen to potentiate the 
increased risk of developing microvascular complication through its effect of causing 
endothelial dysfunction and increased inflammation. It is also known to potentiate the advent 
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and progress of cardiovascular complications hence leading to increased mortality (Eliasson, 
2003; Hovind et al. 2003). 
The relationship between poor health and poor socioeconomic indices are well documented, 
with a socioeconomic health gradient in which poorer members of society are prone to more 
substantial effects of morbidity and mortality in comparison to more affluent individuals 
(Grintsova, Maier, & Mielck, 2014; Brown et al. 2004). A systematic review by Scott et al. 
(2017) established that regardless of health systems, T1D patients exhibited similar findings of 
increased risk of morbidity and mortality for those with lower socioeconomic status. This is 
supported by findings from the study carried out by Rawshani et al. (2015).  
1.7 Future challenges in T1D 
T1D remains a condition that occurs through a complex interplay of genetic and environmental 
factors. Future trends in the management of this condition attempt to utilise several options to 
stem the rising incidence of T1D. One of the areas being investigated are possible interventions 
to prevent the onset of T1D. Two trials done were the European Nicotinamide Diabetes 
Intervention Trial (ENDIT), and the Diabetes Prevention Trial – type 1 (DPT-1) which 
observed no protective effects on the onset of T1D (Gale et al. 2004; Vehik et al. 2011). Several 
studies have been designed and are ongoing in different stages that target immunomodulatory 
mechanisms to influence either specific antigens or broad-based immune modulators all with 
limited success. They are designed to interfere with processes that activate pathogenic cells or 
enhance regulatory mechanisms. 
Furthermore, some other studies were designed to alter metabolic or environmental 
determinants by altering nutritional component implicated in the onset of T1D. The overall aim 
of these studies was to slow down the onset of β-cell destruction while restoring self-tolerance. 
Some of which include nutritional therapies involving the use of Omega-3 fatty acids and 
vitamin D supplementation and Cow’s milk protein administration (Tooley, Waldron-Lynch, 
& Herold, 2012). They have shown limited success; however, these trials have provided new 
insights into the possibility of using combination therapies targeting multiple pathologic 
pathways to harness the beneficial effects of the various single therapies. Other areas being 
examined include possible stem cell therapies in rejuvenating β-cell regeneration (Anzalone et 
al. 2011). Transplant therapies are available with success rates of almost 80% in the first year 
decreasing to 20% in the fifth year. Recent progress in transplanted procedures was made under 
the auspices of the Diabetes Research Institute in 2016 utilising insulin-producing cells within 
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a biological scaffold engineered onto the surface of the omentum.  This procedure was a success 
as the recipient was able to achieve freedom from insulin therapy. This highlights advancement 
in transplant techniques through insights from bioengineering. Another area showing promise 
is the microencapsulation for cell therapy (Calafiore, 2018). Overall, two main strategies are 
on the horizon to tackle T1D; one is to establish interventions that prevent the onset of 
autoimmunity and second to establish therapy that limit the progression of autoimmunity as 
well enhance β-cell regeneration. 
In summary, this chapter has critically explored the literature with regards to T1D. It has shown 
that T1D is associated with increase in premature or excess mortality, and as such there is a 
need to explore an overview of the current evidence on trends in mortality from T1D using a 
systematic review of evidence (see chapter 3). There is also the explore the factors that 
contribute to premature mortality in T1D by exploring the following aims and objectives. 
Aims 
This study aimed to identify predicting risk factors for mortality and survival in T1D in the 
Wirral.  
Objectives 
This study had the following objectives: 
1. To evaluate factors relating to all-cause mortality, cardiovascular and non-
cardiovascular mortality in T1D. 
2. To conduct a systematic review and meta-analysis, in order to present current evidence 
of all-cause and cause-specific mortality amongst T1D patients. 
3. To examine the role of variables such as socioeconomic status, smoking, body mass 
index, blood pressure measurements, glycaemic control, lipid profile, nephropathy, and 
retinopathy as predictive risk factors of mortality in the Wirral 
4. To evaluate the influence of age at diagnosis, duration of diabetes, year of diagnosis 
and gender on mortality in the Wirral. 
5. To evaluate survival, life expectancy and mortality patterns in T1D 
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The next chapter is the methodology chapter that explores methodological perspectives to the 
conduct of a retrospective cohort study. It further provides the procedural methods in the 
conduct of this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2: Methodology 
This chapter on methodology followed a logical description of how the study was carried out. 
It outlined the methodological approach and the methods employed throughout the study 
process. The conduct of any study is governed by the inherent philosophical principles adopted 
by the researcher; these are influenced by a set of beliefs or assumptions held by the researcher 
on the nature of reality, the relationship between the researcher and the researched and the 
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knowledge (Parahoo, 2006). Quantitative methodology was adopted to carry out this study; 
this methodology allows for empirical exploration of the phenomenon under investigation 
using statistical analysis.  
Aims 
This study aimed to identify predicting risk factors for mortality and survival in T1D in the 
Wirral.  
Objectives 
This study had the following objectives: 
1. To evaluate factors relating to all-cause mortality, cardiovascular and non-
cardiovascular mortality in T1D. 
2. To conduct a systematic review and meta-analysis, in order to present current evidence 
of all-cause and cause-specific mortality amongst T1D patients. 
3. To examine the role of variables such as socioeconomic status, smoking, body mass 
index, blood pressure measurements, glycaemic control, lipid profile, nephropathy, and 
retinopathy as predictive risk factors of mortality in the Wirral 
4. To evaluate the influence of age at diagnosis, duration of diabetes, year of diagnosis 
and gender on mortality in the Wirral. 
5. To evaluate survival, life expectancy and mortality patterns in T1D 
2.1 Methodology 
Quantitative methodology allowed for numerical estimation of the total number of deaths in a 
cohort with T1D in the Wirral and the cause of mortality. Further statistical analysis allowed 
for the evaluation of several variables as predictive risk factors of mortality in T1D. Using the 
quantitative approach ensured that the observed mortality in T1D in the Wirral was reliably 
credited to the effects of the predictor variables without influence from biases (Creswell, 2013; 
Crossman, 2014; Jakobsen, 2013). For this study, quantitative methodology enabled for the use 
of statistical analysis, inferential statistics and hypothesis testing to arrive at results that could 
be generalized.  
In carrying out this study, the ontological approach adopted was a positivist view of synthesis 
that follows a hypothetical-deductive process of research. The measurement of the observations 
in this study was based on the presumption that the objective reality as obtained from the 
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statistical analysis was independent of the views of human perception (Sale, Lohfeld, & Brazil, 
2012). The observations (number and trends) of the dependent variable mortality were 
observed independent of predictor variables, this allowed for reliable estimate(s) of the causal 
relationship between exposures (predictor variables) and results observed (mortality) (Tuli, 
2010; Jörg & Björn, 20007; Shanks, 2002). The epistemological view adopted in this research 
was an independent view of observations within this study without any direct influence on the 
variables. This enabled for valid observations of the estimates obtained. The ontological 
approach within this study was objectivism; the researcher was able to establish a causal 
relationship between the predictor variables and mortality. Axiological view in this study was 
to remain unbiased (Creswell, 2013). 
The cohort study design was used to address the research aim in establishing the relationship 
between predictor variables and outcome measure (mortality). Although the use of any form of 
a descriptive study may have been appropriate to address the study aim by providing point 
estimate of mortality indices during the follow-up period. However, its use may not have 
provided any timeline of the cycle of events, making it difficult to ascertain or infer any causal 
relationship between the predictor variables and mortality (Webb & Bain, 2011; Bonita, 
Beaglehole, & Kjellström, 2006). The cohort study design was able to establish in 
chronological order the effects of the predictor variables on the outcome measure of mortality; 
it also allowed analysis to establish significant predictors of mortality (Webb & Bain, 2011; 
Levin, 2006; Mann, 2003). 
For this study, the cohort study design was used to:  
• Generate evidence on morbidity and mortality indices in T1D in Wirral peninsula  
• Establish the association between the onset of T1D and progression of complications 
providing insight into the management of the condition. 
• Generate composite outcomes in T1D such as all-cause mortality, cause-specific 
mortality, changes in morbidity, treatment effects, and disease-specific outcomes such 
as survival. 
The conduct of cohort studies has the following inherent procedural characteristics (Hubert, 
2014): 
• The identification of a sample of participants (cohort), with or without a known 
exposure but at risk of developing a particular outcome of interest.   
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• The collation and analysis of data from the participants (cohort) with exposure to risk 
factors and outcomes measures over a period 
• Drawing inference or associations between exposure and outcome measures 
The essential design elements of cohort studies are: 
• The development of a hypothesis to be tested 
• Identifying the groups and subgroups of participants to be investigated 
• Defining the exposure(s) of interest and its measures 
• Measuring the confounders 
• Defining the outcome(s) of interest and its measurement(s) including analysis 
• Drawing inferences between exposure and outcome measures 
The inherent design elements of cohort studies helped to address the research aim for this study 
in two dimension aetiological and prognostic dimensions (Herbert, 2014; Imamnovic, 2014). 
In looking at the etiologic dimension to this study, for a cohort of participants with T1D, this 
study attempted to establish the causal associations between predictive risk factors and 
mortality in T1D, and the extent to which any of these factors modified mortality in T1D. This 
was based on the premise that one or several of the predictive risk factors could occupy the 
continuum that led to mortality in T1D and also that some of the predictive risk factors could 
potentiate, mediate, or have additive effects on the outcome of mortality (Hernán, & Robins, 
2019; Steyerberg, 2009). In this study, the prognostic dimension was to estimate survival from 
T1D, considering the predictive risk factors. This was done by using statistical analysis to 
estimate the median survival times of various strata of the predictive risk factors. This had the 
advantage of identifying particular groups with poorer prognosis in T1D, with the potential of 
providing insight into preventive measures for these target groups (Grobbee & Hoes, 2015; 
Kaufmana, Kaufmanc, & Poolea, 2003).   
This study followed a retrospective approach (sometimes referred to as historical cohorts) that 
involved the collation of pre-existing data on predictive risk factors individuals diagnosed with 
T1D and data on the outcome measure of mortality (Hubert, 2014; Grobbee & Hoes, 2015; 
Webb & Bain, 2011). This had the advantage of reduced cost during the data collation process. 
In this study, because the researcher was unable to influence allocation into subgroups, the 
study was able to identify incidence, prevalence, and mortality patterns, hence identifying the 
natural progression of T1D and mortality. Other advantages of cohort study as it applies to T1D 
are outlined in table 2.1 below. 
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Table 2.1: Advantages of cohort studies 
• Establishes the temporal sequence between exposure and outcome measures such as the 
development of morbidity and mortality (Song & Chung, 2011) 
• Establishes the direction of the temporal sequence observed (direction of causality) 
• Enables indices that compute the effects of exposure outcomes to be calculated such as 
incidence rates, mortality rates, morbidity rates,  relative risk and risk ratios [RR], 
attributable risk [AR], risk difference, and confidence intervals (Webb & Bain, 2011) 
• Linked to essential steps in the estimation of hazard ratios [HR], survival analysis, and life 
table analysis (Lee et al. 2007; Hsu et al. 2017). 
• Function to examine multiple effects of a single exposure as well as multiple exposures and 
effects. 
• Facilitate the study of rare disease occurrences or conditions 
• Generate hypotheses that can be further be evaluated by randomised control trials (Webb & 
Bain, 2011) 
• Cohort study limits the bias attributed to knowledge of outcome status because, at the time 
of enrolment, study participants do not have the outcome measure evident. 
• Cohort study ensures that data collection is accurate when it pertains to exposure, 
confounders and outcome measures. 
• Cohort study can provide a time-efficient way of using existing data to  provide answers or 
generate hypotheses to disease occurrence that are of increasing public health relevance 
The landmark large-scale cohort study, the Diabetes Control and Complications 
Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC) 
highlighted the importance of tight glycaemic control to limit the onset and progression of 
complications in T1D (Nathan et al. 1993). However, this study noted that those on intensive 
therapy (INT) were at an increased risk of hypoglycaemic episodes (Nathan et al. 2014; Zinman 
et al. 2014). This provided further insight for this study as one of its objectives was to establish 
the risk of mortality according to various glycaemic levels; this helped to provide an insight 
into those that were at the highest risk of mortality so that targeted measures could be 
implemented at those with high risk. 
In this study, some participants may be lost to follow up for reasons such as withdrawals, 
inadequate communication, and relocation from the study area. These factors may have 
affected the study results leading to over-or-underestimation of outcomes (Sedgwick, 2014). 
Cohort studies study can be affected by differential methods during the study such as changes 
in classification of diagnosis, measurement parameters, diagnostic procedures, and the 
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aetiology of death. These present difficulty in ensuring consistency in the measurement of 
outcome measures limiting the validity of results. In this study, one of such difficulty 
encountered was a change in the target levels for HbA1c from ≤ 58 mmol/mol (7.5%)  prior to 
2015 to ≤ 48mmol/mol (6.5%) after 2015   (Song & Chung, 2010; Mann, 2003; NICE, 2015a, 
2015b). Another difficulty encountered which limited impact on this study was a transition of 
from ICD-9 to ICD-10 for the classification of the aetiology of death during the study period. 
Cohort studies are prone to several forms of bias. Bias is the tendency for a systematic error to 
occur in a study that limits the exact effect estimate in outcome measure(s) either during the 
design, conduct or during data analysis (Norvell, 2010; Grimes & Schulz, 2002). They include: 
• Selection bias: a systematic error that occurs when the selection of participants into 
subgroups is based on inherent characteristics that may impact the results of outcome 
measures. To overcome the influence of selection bias in this study, participants for this 
study had to meet strict inclusion criteria. 
• Confounding: evident when differing competing risks not accounted for during the 
study that interferes with the accurate effect estimate of results. One way to minimise 
the influence of confounding variables is by randomisation. The study design did not 
allow for randomisation of participants and also due to ethical consideration, however, 
to limit the impact of confounding an internally matched controls were identified that 
were closely identical to the exposed subjects (Sjölander, & Greenland, 2013; Faresjö, 
& Faresjö, 2010; Cummings, McKnight, & Greenland, 2003; Greenland, & 
Morgenstern, 1990).  
Other methods employed to limit the influence of biases in this study was the use of 
multivariate analysis which employed a statistical approach to analysis that allows for the 
simultaneous consideration of several risk factors to establish the relationship between these 
variables (Chatterjee, Sinha, Diver, & Feigelson, 2010; Giroux, 2008; Breslow, 1985).  
2.2 Methods 
This section critically describes the methods used to collect and analyse data to answer this 
study research question. Some of the variables that were examined to answer the research 
objectives are the age at diagnosis, sex distribution, socioeconomic status, and cardiovascular 
implications. It examined a cohort of 1800 participants with T1D in the Wirral peninsula using 
data from the Wirral Diabetes Register [WDR]. The data was collected between December 
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2016 and March 2018. Diagnosis of the participants was made in primary or secondary care; 
the follow-up period was from January 1st, 2000 and December 31st, 2012. 
The key areas that this section will address are: 
• Description of Wirral peninsula, a setting in which the study took place  
• The process of obtaining ethical approvals for the study 
• Sampling methods and selection criteria 
• The process of data collection and management  
• Statistical techniques and analysis  
2.2.1 Wirral Peninsula  
The Wirral is a metropolitan district covering an area of approximately 15,704.63 hectares in 
the Northwest of England. It comprising 22 wards including Clatterbridge in the central axis, 
Caldy, Hoylake & West Kirby situated in the western axis, Wallasey in the northern axis, and 
Birkenhead in the eastern axis. The peninsula shares a boundary with Liverpool with an 
interjection from the River Mersey in the east. The river Dee separates it from Wales in the 
west while it is bordered to its north axis by the Irish Sea. It also shares a boundary with the 
county of Cheshire West and Chester in the south. The Wirral comprises of rural, semi-urban, 
urban, and industrial areas.  
In 2016, the mid-year population estimates for the Wirral was 321,238, with females 
numbering 166,007 (51.7%) and males 155,231 (48.3%). These figures are extrapolations of 
the 2011 census figures, where Wirral had an overall population of 319,800, showing an overall 
increase of 1,438 between 2011 and 2016 (Office of National Statistics [ONS], 2017, Wirral 
Compendium of Statistics, 2017, Wirral Compendium of Statistics, 2012, Wirral Joint Strategic 
Needs Assessment [JSNA], 2012). The proportions of males in Wirral are lower than estimates 
obtained for England and United Kingdom estimates, while the proportions of females in 
England and UK are lower. Table 2.2 highlights comparisons between Wirral, England and 
UK estimates.  
Table 2.2: Comparison of the Wirral, England and UK Estimates of Mid-Year Population 
Estimates 2016 (adapted from Wirral Compendium of Statistics, 2017 and ONS, 2017). 
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The annual population growth in the UK is 0.8%; Wirral is noticing an annual population 
growth of 0.11%, which is higher than the national average of 0.8%. A projection of this notable 
increase is in the age groups above the age of 65 years. Estimates project an overall increase in 
the population of Wirral from 321,238 in 2016 to approximately 330,800 in 2035. Population 
estimates for 2016 showed that the age group with the highest population was the 50- 54-year-
olds, with a projected contraction for population estimates in the age groups between 15 – 29 
years from 2016 to 2035 (Wirral Compendium of Statistics, 2017). Table 2.3 highlights the 
2016 population breakdown into age groups. 
Ethnicity: Ethnic configurations in the Wirral showed that the White-British were the primary 
ethnic group resident in this area. They accounted for 95.7% of the total population as 
compared to the national average of 92.1% (ONS, 2017). Other ethnicities extant within the 
populations include White-Irish, White and Black Caribbean, Black Africans, Asians and Other 
Mixed Ethnicities. 
 
 
 
 
 
Table 2.3: Estimated Resident Population by 5-Year Age Group and Gender Wirral, Mid-
2016. (Adapted from Wirral Compendium of Statistics, 2017). 
Age Group 
Males Females Persons 
Number % Number % Number % 
0-4       9,853  3.1%       9,143  2.8%     18,996  5.9% 
5-9       9,838  3.1%       9,492  3.0%     19,330  6.0% 
10-14       9,292  2.9%       8,843  2.8%     18,135  5.6% 
15-19       9,284  2.9%       8,695  2.7%     17,979  5.6% 
20-24       8,352  2.6%       7,832  2.4%     16,184  5.0% 
25-29       9,188  2.9%       9,539  3.0%     18,727  5.8% 
 Wirral England United Kingdom 
Total population 321, 238 55, 268, 067  65, 648, 054 
Males 155, 231 (48.3%) 27, 300, 920 (49.4%) 32, 377, 674 (49.3%) 
Females 166, 007 (51.7%) 27, 967, 147 (50.6%) 33, 270, 380 (50.7%) 
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30-34       8,652  2.7%       9,368  2.9%     18,020  5.6% 
35-39       8,398  2.6%       9,333  2.9%     17,731  5.5% 
40-44       9,287  2.9%     10,074  3.1%     19,361  6.0% 
45-49     10,993  3.4%     11,805  3.7%     22,798  7.1% 
50-54     11,472  3.6%     12,647  3.9%     24,119  7.5% 
55-59     10,709  3.3%     11,462  3.6%     22,171  6.9% 
60-64       9,476  2.9%     10,255  3.2%     19,731  6.1% 
65-69     10,175  3.2%     10,579  3.3%     20,754  6.5% 
70-74       7,631  2.4%       8,432  2.6%     16,063  5.0% 
75-79       5,506  1.7%       6,931  2.2%     12,437  3.9% 
80-84       3,932  1.2%       5,483  1.7%       9,415  2.9% 
85-89       2,253  0.7%       3,703  1.2%       5,956  1.9% 
90+          940  0.3%       2,391  0.7%       3,331  1.0% 
All Ages   155,231  48.3%   166,007  51.7%   321,238  100.0% 
 
Socioeconomic Indices: A measure of the prevalent social and economic status of a particular 
area can be obtained from an assessment of the index of multiple deprivations (IMD). IMD is 
a ranking that assesses seven distinct domains to ascertain unmet needs secondary to the lack 
of resources (Wirral Intelligence Service, 2016). The Wirral peninsula ranked 66th position in 
the year 2015, just one ranking above the 65th position, which is considered to be among the 
20% most deprived authorities in England. However, spatial disparities exist in some regions 
of the Wirral, with Birkenhead being the most deprived. Although study highlights the links 
between poverty and ill health, this study has one of its aims as assessing the relationship 
between socioeconomic status, glycaemic control and impacts on mortality making such 
disparities important to this study. 
Life Expectancy in the Wirral: Life expectancy refers to a statistically derived average 
number of years an individual in a particular cohort is expecting based on current estimates of 
age-specific mortality rates of that cohort (WHO, 2003; Mathers et al. 2014). The process of 
estimation involves survival analysis using either period or cohort life tables. The life 
expectancy in the Wirral shows a marginal improvement over time but remains lower than 
those for England. Tables 2.4 and 2.5 show life expectancy for males and females in Wirral for 
2011 – 2013 were 77.8 years and 82.3 years respectively, compared to England with an average 
of 78.9 years and 82.7 years for males and females respectively (Wirral Compendium of 
Statistics, 2017, ONS, 2016).  
Table 2.4Trend in Life Expectancy at Birth with 95% Confidence Limits, Wirral, 1998-2000 
to 2013-15 (adapted from Wirral Compendium of Statistics, 2017)  
Period 
Males Females 
95% Confidence 
Intervals 
95% Confidence 
Intervals 
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Life 
Expectancy 
(Years) 
Lower 
Limit 
Upper 
Limit 
 Life 
Expectancy 
(Years) 
Lower 
Limit 
Upper 
Limit 
1998-2000 73.9 73.5 74.3 79.2 78.8 79.6 
1999-2001 74.3 73.9 74.7 79.7 79.3 80.0 
2000-2002 74.9 74.5 75.3 79.9 79.6 80.3 
2001-2003 75.2 74.8 75.6 80.0 79.7 80.3 
2002-2004 75.4 75.0 75.8 80.2 79.8 80.5 
2003-2005 75.6 75.2 76.0 80.3 79.9 80.6 
2004-2006 75.8 75.4 76.2 80.8 80.4 81.1 
2005-2007 75.9 75.5 76.3 81.0 80.6 81.3 
2006-2008 76.2 75.8 76.6 81.0 80.7 81.4 
2007-2009 76.6 76.2 76.9 81.0 80.6 81.4 
2008-2010 77.3 77.0 77.7 81.0 80.6 81.3 
2009-2011 77.6 77.2 78.0 81.7 81.3 82.0 
2010-2012 77.9 77.6 78.3 81.9 81.6 82.2 
2011-2013 77.8 77.4 78.2 82.3 82.0 82.7 
2012-2014 78.0 77.6 78.4 82.2 81.8 82.5 
2013-2015 77.9 77.6 78.3 81.9 81.5 82.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.5: Trend in Life Expectancy at Birth with 95% Confidence Limits, Wirral, 1998-2000 
to 2013-15 in comparison with England (adapted from Wirral Compendium of Statistics, 
2017; ONS, 2017)  
Period 
Males (life 
expectancy 
Wirral) 
Males (life 
expectancy 
England) 
Females (life 
expectancy 
Wirral) 
Females (life 
expectancy 
England) 
1998-2000 73.9 76.01 79.2 80.66 
1999-2001 74.3 76.24 79.7 80.72 
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2000-2002 74.9 76.55 79.9 80.91 
2001-2003 75.2 76.90 80.0 81.14 
2002-2004 75.4 77.32 80.2 81.55 
2003-2005 75.6 77.65 80.3 81.81 
2004-2006 75.8 77.93 80.8 82.02 
2005-2007 75.9 78.30 81.0 82.30 
2006-2008 76.2 78.40 81.0 82.60 
2007-2009 76.6 78.00 81.0 82.09 
2008-2010 77.3 78.31 81.0 82.33 
2009-2011 77.6 78.71 81.7 82.68 
2010-2012 77.9 79.02 81.9 82.83 
2011-2013 77.8 79.21 82.3 82.96 
2012-2014 78.0 79.35 82.2 83.05 
2013-2015 77.9 79.38 81.9 83.00 
 
The specific research setting for this study was The Wirral University Teaching Hospital 
Foundation Trust (WUTH) is the resident custodian of the Wirral diabetes register. WUTH 
delivers healthcare services to people of the Wirral Peninsula and its environs extending to the 
North West of England and North Wales. 
Wirral Diabetes Register 
The process involved the identification of all T1D patients in the Wirral Diabetes register up 
until December 2012. This register operated from 1997 to May 2013 and contained data of 
patients diagnosed with diabetes (T1D and T2D), from both primary and secondary care. 
However, the register began winding down to closure from December 2012. This register was 
an electronic register that had linkages to parameters such as age at diagnosis, demographics, 
socioeconomic status, biochemical profiles such as HbA1c, lipid profiles and renal status. 
These parameters were used to evaluate their relationship to morbidity, mortality and life 
expectancy in various subgroups. Where possible, medical notes were retrieved to obtain any 
other outcomes of interest.  
It had its origins when the UK subscribed to the ‘St. Vincent declaration’ of 1990. This set the 
tone for which the labour government of 1999 produced the National Service Framework 
[NSF] Standards (2001), which was essential in the management of diabetes. The National 
Service Framework delivery Strategy (2002) proposed measures to be attained within ten years 
proffered by the NSF standards. These strategies included the setting up of disease registers, 
implementation of eye screening, upscale of support services and implementation of system-
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wide diabetes therapeutic regimens (DOH, 2002). The Wirral Diabetes Register, which ran 
from 1997 to early 2013. 
The term register as defined by the Dictionary of Epidemiology is  
“A file of data concerning all cases of a particular disease or other health-relevant condition 
in a defined population such that the cases can be related to a population base…If these cases 
are regularly followed up, information on remission, exacerbation, prevalence, and survival 
can also be obtained” (Porta et al. 2009, pg. 243). 
The adequate management of any long-term condition is dependent on the establishment and 
optimum functioning of an accurate well-maintained register. Historical perspectives suggest 
the White Paper ‘Saving Lives: Our Healthier Nation’ supported the introduction of disease 
registers to strengthen the information resource available on chronic medical conditions in the 
UK. The duty of setting up and maintaining disease registers was entrusted to primary care 
trusts (Newton & Garner, 2002).  
The Wirral Diabetes Register had the following functional objectives: 
• Ensure optimum levels of patient care, whereby information garnered provided the 
basis for regular recall and review of management, providing structured individualist 
care, risk assessment and stratification, and regulating access 
• Application to public health where data from the register was used for disease 
surveillance, planning for the allocation of resources, assessing the impact of preventive 
measures and estimating the burden of the disease 
• Regular update and appraisal of the register to ensure that technology assessment was 
regularly updated keeping it at pace with technology improvements 
• Provide a basis for research to be carried out, generation of hypotheses, improvement 
of study designs, and analytic study 
To ensure that the WDR was a valid register, it had to conform to laws that governed 
confidentiality, data protection and security such as the ‘EU Data Protection Directive 1995',  
‘Data Protection Act, 1998’, ‘Health and Social care Act 2001’, and Human Rights Act 1998. 
It also had to conform to guidance such as the NHS policy on Confidentiality, Medical 
Research Council guidance, and the General Medical Council Guidance (Newton & Garner, 
2002). The register was set up with collaboration from primary, secondary, and community 
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care services with strict adherence to confidentiality and security. Database administrators 
updated changes to patient data such as updates on various parameters, co-morbidities, and 
changes of address. A WDR was a unique database that became a central repository with 
several linkages; a unique patient identification number assigned (PIDN) to each patient at the 
point of diagnosis was linked to the electronic patient health record (EPR). The EPR using the 
PIDN contained records of NHS numbers, the date of confirmation of diagnosis, biophysical, 
and biochemical parameters, links to the laboratory, GP, hospital, eye screening and supportive 
services such as podiatry.  
The register is an electronic register under the custody of the Wirral University Teaching 
Hospital NHS Foundation Trust. The central identifiers used to recognise patients were their 
NHS number, hospital number and Personal Identification numbers (PIDNs). The informatics 
department did linkages between the various sources of data. The collation of data from various 
sources ensured that the process of data collection was comprehensive, data collation from 
primary and secondary care provided robust evidence in accurately predicting risk associated 
with T1D.  
2.2.2 Ethical approvals  
Ethical approval for this was sought from the University of Chester (PhD study base) and 
Wirral University Teaching Hospital (custodian of the Wirral Diabetes Register). Also, consent 
was also sorted for IRAS ethics approval. However, after reading the study protocol, the Trust 
decided that IRAS ethics approval was not required. Trust research and development unit 
provided permission to access and use the data (letter attached in the appendix).   
2.2.3 Data Collection and Handling 
Records from the register were collated between 1997 and 2012. These records were stored on 
dedicated servers under the auspices of WUTH.  Data for this study were extracted from the 
database between December 2016 and March 2018. Supplementary data was collected by 
gaining access to case notes. These case notes were accessed weekly in batches of between 20 
to 30 case notes at a time from records kept at a storage location in Manchester. Due to data 
protection, data was kept for eight years after death and then destroyed. This created a study 
limitation because once the 8-year period had elapsed access to the information in case notes 
were lost which meant that data regarding the cause of death from some participants in the 
study could not be retrieved. 
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The process of data collection entailed extracting data from the register into an excel 
spreadsheet in preparation for data analysis. The data extracted included the following; 
Patient’s Personal Identification numbers (PIDNs), NHS number, gender, date of birth, age at 
diagnosis, confirmation status of the patient, weight and height. Other information included 
eye screening status, baseline, average and most recent values for HbA1c, systolic blood 
pressure (SBP), diastolic blood pressure (DBP), serum creatinine, albumin, cholesterol, 
triglycerides, HDL, LDL, thyroid stimulating hormone (TSH), smoking and alcohol intake. 
Data on cause of mortality was obtained from retrieved case notes and triangulated with online 
data from the General Register Office.  
2.2.4 Data validity 
This database was used for a similar PhD project studying the Type 2 diabetes cohort, during 
which the IT department checked that the process of validation had been carried out yearly to 
ensure the accuracy of data used. This process involved the removal of invalid data, retrieving 
more data from laboratory services, updating mortality status and date of death. The IT 
department regularly did quality assurance and data integrity. This was to ensure that the data 
uploaded from the various sources met the set procedures for the establishment of the register. 
The measures used were data encryption and access controls to ensure no unwanted access, 
including imposed restrictions of read-only and write privileges to sections of the database. 
Data backup was in place as alternate servers provided backup and input validation to ensure 
that incorrect data was not inputted into the database. Data validation ensured high-quality 
transmission of data without corruption from the sources. Outlier values were deleted, and no 
coding changes occurred throughout the existence of the register (Gliklich Dreyer, & Leavy, 
2014). 
In this study power and sample size calculation was performed in order to ensure that the 
differences between the variables under consideration are accurate thereby avoiding type II 
error (Hulley et al. 2013; Chow, Shao & Wang, 2008; Jones, Carley, & Harrison, 2001). One 
constraint to ascertaining the sample size was the limited number of T1D participants in this 
cohort from the database. However, to ensure the sample size was sufficient to create an 
adequate effect estimate, a consideration of the sample sizes of a systematic review looking at 
mortality in T1D was used for the power calculation. The review had six cohort studies done 
in the UK, with sample sizes varying from 128 to 25,752 participants. Two of the studies 
included used registers of T1D and had populations of 828 and 1,854 participants. To estimate 
a sample size between 1000 and 1500 was, therefore, an appropriate sample size for this study 
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(Edge, Ford-Adams, Dunger, 1998; Liang et al. 2003; Robert et al. 2004; Swerdlow et al. 
2004).  
The power of this study was dependent on the variables being measured. Below is the probable 
power (effect size) calculation for this study with an approximate number of 1300 participants 
using the means effect sizes. Instead of taking the effect size as the input and calculating the 
group sizes, this calculation took the group sizes as inputs and calculated the effect size that 
the study had (1 - β) power to detect. The effect size was then calculated in two different ways: 
first using the T statistic (with a non-centrality parameter), then using the Z statistic. The Z 
statistic approximates the T statistic but provides an effect size that is slightly too small. 
However, the Z statistic calculation was considered appropriate because it allowed comparison 
with other calculators that use the Z approximation. 
𝛼 (𝑡𝑤𝑜 − 𝑡𝑎𝑖𝑙𝑒𝑑)  =  0.05 Threshold probability for rejecting the null hypothesis. Type I error 
rate. 
𝛽 =  0.2 Probability of failing to reject the null hypothesis under the alternative hypothesis. 
Type II error rate. 
𝑇𝑜𝑡𝑎𝑙 𝑔𝑟𝑜𝑢𝑝 𝑠𝑖𝑧𝑒 =  𝑁𝑡𝑜𝑡𝑎𝑙  =  𝑁1 + 𝑁0 =  1300  
The proportion of subjects in Group 1 (𝑞1) = 𝑁1 𝑁 𝑡𝑜𝑡𝑎𝑙⁄ =  0.846 
Proportion of subjects in Group 0 (𝑞0) = 1 −  𝑞1 =  0.154  where q1 is Proportion of subjects 
that are in Group 1 (exposed) and q0 is the proportion of subjects that are in Group 0 
(unexposed); 1-q1 
1. Calculation using the T statistic and non-centrality parameter: 
Degrees of freedom (𝐷𝑜𝐹) =  𝑁𝑡𝑜𝑡𝑎𝑙 − 2 = 1298 
The standard T value corresponding to α (𝑇𝛼) = 1.962 
Where K is the non-centrality parameter, E is the effect size, and S is the standard deviation of 
the outcome in the population. 
𝑘 = √(1 𝑁1
⁄ + 1 𝑁0
⁄ ) =  0.07687𝐾  
Non-centrality parameter (𝛿)  =  2.80371 
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𝐸 
𝑆⁄ =  𝑘 ∗  𝛿 =  0.21552  
This study has 80.0% power to detect an effect size of 
𝑬 =  𝑺 ∗ 𝐸 𝑆⁄ =  𝟎. 𝟖𝟎𝟒  
2. Normal approximation using the Z statistic instead of the T statistic: 
Standard normal deviate for 𝛼 =  𝑍 𝛼 =  1.95996 
Standard normal deviate for 𝛽 =  𝑍 β =  0.84162 
𝐴 =  (𝑍 𝛼 +  𝑍 β)
2 =  7.84887 
𝐵 =  1 𝑞 1
⁄ +  1 𝑞 0
⁄ =  7.68182 
𝐶 =  𝐴𝐵/𝑁total =  0.04638 
𝐸
𝑆⁄ =  √𝐶 =  0.21536 
This study has  80.0% power to detect an effect size of 
𝐸 =  𝑆 ∗ 𝐸 𝑆⁄ =  0.803  
Because the formula used here is based on approximating the T statistic with a Z statistic, it 
slightly underestimated the effect size for smaller values of Ntotal (Hulley et al. 2013). Hence, 
the total number of 1300 participants was required for 80% power for this study. 
2.2.5 Hypothesis testing 
This study examined the following hypothesis: 
Null Hypothesis H0: There will be no significant difference in mortality in T1D by the impact 
of the predictor risk factors except that due to chance. 
Alternate Hypothesis H1: The predictor risk factors will predict mortality in T1D 
2.2.6 Eligibility criteria 
Inclusion 
Participants were included in the study if they met the following criteria: 
• Diagnosis of T1DM confirmed by healthcare practitioners in primary and secondary 
care and registered in the register  
• Patients who were commenced on insulin therapy at diagnosis. 
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Exclusion 
• Patients with T2DM confirmed and registered in the register 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Study flow chart 
2.2.7 Measurement of Clinical Parameters 
The measurement of various outcomes of interest biochemically was done using the cobas® 
8000 modular analyser series. The 8000 series modular platform is a high volume analyser 
capable of conducting 2000 test/hour comprised of four units. The platform consists of a core 
unit, high volume clinical chemistry modules (Cobas c 701 module and Cobas c 702 module), 
medium volume clinical chemistry module (Cobas c 502 module) and an immunoassay module 
(Cobas e 602 module). 
Total Patients in database (23,786) 
 
                              Total T1DM 
N= 1786 (7.5%) 
Total T1DM Included below the age of 40 years  
N=1468 (6.2%) 
Participants selected meeting inclusion criteria 
N= 1468(6.2%) 
Total T2DM 
Excluded due to 
exclusion criteria 
Excluded based 
on study follow 
up period 
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The process of analysing plasma glucose was the enzymatic hexokinase method of 
phosphorylation of glucose in the Cobas analyser CLUC3 (McGlothlin, & Jordan, 1975; Junge, 
Wilke, Halabi, & Klein, 2004). The measurement of HbA1c utilised an automated ion-
exchange chromatographic method (HPLC). The units to which HbA1c was reported in the 
DCCT trial served as a reference for reporting in this study. The results were standardised by 
the International Federation of Clinical Chemistry (IFCC) using the formula: 
𝐼𝐹𝐶𝐶 𝑢𝑛𝑖𝑡 𝐻𝑏𝐴1𝑐 (𝑚𝑚𝑜𝑙/𝑚𝑜𝑙)  =  [𝐷𝐶𝐶𝑇 𝐻𝑏𝐴1𝑐 (%) − 2.15] × 10.929 
Serum creatinine was initially measured using alkaline picrate (Jaffe) method and then 
underwent a method of enzymatic and high-performance liquid chromatography (HPLC) 
which was standardised using an isotope dilution mass spectrometry (IDMS) (Delanghe, & 
Speeckaert, 2011).  
The enzymatic colourimetric method was used to assay levels of total cholesterol (TC). The 
Friedewald equation was used to ascertain levels of LDL  
𝐿𝐷𝐿 =  (𝑡𝑜𝑡𝑎𝑙 𝑐ℎ𝑜𝑙𝑒𝑠𝑡𝑒𝑟𝑜𝑙 –  𝐻𝐷𝐿 𝑐ℎ𝑜𝑙𝑒𝑠𝑡𝑒𝑟𝑜𝑙 –  𝑡𝑜𝑡𝑎𝑙 𝑡𝑟𝑖𝑔𝑙𝑦𝑐𝑒𝑟𝑖𝑑𝑒) ÷ 2.19 
The Cobas Core Immunoassay analyser is the automated system used to assay levels of TSH; 
it utilises a big bead EIA technology (Michotey et al. 1995). 
2.2.8 Measurements during clinic sessions 
Clinic sessions involved initial checks and records of weight, height, and blood pressure. The 
automated BP machine (Omron T4) was used in BP measurements. Clinic sessions also 
involved the confirmation of demographic parameters of age, sex, address, smoking and 
alcohol status. Obtaining IMD scores from postal codes was done electronically, extracted from 
the Department for Communities and Local Government website. 
2.2.9 Handling missing data and dropouts 
Missing data is defined as data value not recorded for a variable of interest in a set of 
observations of interest. Handling of missing data is essential as poor handling of this aspect 
of research can affect the conclusions drawn from data analysed (Kang, 2013; Graham, 2009). 
For this study, the definition of missing data was unrecorded data in more than two places for 
age at diagnosis, age at death and duration of diabetes. Dropouts for this study refer to data for 
participants for which all variables are missing. The approach to handling missing data was to 
statistically use Little’s Missing at Random Test (MCAR) for random missingness (Lindsey, 
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2000). Instead of excluding missing values in a listwise approach, the decision was to 
incorporate this data because of information from other non-missing variables for participants. 
This was to preserve the analytic robustness of the data (Diggle, & Kenward, 199; Little, 1995; 
Kang, 2013). 
Missing data were as follows: gender (128), HbA1c (382), Creatinine (203), Cholesterol (332), 
Triglycerides (277), HDL (516), LDL (376), TSH (264), SBP (523), DBP (523), and BMI 
(555). 
2.2.10 Measurement of parameters and Definition of Variables 
The variables of interests that were measured during this study were gender, age and year of 
diagnosis, duration of diagnosis, age at death, and the year at death. Others were BMI, TSH, 
TG, HDL, LDL, DBP, SBP, serum creatinine, HbA1c and mortality status. 
Lipids profile 
Lipids are defined as a subset of essential fatty acids involved in several functions such as the 
stabilisation of biological membranes, hormone transport and receptor signalling. 
Biochemically, they are measured to approximate the risk of development of cardiovascular 
disease (Orozco-Beltran et al. 2017). The parameters measured in the lipid profile test are total 
cholesterol; Low-density lipoprotein (LDL) cholesterol in high amounts deposit in the intima 
layer of blood vessels precipitating atherosclerosis and increasing the risk of developing 
cardiovascular disease. High-density lipoprotein (HDL) cholesterol aids in the transport of 
cholesterol from blood vessels back to storage in the liver as well as other regulatory functions. 
High levels of HDL are regarded as being protective and has an inverse correlation to the risk 
of developing cardiovascular disease (Ridker et al. 2010). Triglycerides are essential for energy 
production. However, very high levels are a risk factor for the development of cardiovascular 
diseases. The European Atherosclerosis Society Consensus Panel (2013) and the Third Report 
of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, 
and Treatment of dyslipidaemia in Adults (Adult Treatment Panel III) (2002) specify lipid 
profiles and their categorical risk values as shown in Table 2.6. 
Table 2.6: Lipid profiles and categorical risk for the general population including T1D 
Risk Categories LDL Cholesterol (mmol/L)  
Optimal ≤ 2.59 
Near optimal 2.59 - 3.34   
Borderline high 3.37 - 4.1 
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High 4.15 - 4.90 
Very high ≥ 4.90 
Risk Total Cholesterol (mmol/L) 
Desirable ≤  5.18  
Borderline high 5.18 - 6.18  
High ≥ 6.22  
Risk TG (mmol/L) 
Desirable ≤ 1.70 
Borderline high 1.7 - 2.2 
High 2.3 - 5.6 
Very high ≥ 5.6  
Risk Non-HDL Cholesterol (mmol/L) 
Optimal 3.37 
Above optimal 3.37 - 4.12 
Borderline high 4.15 - 4.90 
High 4.9 - 5.7 
Very high ≥ 5.7 
HDL Cholesterol (mmol/L) 
Risk Males Females 
Low level, increased risk ≤  1.0 ≤  1.3 
Average level, average risk - 1.3 1.3 - 1.5 
High level, less than average risk ≥ 1.55 ≥ 1.55 
 
Treatment recommendations from the NCEP Adult Treatment Panel III guidelines suggest that 
levels of LDL remain essential in mitigating the development of cardiovascular complications 
and management if individuals have the following: 
• ≤  2.59 mmol/L with diabetes or cardiovascular condition  
• ≤ 3.37 mmol/L with 2 or more risk factors 
• ≤ 4.14 mmol/L with 0 or 1 risk factor  
TC/HDL and LDL/HDL ratios also play essential roles in the onset and prognosis of 
cardiovascular conditions (Reeder et al. 1997; Wang et al. 2002; Genest, Frohlich, Fodor, & 
Mcpherson, 2003; Gambardella et al. 2011; Qing-Jie et al. 2016). The categorisation of 
associated risk is shown in Table 2.6, 2.7 and 2.8. 
Table 2.7: Lipid Profiles (TC/HDL-C) of the general population including T1D   and 
associated risk of developing cardiovascular complications for both men and women. 
TC/HDL ratio 
Risk category Men Women 
Very Low <3.4 < 3.5 
Low 4.0 3.8 
Average 5.0 4.5 
Moderate risk 9.5 7.0 
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High Risk >23 >11 
 
Table 2. 8: Lipid Profiles (LDL/HDL) among male and female that are associated with the 
risk of cardiovascular complications in the general population including T1D. 
LDL/HDL ratio 
Risk categories Men Women 
Very Low 1.0 1.5 
Average risk 3.6 3.2 
Moderate risk 6.3 5.0 
High risk 8.0 6.1 
 
Table 2.9: Lipid ratios (TC/HDL LDL/HDL) among male and female that are associated with 
the risk of cardiovascular complications in the general population including T1D. 
Ratio Primary prevention Secondary prevention 
 Risk level Target Risk Level Target 
 Men Women Men Women Men Women Men Women 
TC/HDL >5.0 >4.5 <4.5 <4.0 >4.0 >3.5 <3.5 <3.0 
LDL/HDL >3.5 >3.0 <3.0 <2.5 >3.0 >2.5 <2.5 <2.0 
 
Serum creatinine levels 
Serum creatinine levels serve as an essential variable in the assessment of kidney function. It 
is used to estimate the glomerular filtration rate (GFR) which assesses kidney function. 
Elevated creatinine levels are an indication of worsening renal function. A level of creatinine 
≥ 177µmol/L is an indication of nephropathy (Baumgarten, & Gehr, 2011; Mendelssohn et al. 
1999). One of the complications of T1D is diabetic nephropathy and manifest in its earliest 
form as microalbuminuria. This is evident in approximately half of all patients with T1D and 
occurs at a rate of 3% annually. The progression of diabetic nephropathy leads to chronic renal 
failure and end-stage renal failure manifesting biochemically with abnormal creatinine and 
glomerular filtration rates (GFR). Diabetic nephropathy is a risk factor for the development of 
cardiovascular complications and all-cause mortality in T1D (Daniels et al. 2013; Parving, & 
Hommel, 1989). Although the standard estimate for kidney function is obtained from the eGFR 
- Estimated glomerular filtration rate, due to the historical nature of the database, values 
obtainable  were creatinine level, hence it use as a proxy for kidney function.  
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Table 2.10: Normal creatinine levels and albumin: creatinine ratio in the general population 
including T1D 
Body Mass Index (BMI) 
The WHO (2016) defines the Body Mass Index (BMI) as a simplistic assessment of weight-
for-height. It is estimated by dividing the weight in kilograms by the square of the height in 
metres (Kg/m2). It is the 
measure of classification of 
underweight, 
overweight and obesity in 
adults. The measurement of this parameter was important because of its correlation as a risk 
factor for the early onset of T1D (Abbasi et al. 2017; de Vries et al. 2014; Giménez et al. 2007). 
Table 2.11: Body mass index (BMI) classification in the general population including T1D 
Classification BMI (Kg/m2). 
Underweight < 18.5 
Normal range 18.5 -24.99 
Overweight ≥ 25.00 
Pre-obese 25.00 – 29.99 
Obese class I 30.00 – 34.99 
Obese class II 35.00 – 39.99 
Obese class III ≥ 40 
The international classification of adult underweight, overweight and 
obesity according to BMI : (Adapted from WHO 2017) 
 
The IMD (index of multiple deprivations) 
It is a variable that represents a measure of relative deprivation from some regions of the 
country referred to as Lower Super Output Areas (LSOA). These areas are fixed statistical 
locations assigned by the ONS having approximately 1500 people. In England, IMD ranks 
these small areas from 1 to 32,844 which corresponds from most deprived to the least deprived. 
IMD is a measure extrapolated by evaluating 37 indicators categorised into seven domains with 
differential weighting. These are Income Deprivation (22.5%), Employment Deprivation 
(22.5%), Education, Skills and Training Deprivation (13.5%), Health Deprivation and 
Disability (13.5%), Crime (9.3%), Barriers to Housing and Services (9.3%), and Living 
Environment Deprivation (9.3%). The postcodes of individual participants in the study were 
allocated to LSOA, for which their respective IMD score was extrapolated. These were 
classified into quintiles from 1 [most deprived] to 5 [least deprived] (Abel, Barclay, & Payne, 
2016; Newton et al. 2015). 
Gender The normal range of creatinine levels (µmol/L) 
Male 44 – 80 
Female 62 - 106 
Albumin creatinine ratio (mg/mol) normal values 
Males Females 
< 25 < 35 
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2.2.11 Death Ascertainment 
Records of mortality as inputted in the register were triangulated with case notes that could be 
retrieved and with data from the online database of the general register office. The input of 
mortality statistics followed a standardised format that had the following details date of birth, 
sex, NHS number, and date of death. These parameters were anonymised for analysis; NHS 
number was required for matching data but deleted for analysis.  
Cause of mortality status as recorded in the case notes utilised classification from the 
International Classification of Diseases (ICD), Tenth Revision [ICD-10]. ICD-10 classifies 
cause of death into a grid system. This classified some causes of death with the following codes 
Diabetes (E10 - E14), Septicaemia (A40-A41), Cancer (C00-C97), Acute myocardial 
infarction (I21 - I22), and Cerebrovascular disease (I60 - I69). In cases where the cause of death 
was inconsistent, records from the general register office were preferred. Records of diabetes 
as the direct cause of death is significantly lower at 39%, even though it contributes 
significantly to other causes of death such as cardiovascular syndromes (McEwen et al. 2006). 
Recommendations from ICD suggest that diabetes can be regarded as the principal cause of 
death if mortality was secondary to its complications (hypoglycaemia and other metabolic 
complications). Table 2.12 elaborates on causes of death into an item list as identified from the 
WDR. 
 
 
 
 
 
 
 
Table 2.12: International Classification of Diseases, Tenth Revision [ICD-10], causes of 
death and codes 
Item List Cause of death ICD-10 classification 
1 Diabetes E10 - E14 
2 Cerebrovascular disease I60 - I69 
49 
 
3 Septicaemia A40-A41 
4 Cancer C00-C97 
5 Acute myocardial infarction I21 - I22 
6 Other major cardiovascular diseases I71 - I78 
7 Pneumonia & influenza J09 - J18 
8 Chronic lower respiratory diseases J40 - J47 
9 Chronic liver disease & cirrhosis K70, K73 - K74 
10 Renal failure N17 - N19 
11 Heart disease I00 - I09, I11, I13, I20 - I51 
12 Alzheimer's disease G30 
13 Other infections and parasites 
A00-A09, A20-A39, A42-A49, 
A54-A99, B00-B19, B25-B99 
14 Other accidents & adverse effects 
V01, V05 - V06, V091, V093 - 
V099, V10 - V11, V15 - V18, 
V193, V198 - V199, V800 - 
V802, V806 - V809, V812 - 
V819, V822 - V829, V879, 
V889, V891, V893, V899, V90 
- X599, Y85 - Y869 
14 Parkinson's disease G20 - G21 
 
2.2.12 Allocation of Comparison group 
This study-utilised comparison groups from the resident population in the cohort database, 
local population estimates from the Wirral, and the national population estimates for the years 
within the study period. The national population estimates were used as controls and were 
estimated from mid-year estimates of England and Wales for the period under consideration. 
The local population estimate used for comparison was computed by deducting the TID 
population from the local Wirral population estimates at the time. The use of the resident 
population (internal comparison) within the cohort ensured the closest possible match in patient 
characteristics. This method of comparison provides a unique perspective of comparison for 
ascertaining the temporal sequence between exposure and outcome measures. For T1D, it helps 
to explore multiple outcomes with relative ease, accessibility to data, and less expensive in 
approach. To allow for the use of the general population for comparison, adjustments had to be 
made by stratifying the population according to gender, age, socioeconomic status, and other 
confounding variables. In assessing the use of the general population, it was necessary to note 
that a minute number of people in the general population who were unexposed could be liable 
to exposure to T1D as the period of study progressed. This had the impact of limiting the precise 
effect estimates for this study. Standardised mortality rates were used to quantify the magnitude 
of the association. 
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2.2.13 The process of data management and data analysis  
The process of data analysis had a preparatory stage of data management that involved setting 
up the database into an appropriate format, in preparation for analysis. This involved the 
selection of the appropriate parameters or conversion to the required format for analysis. For 
scientific quality and integrity of data extrapolated from the database, it was essential first to 
categorise data with specified variables as follows 
• Predictor or outcome variables: Mortality status, development of retinopathy 
• Intervening variable (mediating variable): referred to as the possible variable used to 
explore the causal link between variables, this was the diagnosis of T1D. 
• Independent or Explanatory variables: defined as a variable the has a possible influence 
on the outcome variable. In this study, these variables were gender, age, age at 
diagnosis, duration of diabetes, age at death, BMI, smoking status, HbA1c, TC, TG, 
LDL, HDL, TSH, SBP, DBP. 
The next stage was to ensure the data met the required scale of measure in preparation for input 
into the required statistical package. This was to determine if the variable to be inputted was a 
nominal, ordinal, or a scale variable. The nominal variables were categorical variables, having 
no kind of order and inputted as string or numeric equivalents; an example was sex. The ordinal 
variables referred to variables that had possible order example were smoking and IMD. The 
scales variables had origin; order and interval, some variable represented accordingly were 
BMI and HbA1c. All data were classified as nominal, ordinal or scale variable. 
The Statistical Package for the Social Sciences (SPSS) IBM software Version 24 was used for 
statistical analysis. Step in ensuring the appropriateness of data for analysis by SPSS included 
the following: 
• Descriptive statistics for appropriate variables which included minimum and maximum 
values, mean, median, variance, range, interquartile range, variance and standard 
deviation 
• Incidence analysis for categorical variables 
• Test for normality and homogeneity for appropriate variables 
• Recognising and tackling missing values and outliers 
• Re-coding and converting variables when it was appropriate 
• Re-run of frequency distribution checks for recoded variables. 
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Before the process of data analysis began, checks were made to ensure that the appropriate 
tests were used for analysis to minimise error (view decision making table on the appropriate 
Statistical Test in appendix).  
2.2.14 Statistical Methods and Data Analysis 
Before the onset of data analysis, validity checks were done to minimise errors. The use of 
parametric tests in the analysis was based on the following assumptions: 
• Normality: Data had a normal distribution (or at least is symmetric), or drawn from a 
population with normal distribution on the explanatory variable. 
• Interval or ratio scale of measurement 
• There was a random selection of the members of the cohort from a defined population. 
• Homogeneity of variances: Data from multiple groups have the same variance. 
• Linearity: Data have a linear relationship. 
• Independence: Data are independent. 
A model assumption for parametric tests was to ensure that a test of normality was done 
employing the use of the Kolmogorov-Smirnov test (> 100 participants). The test required that 
if the p-value ≥ 0.05, then the explanatory variable under consideration was normally 
distributed. Alternatively, if the p-value was <0.05, then the assumptions for normal 
distribution had failed, leading to the consideration of non-parametric tests for analysis. When 
conditions of normality were violated then consideration favoured the used of median and 
interquartile (IQR) ranges (a measure of variability) as appropriate measures of comparison for 
continuous variables. In normality-distributed conditions, the mean, and standard deviation 
were appropriate for continuous variables.   
Model assumptions for parametric tests at the level of interval data also required that data meet 
the requirement of homogeneity of variance. This was computed by using the Levene's test; if 
the p-value was < 0.05, this assumption was violated.  
The unpaired t-test was used to explore differences between two independent variables that had 
a normal distribution pattern, the Mann Whitney ‘U’ test was used to ascertain differences 
between the comparison groups when they were at an ordinal level of data. The Chi-squared 
(X2) test was used as a test for difference in nominal or categorical variables of independent 
groups. For the Chi-squared test, significantly observed associations was at p-value <0.05. 
With groups of nominal data, McNemar’s test was used to ascertain any changes in the groups. 
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For repeated measures within matched pairs, Wilcoxon Signed ranked test was the non-
parametric approach to explore any differences between the matched pair. Evaluations, when 
continuous data was involved, employed the use of ANOVA. Correlations to determine levels 
of associations between variables employed the use of Chi-squared test of association and 
Spearman’s correlation coefficient respectively when the variables were either nominal or 
ordinal.  
Re-coding and stratification of variables with normal distribution was done to minimise the 
advent of type I and type II errors. The process of re-coding and stratification applied to the 
following variables sex, IMD, TC, TG, LDL, HDL, SBP, DBP, TSH, and serum creatinine. 
Others included age at diagnosis, age at death, and duration of diagnosis.  
Glycaemic control using HbA1c was recoded into categories of deciles:  HbA1c (% ) 
[mmol/mol] ≤ 5.9 [≤41], 6.0-6.4[42-46], 6.5-6.9[48-52], 7.0-7.4[53-57], 7.5-8.0[58-64], 8.1-
8.4[65-68], 8.5-9.0[69-75], 9.1-9.4[76-79], 9.5-10[80-86], ≥ 10.1[>87]. 
Classification based on socioeconomic status was via the parameter IMD, following an 
organization into quintiles; Quintile 1 [most deprived], Quintile 2 [above average], Quintile 3 
[average], Quintile 4 [below average], Quintile 5 [least deprived]. Smoking status was initially 
categorised based on the following responses; non-smokers, smokers, ex-smokers and never 
asked and then realigned into the categories never smoked, smokes and ex-smokers. 
Classification of weight was aligned into the following classification; BMI [kg/m2] 
Underweight [< 18.5], Normal range [18.5 -24.99], Overweight [≥ 25.00], Pre-obese [25.00 – 
29.99], Obese class I [30.00 – 34.99], Obese class II [35.00 – 39.99], Obese class III, [≥ 40]. 
Values for serum creatinine (µmol/l) were categorised into quintiles of < 61, 62-106, 107-129, 
130-149, and ≥ 150. For ease of analysis 3 of these categories were important 107-129 µmol/l 
corresponding to (GFR 45-89ml/min/1.73m2 or mild or stage 2 CKD), 130-149 µmol/l 
corresponding to (GFR 30-45ml/min/1.73m2 or moderate or stage 3 CKD) and ≥ 150 µmol/l 
corresponding to (GFR < 30ml/min/1.73m2 or severe or stage 4 and 5 CKD). Systolic blood 
pressure (mmHg) were categorised into quintiles of ≤ 99, 100–119, 120–139, 140–159, and 
≥160. Diastolic blood pressure (mmHg) were categorised into sextiles of  ≤ 59, 60-69, 70 – 79, 
80 – 89, 90- 99, and ≥100. 
In considering the lipid profiles, values for total Cholesterol [TC] (mmol/L) were initially 
categorised as desirable ≤ 5.18, borderline high 5.18 - 6.18 and high ≥ 6.22 but transformed 
into quintiles in the following order; ≤ 3.9, 4.0-4.5, 4.6-5.2, 5.3-6.1, and ≥6.2. The values 
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obtained for total triglycerides [TG] (mmol/L), had initial classifications of desirable ≤ 1.70, 
borderline high 1.7 - 2.2, high 2.3- 5.6, and very high ≥ 5.6 but re-classified into tertiles of  ≤ 
1.6, 1.7-2.2, ≥ 2.3 to allow for ease of comparison. The values for LDL (mmol/L) had a 
classification into quintiles of optimal ≤ 2.59, near optimal, 2.59 - 3.34, borderline high 3.37 - 
4.1, high 4.15 - 4.90, and very high ≥ 4.90. HDL (mmol/L) was classified into quartiles of 0.4-
0.7, 0.8-1.1, 1.2-1.5, and ≥ 1.6. TC/HDL ratio was organised into tertiles of ≤ 3.5, 3.6-5.0, and 
≥ 5.1, and LDL: HDL ratio into tertiles of ≤ 1.5, 1.6-3.6, and ≥ 3.7. 
The classification of the age of diagnosis, the age of death or censored was categorised into 17 
age groups 0 – 4, 5 – 9, 10 – 14, 15 – 19, 20 – 24, 25 – 29, 30 – 34, and 35 – 39. Adjustments 
were made to account for the variability of effect sizes according to age and sex using the 
standard population of the Wirral peninsula obtained from mid-year population estimates for 
the study period. 
In ascertaining event history analysis, it was essential to establish a follow-up period for the 
study. This period was set from the 1st of January 2000 to the 31st of December 2012. This 
period coincided with the period when the database was quality appraised and the beginning 
of the close of the register. Due to the variability at which participants entered into the study, 
it was essential to establish person-time for the study. This was done to establish the actual 
time for which every participant in the study was at risk (in years). This allowed for the 
estimation of incidence rates, prevalence rates, relative risk, and absolute risk. The prevalence 
rate was the statistical estimation of the number of participants with T1D at a particular given 
time. The incidence rate was an estimation of the number of new cases or diagnosis made 
within a specified period. The incidence and prevalence rates allowed for the computation of 
the relative risk defined as the comparison of the probability of a health event occurring in an 
exposed group (T1D population) as compared to the control group in a given period. In the 
analysis of mortality in this population subset, an estimate for the absolute excess risk was 
computed, this variable determines the difference between the observed mortality and expected 
mortality in the exposed and control groups divided by the person-years at risk. Standardised 
mortality ratios (SMR), provided computed estimates of the ratios of mortality observed in the 
study population as compared to the expected number of deaths while considering the age and 
sex-specific rate of standard populations and their 95% confidence intervals (95% CI). 
Computation of the SMRs utilised the formula below; 
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𝑆𝑀𝑅
= (𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑑𝑒𝑎𝑡ℎ𝑠 𝑖𝑛 𝑒𝑎𝑐ℎ 𝑎𝑔𝑒 𝑔𝑟𝑜𝑢𝑝 𝑖𝑛 𝑇1𝐷) × 100 𝑒𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝑑𝑒𝑎𝑡ℎ𝑠
÷ (𝐴𝑔𝑒 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑚𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦 𝑟𝑎𝑡𝑒)(𝑡𝑜𝑡𝑎𝑙 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑖𝑛 𝑇1𝐷 𝑖𝑛 𝑒𝑎𝑐ℎ 𝑎𝑔𝑒 𝑔𝑟𝑜𝑢𝑝) 
Values for relative mortality and excess mortality were also estimated. The relative mortality 
was an estimate of the division of the observed mortality by the expected mortality while the 
excess mortality was the observed difference between the observed mortality and expected 
mortality (Elie et al. 2011; Lau, Cole, & Gange, 2009). Estimates for the age-specific, age-
adjusted and sex-specific mortality rates were computed. The age-specific mortality rate is an 
estimate of the total number of deaths for each age group per 1000 populations in a given year. 
The estimations of age-specific, age-adjusted and sex-specific mortality rates allowed for 
mitigating the influence of age and sex in this cohort, it also allowed for overall comparisons 
to the national estimates.  
A complex algorithm was designed using Cox regression with left-truncation used to provide 
reliable estimates of competing risks as stratifying factors; this method allowed for 
computation of survival analysis using the Kaplan-Meier method. The Cox regression model 
was also used to allow for the computation of hazard ratios of mortality. In sub-group analyses 
of repeated measures, multiple linear regressions analysis considered the variables of HbA1c, 
SBP, and DBP as dependent variables, while the variables of age, sex, smoking duration of 
T1D, BMI, and socioeconomic status were considered as independent variables. The Cox 
proportional hazard model made provisions for the analysis of risk factors as continuous 
covariates. Log cumulative hazard plots were obtained using the assumptions of the 
proportional hazard model, for all variables of the competing risk. The covariates for the Cox 
proportional model were gender, systolic BP (mmHg), diastolic BP (mmHg), smoking status, 
serum creatinine (µmol/l), HbA1c (%), BMI (kg/m2), IMD quintiles, total cholesterol 
(mmol/l), high-density lipoproteins (mmol/l), low-density lipoproteins (mmol/l), triglycerides 
(mmol/l), TC/HDL ratio, LDL/HDL ratio, age at diagnosis, and duration of diagnosis. 
Adjustments were made to determine which variables were significant and on which the Cox 
model was dependent. Computation of within subgroup sensitivity analysis ensured a 
determination of specific subgroups that contributed to the hazards ratios obtained.  
The register and supporting information from available case notes allowed for the computation 
and analysis of large amounts of data; however, this study focussed on the following areas for 
analysis: 
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• Glycemic levels and mortality 
• All-cause mortality 
• Biochemical parameters and mortality 
• Socioeconomic status and mortality 
• Life expectancy  
• Analysis of microvascular complications in which retinopathy was used as a proxy 
The analysis of life expectancy of the participants in this study utilised the abridged model 
extrapolated using SPSS, following principles set out by Reed & Merrell (1997). This method 
utilised an age-specific mortality rate for specific age bands. However, there was a potential 
for skewed observations because of the relatively small sample sizes and small numbers of 
observed death.  
Additionally, Years of Potential Life Lost (YPLL) were also calculated. This is a measure of 
premature mortality for each participant that died during the study period. This allowed 
comparative analysis of excess mortality in T1D study participants were compared to the 
standard population. Median survival, defined as a statistical measure of survival for study 
participants, was also computed. 
The objectives of this study were: 
• To evaluate factors relating to all-cause mortality, cardiovascular and non-
cardiovascular mortality 
•  To examine the role of variables such as socioeconomic status, smoking status, body 
mass index, blood pressure measurements, glycaemic control, lipid profile, 
nephropathy, and retinopathy as predictive risks of mortality 
• To evaluate the influence of age at diagnosis, duration of diabetes, year of diagnosis 
and gender on mortality. 
• To evaluate life expectancy and mortality patterns in T1D 
In summary, this chapter provides an overview of the conduct of this research. The next chapter 
is a systematic review that explores current global evidence on trends in mortality risk for T1D 
relative to the general population, including all-cause, cardiovascular and non-cardiovascular 
mortality. 
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Chapter 3: A Systematic Review and Meta-Analysis of All-Cause and Cause-Specific 
Mortality in Type I Diabetes Mellitus Including Gender Specific Risk and Time-Based 
Trends 
3.1 Introduction 
This chapter is a systematic review designed to review the research objective of establishing 
what the current evidence on trends in mortality risk is for T1D relative to the general 
population, including all-cause, cardiovascular and non-cardiovascular mortality. The 
diagnosis of T1D confers the risk of developing both micro- and macro-vascular complications 
which can be either acute or chronic. These complications contribute to the mortality index of 
T1D (IDF, 2013) with studies revealing mortality rates as high as 42.6 deaths per 100,000 
children in countries such as Sudan, and as low as 0.63 deaths per 100, 000 children in the USA 
(IDF, 2013). In the lower age groups (15- 34 years), there is increased risk of mortality of 
almost 3 times that of the general population which is attributed to acute metabolic 
complications. Diabetic ketoacidosis (DKA) is reported to account for 20% of deaths and 
hypoglycaemia is reported to account for almost 4% of deaths. For those in the older age groups 
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(above 30 years), mortality is primarily due to chronic complications including cardiovascular 
disease (CVD) which accounts for 10 times higher risk compared to the general population 
(National Diabetes Audit, 2011). One study reported that CVD accounts for the highest cause 
of death in T1D at 44% of all deaths, and diabetic nephropathy accounted for 21% of all-cause 
mortality. 
Some studies have proffered that T1D confers an increased relative risk of mortality as 
compared to the general population; however, there have been very few systematic reviews to 
attest to this finding. Only one study Lung et al. (2014) suggested an increased relative risk of 
mortality in T1D as compared to the general population with significant heterogeneity across 
studies included. However, there is a lack of research in ascertaining what the relative risk of 
mortality is in cause-specific complications of the T1D as compared to the general population.   
Another trend is the gender-specific mortality difference that T1D confers. Studies reveal that 
women with T1D possess an increased risk of mortality that could be as high as 9 times that of 
the general population, although this trend varied across studies (Dahlquist, and Källén, 2005; 
Soedamah-Muthu et al. 2006) but a systematic review showed an increased risk of premature 
mortality in women (Huxley, Peters, Gita, & Woodward, 2015). 
Management modalities in T1D have also witnessed significant improvements in the last 2 
decades such as the availability and use of insulin pumps, continuous glucose monitoring 
(CGM), use of statins to protect against atherogenic risk factors, and use of ace inhibitors for 
renal and cardiac protection. However, despite these advancements in treatment, there has been 
only marginal improvements in life expectancy with a 2014 Diabetes UK report showing that 
those with T1D can expect a reduced life expectancy of almost 20 years (Diabetes UK, 2014) 
as compared to 27 years in the 1970s (Goodkin, 1975). Some variations have been reported by 
various studies between 11 and 13 years by Livingstone et al. (2015) 16.5 years in the 1980s 
by Brown, Scott, & Moir, (2001), and 4 years by Miller et al., (2012). 
In summary, there is a lack of research to show what the relative risk of mortality is in cause-
specific complications of the T1D relative to the general population, the current discrepancy 
with variations in gender-specific mortality risk, and variations in life expectancy despite 
improvements in management modalities. The purpose of this study is to complete a systematic 
review and meta-analysis to establish all cause and cause-specific mortality as it relates to those 
with T1D, including gender-specific risk and time-based trends associated with the condition. 
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3.2 Methods 
Aim: Is to conduct a systematic review and meta-analysis, in order to present current evidence 
of all-cause and cause-specific mortality amongst T1D patients.  
Objectives 
• To assess all-cause mortality in T1D as compared to the general population. 
• To assess cause-specific mortality in T1D as compared to the general population. 
• To compute any gender variations in cause-specific mortality associated with T1D 
• To explore subgroup meta-analysis in showing time-based trends inT1D. 
3.2.1 Inclusion criteria for studies 
Studies were included if they meet the following methodological criteria; 
• Existing systematic reviews 
• Randomised Controlled Trials  
• Cohort studies 
• Epidemiological studies  
Population/types of participants and characteristics 
Studies included had participants diagnosed with Type 1 Diabetes before the age of 40 years, 
as it becomes progressively challenging to differentiate between type 1 and type 2 diabetes. 
Included also were individuals receiving insulin therapy within the first year of diagnosis, 
physician-diagnosed type 1 diabetes at enrolment. 
Comparator: The studies included had a comparison population that was either a comparison 
cohort or general population. 
Outcome measures: The outcome measures used were standardised mortality ratio (SMR) a 
form of relative risk (RR). Primary outcome of this study was. Overall mortality rates/all-cause 
mortality. Secondary outcomes for this study were; 
1. Gender and mortality risk 
2. Year of study baseline 
3. Follow-up duration 
4. Cause-specific mortality (overall and according to gender) 
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a) Cardiovascular disease (inclusive of coronary artery disease, myocardial infarction, 
heart failure/disease, ischemic heart disease) 
b) Cerebrovascular disease (stroke) 
c) Renal disease 
d) Cancer  
e) Accidents and suicide 
3.2.2 Exclusion criteria for studies 
Studies that did not explicitly meet the inclusion criteria were not included, any study that had 
a CASP score (Quality appraisal) less than 8 were excluded, other reasons for exclusion of 
studies were any studies whose participant acquired type 1 diabetes from a secondary cause; 
those that only had abstract without being able to access the full paper; studies that had diabetes 
alone without any differentiation between type 1 and type 2 diabetes; studies that never had 
any comparison population (either cohort or general population) and studies without adequate 
data for analysis were excluded. 
3.2.3 Search strategy 
A systematic, detailed search was conducted on both published and unpublished data that were 
eligible to meet the inclusion criteria. Databases were searched using MeSH terms and Boolean 
keyword phrases. An initial search was done covering electronic databases PubMed, Medline, 
Campbell Library of systematic reviews, Cochrane database of systematic reviews (CDSR), 
EMBASE and PAIS international, Cochrane Central Register of Controlled Trials 
(CENTRAL), LILACS, World Health Organisation Library and Information Network for 
knowledge database (WHOLIS), The Centre for Evidenced-Based Medicine, PsycINFO, 
National Library for Health, Ongoing Reviews database, British Nursing Index and SCOPUS  
(Higgins & Green, 2011). 
The search was extended to unpublished data such as the UK National Research Register 
(NRR), ReFeR, Kings Fund and Conference Papers Index. FADE, ProQuest Dissertation and 
mTheses, and other Indexed Citations up to 2015, National Technical Information Service 
(NTIS) and Health Management Information Service. Finally, a manual search of reference list 
of some studies was done to identify any potential studies that meet the inclusion criteria. 
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Studies included were written in the English language. Search period used was between 
January 1960 and March 2016 to provide an overview of trends about more recent evidence. It 
is also the period where significant changes in the management of T1D were instituted. 
3.2.4 Search Terms 
Keywords and phrases, including Medical Subject Headings (MeSH), will include; ‘‘Type 1 
diabetes mellitus mortality’’, “Type 1 diabetes mortality”, ‘‘mortality and type 1 diabetes’’, 
‘‘excess mortality and type 1 diabetes’’, ‘‘mortality rates and type 1 diabetes’’,  “Type I 
diabetes and mortality”, “Type 1 DM and mortality”, “Type 1 DM and mortality”, 
“determinants of mortality and type 1 diabetes”, ‘‘mortality predictors and diabetes’’.   
3.2.5 Data extraction and synthesis 
Data extracted from the studies were as follows; 1st Author (year of publication), Title and 
Design of study, Setting (year of Study), Study size [number deceased], Comparison 
population, Participants Characteristics (age range, male-female distribution), Definition of 
incident cases, Duration and follow up period and Outcome Measures. See table 1 in the results 
section 
3.2.6 Quality appraisal 
To ensure a transparent, rigorous process, quality appraisal was done using the Critical 
Appraisal Skills Programme (CASP) tool. A quality score was calculated for each of the 
included studies by AE, and these scores were verified and triangulated by HC and DBJ. Any 
discrepancies were discussed within the team to ensure transparency. (see appendix)  
3.2.7 Statistical analysis  
The software Review Manager (version 5.3) was used for statistical analysis, for the outcome 
all-cause mortality, the inverse variance method was applied using the random effect model to 
estimate the risk ratios (RR). The estimations of risk ratios (RR) involved calculating the log 
[SMR] and standard errors (SE), back-transformed to estimate the risk ratios (RR) at 95% 
confidence limit. The I-squared (I2) estimates were accessed to test for heterogeneity across 
studies. Other outcomes that employed the inverse variance method but used the fixed effect 
model of analysis were cardiovascular risk with T1D; renal mortality risk with T1D; and 
neoplasms mortality risk with T1D; likewise, subgroup analysis such as year of study published 
and follow-up duration employed the inverse variance method using the fixed effect model of 
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analysis. The outcomes of gender-specific mortality made use of dichotomous data employing 
the Mantel-Haenszel statistical method, using the random effect analysis model to estimate the 
average effect estimate of the measure risk ratio. The outcomes cardiovascular mortality risk 
according to gender also employed a similar method. The outcomes renal mortality risk 
according to gender, neoplasms mortality risk according to gender, cerebrovascular mortality 
risk according to gender, and accidents and suicides mortality risk according to gender 
employed the Mantel-Haenszel statistical method using dichotomous data but used the fixed 
effect model analysis. The decision to make use of either the random or fixed model of analysis 
was predicated on information retrieved from a book on meta-analysis written by Borenstein 
and colleagues in (2009). 
3.3 Systematic review results 
The result section will elaborate details on search results, study selection process, an overview 
of included studies, quality appraisal and meta-analysis. 
3.3.1 Search Results  
Table 3.1 shows a summary of the search process of accessing the databases. The study 
selection process involved a liberal search of electronic databases. This yielded a total of 
10,572 articles with subject heading related to T1D, after removal of duplicates (160) we were 
left with 10,412 articles, with the application of the inclusion criteria (at abstract level), 238 
articles were obtained, a full-text review of these 238 articles showed that 35 articles meet the 
inclusion criteria and these articles were used for qualitative and quantitative data synthesis 
(Figure 3.1). Following retrieval of these 35 studies, quality appraisal using the CASP tool 
(appendix VI) and full descriptive synthesis was done (table 3.3). 
Table 3.1: Initial study search process 
Database 
Search 
Search 
terms 
(Keywords) 
Date 
assessed 
(2015) 
Number of 
studies 
identified with 
the liberal 
screening of 
database 
Excluded due 
non-relevance 
to inclusion 
criteria and 
research 
question. 
Studies 
for more 
detailed 
evaluation 
Limit to the 
number of years 
and language 
restrictions 
(January 1960 to 
December 201)  
CINAHL 
Plus with full 
text 
“Type 1 
diabetes 
mellitus 
mortality.’’ 
1/03/16 1667 1607 60 Limit to 55 years, 
no language 
restrictions. 
PubMed 
Central 
“Type 1 
diabetes 
mellitus 
mortality.’’ 
1/03/16 4679 4642 37 Limit to 55 years, 
no language 
restrictions. 
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PubMed “Type 1 
diabetes 
mellitus 
mortality.’’ 
1/03/16 3011 2876 135 Limit to 55 years, 
no language 
restrictions. 
Cochrane 
Library 
“Type 1 
diabetes 
mellitus 
mortality.’’ 
1/03/16 554 552 2 Limit to 55 years, 
no language 
restrictions. 
WHOLIS “Type 1 
diabetes 
mellitus 
mortality’’ 
1/03/16 3 0 0 Limit to 55 years, 
no language 
restrictions. 
ProQuest “Type 1 
diabetes 
mellitus 
mortality.’’ 
1/03/16 592 588 4 Limit to 55 years, 
no language 
restrictions. 
LILACS “Type 1 
diabetes 
mellitus 
mortality’’ 
1/03/16 62 0 0 Limit to 55 years, 
no language 
restrictions. 
CAMPBELL “Type 1 
diabetes 
mellitus 
mortality’’ 
1/03/16 0 0 0 Limit to 55 years, 
no language 
restrictions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records identified through 
database searching  
(n =10,568) 
Records after duplicates removed  
(n =10,412) 
Records excluded (non-relevance 
to inclusion criteria)  
(n =10, 174) 
Additional records identified 
through other sources  
(n =4) 
Full-text articles excluded, with 
reasons (n= 203) 
• studies whose participant acquired 
type 1 diabetes from a secondary 
cause 
• Studies not based on human 
subjects 
• those that only had abstract 
without being able to access the 
full paper 
• studies that had diabetes alone 
Full-text articles 
assessed for eligibility  
(n = 238) 
Studies included in 
qualitative synthesis  
(n = 35) 
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Figure 3.1: Flow diagram of the study selection process adapted from the PRISMA statement 
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Table 3.2: Overview of included studies and initial descriptive synthesis 
       
S/
N 
1st Author 
(year of 
publication) 
Title and 
Design of 
Study 
Setting 
(year of 
Study) 
Study size 
[number 
deceased] 
Comparison 
population 
Participants Characteristics (age range, 
male-female distribution); Definition of 
incident cases 
Duration and 
follow up 
period 
 
Outcome measures 
 
1 
Asao et al. 
2003 
Retrospective 
cohort  study 
Japan 
and 
Finland 
(1994 to 
2003) 
6516 overall 
(1,390 Japan 
and 5,126 
Finland); 
[456 overall] 
With 
diabetes and 
the general 
population 
Japan (men 566, women 842), Finland (men 
2817, women 2309). Definition of cases for 
Japan gotten from attending doctors, 
residence registry, family registry, for 
Finnish cohort was from the National Social 
Insurance Institution with record linkage to 
the National Death Registry 
16.3 ± 3.8 and 
17.8 ± 4.5 
patient-years 
(mean follow 
up). The study 
was 25 years. 
All-cause mortality 
2 
Alleman 
2009 
Retrospective 
cohort  study 
Switzer-
land 
533 patients 
(225 type1, 
308 type2 
diabetes, 
52.2% men) 
were 
followed for 
30 years 
With 
Diabetes and 
the general 
population 
Protocol from the WHO Multinational Study 
of Vascular Disease in Diabetes 
30 years 
All-cause mortality, 
gender-specific 
cardiovascular and 
non-cardiovascular 
mortality 
3 
Barcelo 
2006 
Retrospective 
study 
USA and 
Cuba 
1391 overall 
(887 US and 
504 Cuba); 
[137 overall] 
With 
Diabetes and 
general 
population 
US (men 449, women 438); Cuba (men 259, 
women 226).Diagnosis by a physician, daily 
insulin injection before the 15th birthday. 
18.8 years 
All-cause mortality, 
acute complications, 
nephropathy, CVD, 
Infections, Unknown, 
others 
4 
Bosnyak et 
al. 2005 
Longitudinal 
study 
USA 1261 overall 
With 
Diabetes and 
general 
population 
(men 595, women 626); participants from 
two Type 1 diabetes incidence registries, the 
Allegheny County, PA Registry and the 
Children’s Hospital of Pittsburgh Registry 
 
All-cause mortality, 
Acute complications, 
chronic complications, 
Non-diabetes related 
causes 
5 
Bruno et al. 
2008 
Cohort study Italy 
1210 overall 
[19] 
No 
comparison 
(males 688, females 522)a population-based 
cohort of incident cases of the type 
1Diabetes Registry of the Province of Turin 
15.8 years 
All-cause mortality, 
Acute complications, 
chronic complications, 
Non-diabetes related 
causes 
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6 
Burnet et 
al. 2007 
Cohort study USA 
1238 overall 
[36] 
With 
diabetes 
(males 680, females 558); Childhood 
Diabetes Registry with a cohort of subjects 
diagnosed with diabetes before age 18 years 
7.75 years 
All-cause mortality, 
Acute complications, 
CVD, Infection, 
Trauma, other causes, 
unknown causes 
7 
Collado-
Mesa et al. 
1997 
Cohort study Cuba 
504 overall 
[70] 
With 
Diabetes and 
the general 
population 
(males 259, females 245) Registry data of 
onset of IDDM subjects, onset < 15 years 
17.5 years 
All-cause mortality, 
Acute complications, 
CVD, Infection, 
Trauma, other causes, 
unknown causes 
8 
Conway 
2012 
Cohort study USA 1098 adults 
Compared 
with 49,914 
without 
diabetes 
Registry data of onset of T1D subjects, onset 
< 30years years 
20 years 
All-cause mortality, 
cause-specific 
mortality (CVD, 
suicide, 
9 
Cooper 
2014 
Cohort study Australia 1309 
Compared 
with 6451 
without DM 
(males 660, females 649); Western 
Australian Children’s Diabetes Database and 
clinical data 
 
All-cause mortality, 
cause-specific 
mortality (CVD, 
suicide, 
10 
Dahlquist 
2005 
Cohort study Sweden  
Compared 
with control 
subjects 
Swedish childhood diabetes 
register 
15 years 
All-cause mortality, 
cause-specific 
mortality (CVD, 
suicide, 
11 
Dawson 
2008 
Cohort study 
New 
Zealand 
995 overall 
subjects 
Compared 
with the 
general 
population 
(261 females, 264 males); Canterbury 
Diabetes Registry 
20 years All-cause mortality 
12 Edge 1999 
Retrospective 
study 
UK 
128 subjects 
overall 
Compared 
with the 
general 
population 
The Office of National Statistics (ONS) and 
General Register Office for Scotland 
 
All-cause mortality, 
cause specific mortality 
(acute complications, 
cerebral edema). 
13 
Florkowski 
2002 
Prospective 
cohort study 
New 
Zealand 
995 
Compared 
with Type 2 
DM and the 
general 
population. 
(502 females and 493 males); The 
Canterbury Diabetes Registry 
15 years 
All-cause and cause-
specific death rates 
(Cardiovascular 
disease, Renal failure, 
Respiratory disease, 
malignancy). 
14 
Harjutsalo2
011 
Cohort study Finland 
17 306type 1 
diabetes 
Compared 
with and the 
Drug reimbursement register 21.4 years 
All-cause mortality, 
cause-specific 
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general 
population 
mortality 
(cardiovascular 
disease, renal failure). 
15 Laing 1998 Cohort study 
United 
Kingdom 
23 752 
diabetic 
patients 
No 
comparison 
Male to female ratio (62%: 38%); data from 
various register and GP clinics 
30 years All-cause mortality 
16 
Laing(a) 
2003 
Cohort study 
United 
Kingdom 
23 751 
diabetic 
patients 
No 
comparison 
Male to female ratio (62%: 38%);  data 
National Health Service Central Registers 
for patients from England, Wales 
28 years 
Cerebrovascular 
mortality 
17 
Laing(b) 
2003 
Cohort study 
United 
Kingdom 
23 752 
diabetic 
patients 
No 
comparison 
Male to female ratio (62%: 63%);  data 
National Health Service Central Registers 
for patients from England, Wales 
28 years 
Cardiovascular disease 
mortality 
18 
Laron-
Kenet 2001 
Cohort study Israel 
A whole-
country 
cohort of 
1861 
children 
with Type 1 
DM 
General 
population 
Male to female ratio (49%: 51%); data from 
Israel registry of Type 1 childhood diabetes 
31 years 
All-cause mortality, 
cause-specific 
mortality. 
19 Lin  2014 
Retrospective 
Cohort study 
Taiwan 
7,225 
incident 
cases of 
Type 
1Diabetes 
No 
comparison 
Male and female T1D was 3,471 (48%) and 
3,754 (52%); data from National Health 
Insurance Service 
10 years All-cause mortality 
20 Lind 2014 
Registry-
based 
observational 
study 
Sweden 
33,915 
patients with 
type 1 
diabetes 
Controls 
Total number (N = 33,915), females (N = 
15,302) 
13 years 
Cause specific 
mortality 
(cardiovascular 
disease, 
cerebrovascular 
disease). 
21 
Moss et al. 
1991 
Cohort study USA 
1200 
patients with 
type 1 
diabetes 
General 
population 
Diabetic persons were identified by a review 
of the records of 452 of the 457 physicians 
providing primary care to diabetic persons in 
the year beginning July 1, 1979. 
10 years 
All-cause mortality and 
cause-specific 
mortality. 
22 
Morimoto 
2013 
Cohort study Japan 
A total of 
1,385 
patients with 
a diagnosis 
General 
population 
Data were retrieved from two nationwide 
surveys conducted on childhood-onset 
diabetes in 1970 and 1981. 
40 years 
All-cause mortality and 
cause-specific 
mortality. 
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of type 1 
diabetes at 
age <18 
years 
23 
Nishimura 
2001 
Cohort Study USA 
1,075 
patients with 
type 1 
diabetes 
No 
comparison 
Females 517 and 558 males 
19 years 
minimum 
All-cause mortality, 
sex and race-specific 
mortality 
24 Otani 2014 Cohort Study Japan 
1054 
Japanese 
subjects 
diagnosed as 
T1D 
No 
comparison 
Males 386 Females 668; patients registered 
at the Diabetes Centre of Tokyo Women’s 
Medical University (TWMU) 
20 years 
All-cause mortality, 
cause-specific 
mortality (Acute 
diabetic complication, 
cardiovascular disease, 
Infections, cancers, 
suicide) 
25 
Pambianco 
2006 
Cohort Study USA 
906 subjects 
diagnosed as 
T1D 
General 
population 
prospective type 1 diabetes cohort visiting 
children’s Hospital of Pittsburgh 
30 years 
All-cause mortality, 
Cause-specific 
mortality 
(cardiovascular 
disease, nephropathy). 
26 
Patterson 
2007 
Population-
based Cohort 
study 
Multiple 
sites 
(EUROD
IAB) 
28,887 
children 
diagnosed 
with Type 1 
Diabetes 
General 
population 
EURODIAB registers 
Minimum 18 
years 
All-cause mortality 
27 Podar 2000 
Population 
based Cohort 
study 
Multiple 
sites; 
Estonia, 
Lithuania 
and 
Finland 
Estonia 
(n=518), 
Finland 
(n=5156), 
Lithuania 
(n= 698) 
General 
population 
childhood type 1 diabetes registers 12 years All-cause mortality 
28 
Raymond 
1995 
Population-
based 
retrospective 
Cohort study 
United 
Kingdom 
(n=4680) 
patients 
Identified 
General 
population 
Population-based mortality register and all 
insulin-treated 
diabetes mellitus cases notified to the 
Leicestershire diabetes register 
 
All-cause mortality, 
cause-specific 
mortality 
29 Riley 1995 Cohort study Australia 
835 patients 
with type 1 
Diabetes 
General 
population 
Female: Male ratio (54.8% to 52.4; 
Tasmanian Insulin-Treated Diabetes 
Minimum of 8.5 
years 
All-cause mortality 
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Register who were resident in Tasmania and 
using insulin on May 1, 1984 
30 
Roberts et 
al. 2004 
Cohort study UK 
4992particip
ants 
General 
population 
Hospital admission data 28 years All-cause mortality 
31 
Schober 
1997 
Cohort study Austria 
1185patients 
with Type 1 
diabetes 
No 
comparison 
Males 616, Females 569; Austrian IDDM 
registry 
12 years 
All-cause mortality, 
cause-specific 
mortality (acute 
complications) 
32 
Swerdlow 
2003 
Cohort study UK 
828 South 
Asian 
Compared 
with 27 962 
non-South 
Asian 
patients 
Data from Diabetes UK cohort study 28 years 
All-cause mortality, 
cause-specific 
mortality 
33 
Skrivarhaug
2005 
Cohort study Norway 
1,906 
Norwegians  
type 1 
diabetic 
patient 
General 
population 
Males 1,034, Females 872; Norwegian 
Childhood Diabetes Registry 
28 years 
All-cause mortality, 
cause-specific 
mortality (Coronary 
Artery disease, 
Cardiovascular disease, 
Diabetic Ketoacidosis, 
Ischaemic Heart 
Disease). 
34 
Warner et 
al. 1998 
Cohort study 
United 
Kingdom 
1854type 1 
diabetic 
subjects 
General 
population 
Yorkshire Children’s Diabetes Register 15 years 
All-cause mortality, 
cause-specific 
mortality 
35 
Washington 
et al. 2012 
Cohorts study USA 
1075 in 
Allegheny 
County 
General 
population 
USVI Childhood (<19 years old) Diabetes 
Registry 
26 years All-cause mortality. 
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Of the 35 studies selected for the review, 32 studies acquired their data from registers, 2 studies 
acquired data from hospital admission records (Roberts et al. 2004; Moss, Klein, &  Klein, 
1991) and 1 study from a survey conducted (Morimoto et al. 2013).  Roberts et al. (2004) were 
conducted in Oxford, UK; the study considered a total number of 4992 admissions for T1D 
between 1968 and 1996. Moss, Klein and Klein (1991) used 2982 patients identified through 
clinic visits and hospital records between 1980 and 1988 in 11 counties of Southern Wisconsin, 
USA. Morimoto et al. (2013) identified the participant cohort from nationwide surveys 
conducted in 1970 and 1981, with a total of 1, 385 patients.  All studies were cohort studies.  
Some studies provided multiple relative risk [RR] estimate for analysis because they had more 
than one population group being studied (Asao et al., 2003; Harjutsalo, Forsblom, & Groop, 
2011; Podar et al. 2000). Asao et al. (2003) had 2 distinct sub-populations from different 
countries Japan and Finland, Podar et al. (2000) 3 sub-populations Estonia, Finland and 
Lithuania. Barcelo, Bosnyak, and Orchard (2007) 2 subpopulations from Cuba and the USA, 
but Harjutsalo, Forsblom, and Groop (2011) had 2 sub-populations early and late onset cohorts. 
These provided relative risk (RR) estimates for meta-analysis.  
The studies included spanned various geographical regions, Europe; United Kingdom (Edge, 
Ford-Adam, & Dunger, 1999; Laing et al., 1998, 2003a, 2003b; Raymond et al., 1995; Roberts 
et al., 2004; Swerdlow et al., 2003; Patterson, 2007; Warner, McKinney, Law, & Bodansky, 
1998), Finland (Asao et al., 2003; Harjutsalo, Forsblom, & Groop, 2011; Patterson et al., 2007; 
Podar et al., 2000), Austria (Schober, Schneider, Friedl, & Unsinn, 1997; Patterson et al., 
2007), Sweden (Dahlquist & K¨all´en, 2005; Patterson et al., 2007), Italy (Bruno et al., 2009), 
Germany (Patterson, 2007), Estonia (Podar et al., 2000), Lithuania (Podar et al., 2000; 
Patterson et al., 2007), Hungary (Patterson et al., 2007), Spain (Patterson et al., 2007), Bulgaria 
(Patterson et al., 2007), other countries included are, United States of America ([USA] 
Barcelo´, Bosnyak, & Orchard, 2007; Bosnyak et al., 2005; Burnet, Cooper, Drum, & Lipton, 
2007; Conway, May, Signorello, & Blot, 2012; Moss, Klein, & Klein, 1991; Nishimura et al., 
2001; Pambianco et al., 2006; Washington et al., 2014), Switzerland (Alleman et al., 2009), 
Cuba (Barcelo´, Bosnyak, & Orchard, 2007, Collado-Mesa et al., 1997), Norway (Skrivarhaug 
et al., 2006), Australia (Cooper, de Klerk, Jones, & Davis, 2014; Riley et al., 1995), New 
Zealand (Dawson, Willis, Florkowski, & Scott, 2008: Florkowski, Scott, Graham, Han, & 
Moir, 2002), Israel (Laron-Kenet, Shamis, Weitzman, Rosen, & Laron, 2001), Japan (Asao et 
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al., 2003; Morimoto et al., 2013; Otani, Yokoyama, & Uchigata, 2014), Taiwan (Lin et al., 
2014). 
3.3.2 All-cause mortality 
Results of all-cause mortality were from 23 studies which included 27 sub-populations 
(observations). Figure 4.2 revealed an overall pooled average effect estimate of RR 3.73 (95% 
CI 3.19, 4.36) for individuals with Type 1 Diabetes compared to the general population. The I2 
estimate of 97% revealed a high level of heterogeneity within the studies compared but using 
exclusion sensitivity analysis; no study was found to be a major contributor to the heterogeneity 
observed. All 27 observations reported increased mortality risk for T1D.
 
Figure 3.2: Showing forest plot of (27) studies estimating the average effect estimates for 94, 
186 participants with 4436 events. The average pooled effect estimate for all-cause mortality 
shows higher mortality rates associated with Type 1 Diabetes 
3.3.3 Gender-specific mortality 
Figure 3.3 below shows mortality risk about gender, females with T1D had a higher risk of 
mortality compared to their male counterparts with an overall average effect estimate of RR 
1.17 (95% CI 1.06, 1.29). However, 7 studies showed increased mortality risk in males relative 
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to females. Although this analysis of studies reports a moderate level of heterogeneity (46%), 
2 studies Laron-Kernet et al. (2001) and Skrivarhaug et al. (2005) made a significant 
contribution to this level of heterogeneity after exclusion sensitivity analysis plot, this was as 
a result of factors such as methodological and clinical diversity in participant characteristics 
(Higgins, 2003). 
 
Figure 3.3: Showing forest plot of (25) studies estimating the average effect estimates for 61795 
participants with total events of 3624 events. The average pooled effect estimate suggest higher 
risk ratio of Type 1 Diabetes mortality for women as compared to men. 
3.3.4 Cardiovascular mortality risk 
Figure 3.4 below shows that individuals with T1D and cardiovascular conditions have a pooled 
overall average effect estimate of RR 3.48 (95% CI 3.14, 3.86) when compared to the general 
population. This indicates that anyone who has T1D and a cardiovascular condition is at almost 
200% increased risk of mortality when compared to the general population.  
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Figure 3.4: Showing forest plot of (3) studies estimating the average effect estimates 
cardiovascular mortality risk with type 1 diabetes. The average pooled effect estimate suggest 
higher risk ratio of cardiovascular mortality with type 1 diabetes compared to the general 
population. 
3.3.5 Cardiovascular mortality risk according to gender 
By comparison, females with T1D and CVD had a higher risk of mortality compared to their 
male counterparts with an overall average effect estimate of RR 1.41 (95% CI 0.92, 2.17). Out 
of the 12 studies that analysed cardiovascular mortality risk and T1D according to gender. The 
forest plot below (figure 3.5) showed that out of the 12 studies, 5 studies showed an increased 
risk of mortality from cardiovascular conditions and T1D in men while 7 studies presented an 
increased risk of mortality in women.  
 
Figure 3.5: Showing forest plot of (12) studies estimating the average effect estimates for 
60,611 participants with total events of 1708 events. The average pooled effect estimate suggest 
higher risk ratio of Type 1 Diabetes mortality for women as compared to men. 
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3.3.6 Renal mortality risk 
Figure 3.6 below showed that individuals with T1D and renal complications had similar 
mortality risk compared to the general population, with an overall average effect estimate of 
RR 1.06 (95% CI 0.89, 1.26). However, this result should be examined with caution because 
of its statistical significance. 
 
Figure 3.6: Showing forest plot of (4) studies estimating the average effect estimates. The 
average pooled effect estimate suggest marginally higher risk ratio of renal mortality. 
3.3.7 Renal mortality risk according to gender 
Figure 3.7 below shows that by comparison, males with T1D and nephropathy had a marginally 
higher risk of mortality compared to their female counterparts, with an overall average effect 
estimate of RR 0.63 (95% CI 0.38, 1.04). 
 
Figure 3.7: Showing forest plot of (3) studies estimating the average effect estimates for 4074 
participants with total events of 71 events. The average pooled effect estimate suggest 
marginally higher risk ratio of Type 1 Diabetes mortality for men as compared to women 
3.3.8 Mortality risk from Neoplasms 
Four studies reported relative risk values for those with T1D who had any form of neoplasms 
carried a similar mortality risk as individuals in the general population with an overall average 
effect estimate of RR 1.03 (95% CI 0.92, 1.16). 
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Figure 3.8: Showing forest plot of (4) studies estimating the average effect estimates. The 
average pooled effect estimate suggest almost equal risk ratio of mortality due to malignancy 
as compared to the general population. 
3.3.9 Mortality risk from Neoplasms according to gender 
By comparison, females with T1D and neoplasms have a marginally higher risk of mortality 
compared to their male counterparts, with an overall average effect estimate of RR 1.18 (95% 
CI 0.75, 1.86). 
 
Figure 3.9: Showing forest plot of (3) studies estimating the average effect estimates for 1356 
participants with total events of 71 events. The average pooled effect estimate suggests no 
difference in Type 1 Diabetes mortality for women as compared to men. 
3.3.10 Cerebrovascular mortality risk according to gender 
Figure 3.10 below showed no significant difference in cerebrovascular mortality risk between 
men and women with type 1 DM with an overall average effect estimate of RR 0.99 (95% CI 
0.66, 1.48). 
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Figure 3.10: Showing forest plot of (3) studies estimating the average effect estimates for 23998 
participants with total events of 94 events. The average pooled effect estimates suggest no 
difference in cerebrovascular mortality risk with Type 1 Diabetes with gender. 
3.3.11 Accidents and Suicides mortality risk according to gender 
The data showed that women with T1D are at a significantly increased risk of death from 
accidents and suicides compared to the men with RR 2.30 (95% CI 1.31, 4.06). 
 
Figure 3.11: Showing forest plot of (7) studies estimating the average effect estimates for 8778 
participants with total events of 54 events. The average pooled effect estimate suggests higher 
mortality risk in females as compared to males. 
3.3.12 Subgroup analysis 
An analysis of time trends was conducted using subgroup analysis according to the year of 
publication. Whilst findings showed significant heterogeneity among studies, Figures 3.12 to 
3.14 showed temporal improvements in mortality risk over time in T1D as indicated by an 
overall average effect estimate of RR 4.30 (95% CI 3.92, 4.72) before the year 2000, compared 
to RR 3.91 (95% CI 3.75, 4.08) between the year 2000 to 2010, and RR 3.35 (95% CI 3.23, 
3.47) after 2010. 
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Figure 3.12: Subgroup of studies published before or on the year 2000 
 
Figure 3.13: Subgroup of studies published between 2000 and 2010 
 
Figure 3.14: Subgroup of studies published between after year 2010 
Subgroup analysis according to follow up duration 
Follow up duration of patients after the diagnosis of T1D showed two peaks period in mortality. 
Figures 3.15 to 3.17 showed one peak period when follow up duration was less than 10 years 
with overall average effect estimate of RR 3.07 (95% CI 2.63, 3.58) and the other peak period 
when follow up duration was above 20 years with an overall average effect estimate of RR 3.50 
(95% CI 3.37, 3.63). 
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Subgroup of studies with follow-up duration less or equal to 10 years 
 
Figure 3.15: Subgroup of studies with follow up duration ≤ 10 years 
Subgroup of studies with follow-up duration less or equal to 20 years 
 
Figure 3.16: Subgroup of studies with follow up duration ≤ 20 years 
Subgroup of studies with follow-up duration greater than 20 years 
 
Figure 3.17: Subgroup of studies with follow up duration> 20 years 
3.4 Discussion of  systematic review results 
This review set out to investigate the mortality risk in individuals with T1D and in so doing 
aimed to establish risk ratios as they relate to all-cause mortality and cause-specific mortality. 
Inclusive in its objectives was to establish relative risks as it relates to gender, time-based trends 
such as year of publication, and follow up duration. One importance of this study is its ability 
Study or Subgroup
Bruno  2008
Dawson 2008
Florkowski 2002
Nishimura 2001
Otani 2014
Schober 1997
Total (95% CI)
Heterogeneity: Chi² = 116.15, df = 5 (P < 0.00001); I² = 96%
Test for overall effect: Z = 26.57 (P < 0.00001)
log[Risk Ratio]
0.674
0.8335
0.6881
1.6383
0.8755
1.3659
SE
0.2301
0.443
0.0512
0.08
0.1468
0.1034
Weight
2.7%
0.7%
54.4%
22.3%
6.6%
13.3%
100.0%
IV, Fixed, 95% CI
1.96 [1.25, 3.08]
2.30 [0.97, 5.48]
1.99 [1.80, 2.20]
5.15 [4.40, 6.02]
2.40 [1.80, 3.20]
3.92 [3.20, 4.80]
2.73 [2.53, 2.94]
Risk Ratio Risk Ratio
IV, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
Lower RR Higher RR
Study or Subgroup
asao1 2003
asao2 2003
Cooper 2014
Harjutsal1 2011
Harjutsal2 2011
Total (95% CI)
Heterogeneity: Chi² = 57.48, df = 4 (P < 0.00001); I² = 93%
Test for overall effect: Z = 66.02 (P < 0.00001)
log[Risk Ratio]
2.5537
1.3597
1.1704
1.2776
1.0271
SE
0.889
0.0262
0.2438
0.0426
0.0365
Weight
0.0%
52.5%
0.6%
19.8%
27.0%
100.0%
IV, Fixed, 95% CI
12.85 [2.25, 73.41]
3.90 [3.70, 4.10]
3.22 [2.00, 5.20]
3.59 [3.30, 3.90]
2.79 [2.60, 3.00]
3.50 [3.37, 3.63]
Risk Ratio Risk Ratio
IV, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
Lower RR Higher RR
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to increase the precision of estimates by combining studies to yield a total population of over 
90,000 participants with 4,436 deaths. 
3.4.1 All-cause mortality 
It is evident from this study that the diagnosis of T1D confers almost 200% increased risk of 
mortality (RR 3.73 [95% CI 3.19, 4.36]) when compared to the general population without the 
condition. This data correlates closely to findings from Lung et al. (2014). Other studies that 
also revealed excess all-cause mortality associated with T1D when compared to general 
comparative populations included Harding et al. (2014), Lind et al. (2014), Urbonaite (2002), 
and Gatling et al. (1997). Suggested causes for this trend include the impact of the vascular 
complications associated with this condition (Livingstone et al., 2012) and also, the impact of 
early complications in childhood and adolescence (Orchard, Costacou, Kretowski, & Nesto, 
2006; Lung et al., 2014).  
3.4.2 Gender-specific mortality 
Regarding gender-specific associations with all-cause mortality, women were found to have a 
17% increased risk of mortality when compared to their male counterparts (RR 1.17 [95% CI 
1.06, 1.29]). This result confers with that of Huxley and colleagues (2015) who reported similar 
results (rSMR 1·37 [95% CI 1·21–1·56] p<0·0001) and also Lung et al. (2014) who reported 
that males had a RR of 3.25 (95% CI 2.82–3.73) as compared to females with RR of 4.54 (95% 
CI 3.79–5.45). Reasons behind these findings are unclear, but it has been hypothesised that 
women are more prone to the effects of vascular dysfunction such as the calcification of the 
coronary artery and dysfunction of the endothelium (Huxley, Barzi, & Woodward, 2006).   
Other possible reasons are that life expectancy is greater in women than in men, so women are 
exposed to significantly larger cumulative effects of glycaemic variations, i.e. hypo-and hyper-
glycaemia (Huxley, Barzi, & Woodward, 2006). Some studies have also suggested that the 
physiological make up of women, such as inputs from the endocrine pathways (hypothalamus-
pituitary-ovarian axis), and factors associated with puberty and menopause that affect insulin 
sensitivity may contribute to this gender variation (Kim, Elimi, Henderson, Cogen, & 
Kaplowitz, 2012; Kaplowitz, 2012; Paris et al., 2009; Amiel et al., 1986; Huxley, Peters, 
Mishra & Woodward, 2015). 
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3.4.3 Cardiovascular mortality risk 
The results show that CVD in T1D carries the greatest mortality risk. Not only does it carry a 
significantly higher risk of mortality [RR 3.48 (95% CI 3.14, 3.86)] but this risk is over 200% 
greater when compared to the general population. Across all the studies included, death from 
CVD carried the highest risk of mortality. Other studies support this finding (Tu, Twigg, 
Duflou & Semsarian, 2008; Gatling, Tufail, Mukkee, Westacott & Hill, 1997; Huxley, Peters, 
Mishra & Woodward, 2015). 
With gender, women were significantly more susceptible to CVD mortality as compared to 
men [RR 1.41 (95% CI 0.92, 2.17)], indicating a 40% increased risk of mortality to 
cardiovascular conditions as compared to their male counterparts. This result is similar to that 
published by Huxley and colleagues (rSMR 1·86 (95% CI 1·62–2·15) and also Gatling et al. 
(1997). Cardiovascular conditions were, therefore, the major cause of death in both genders, 
but women had significantly higher RR as compared to men. Explanations for this trend include 
the influence of poor glycaemic control which is more apparent in women than in men (Huxley, 
Peters, Mishra & Woodward, 2015; Kautzky-Willer, Harreiter, & Pacini, 2016).  
3.4.4 Renal mortality risk 
According to the results of this study, people with T1D have a negligible risk of mortality from 
renal failure compared to the general population [RR 1.06 (95% CI 0.89,1.26)]. Previous 
studies have suggested a reducing trend in renal mortality risk in T1D (Khalil et al., 2011; 
Andre´sdo´ttir et al., 2015). Explanations for this lowering trend include new management 
measures such as early screening for microalbuminuria, control of blood pressure, and the use 
of new drugs such as statins and ace-inhibitors (Khalil et al., 2011; Andre´sdo´ttir et al., 2015). 
In this study, by comparison, males with T1D with nephropathy had a marginally higher risk 
of mortality compared to their female counterparts with an overall average effect estimate of 
RR 0.63 (95% CI 0.38, 1.04). This indicates an above 30% increased risk of mortality due to 
nephropathy in men as compared to women. However, this result contradicts the study by 
Huxley et al. (2015) [RR 1.44 (95% CI 1.02-2.05)] which indicated an increased risk of 
mortality in women compared to men.   
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3.4.5 Mortality risk from Neoplasm 
The overall mortality risk from neoplasm in T1D is similar to that of the general population 
[RR 1.03 (95% CI 0.92, 1.16)], a result which correlates with that of Secrest et al (2010)  but 
contradicts that of  Hsu et al. (2014) which revealed an increased all cancer risk compared to 
the general population [RR 1.13 (95% CI, 1.05, 1.22)]. In relation to gender, women had almost 
a 20% increased risk of mortality from neoplasm as compared to men [RR 1.18; (95% CI, 0.75, 
1.86)] which is similar to that reported by Hsu et al. (2014) RR 1.19 (95% CI, 1.07, 1.33), and 
Huxley et al (2015) RR 1.23 (95% CI, 0.79, 1.98), however in contrast to a large population 
study by Carstensen et al. (2016) which revealed similar Hazard Ratios in men HR 1.01 (95% 
CI 0.98, 1.04) and women HR 1.07 (95% CI 1.04, 1.10). Carstensen et al. (2016) also reported 
similar findings to this review when they analysed non-sex-specific cancers which revealed a 
HR 1.17 (95% CI 1.13, 1.22) among women. These results demonstrate gender as a major 
contributory factor in all-cause neoplasm mortality in T1D although the relationship between 
T1D and neoplasm is still poorly elucidated, but suggestions include hyperglycaemia as a 
possible link in the underlying the development of neoplasm in T1D and genetic correlations 
with T1D. Obesity has also been mentioned as a possible contributory link to increased risk of 
developing certain neoplasms in T1D (Carstensen et al., 2016). 
3.4.6 Cerebrovascular mortality risk according to gender 
Few studies have tried to establish an overall cerebrovascular risk as it pertains to T1D but 
Laing et al. (2003), in a study cohort of over 23,000 participants, reported an increased risk of 
cerebrovascular mortality as compared to the general population. This study was not able to 
evaluate this parameter due to lack of sufficient data; however, this study found a similar risk 
of mortality in men and women [RR 0.99 (95% CI 0.66, 1.48)]. This result should be viewed 
with caution because of its statistical significance p=0.95. In contrast, Huxley et al. (2015) 
showed an increased risk of mortality in women as compared to men. 
Given that few studies have evaluated this outcome in T1D, previous studies utilised 
comparison with type 2 cohorts. Whilst most of them revealed an increased risk of mortality 
due to cerebrovascular disease in women as compared to men (Kessler, 1971; Barrett-Connor 
& Khaw, 1988), one study reported a comparatively similar risk in both men and women 
(Moss, Klein & Klein, 1991). In terms of overall cause-specific mortality as it relates to 
cerebrovascular risk, factors such as nephropathy, increased blood pressure and serum 
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cholesterol have been shown to significantly increase the risk of cerebrovascular mortality 
(Fuller, Stevens & Wang, 2001).  
3.4.7 Accidents and Suicides mortality risk according to gender 
This study highlighted that women have a significantly higher risk of mortality from accidents 
and suicides than men [RR2.30 (95% CI 1.31, 4.06)]. Similar results have been reported by 
Huxley et al. [rSMR 1.34 (0.97, 1.84)]. Some studies have revealed higher background rates 
of co-morbid depression in T1D the populations being studied (Grey, Whittemore, & Tam, 
2002). Possible mechanisms include alcohol-related deaths, depression and drug overdose 
(Grey, Whittemore, & Tam, 2002).  
3.4.8 Subgroup analysis 
Year of publication 
This study reported an overall average effect estimate of RR 4.30 (95% CI 3.92, 4.72) before 
year 2000, RR 3.91 (95% CI 3.75, 4.08) between the years 2000 to 2010, and RR 3.35 (95% 
CI 3.23, 3.47) after 2010. This indicates a mean progressive reduction in mortality risk from 
T1D over time, a trend also reported by Lung et al. (2014). 
Follow up duration  
This study found that for follow up duration of less than 10 years had overall average effect 
estimate of RR 3.07 (95% CI 2.63, 3.58), follow up duration between 10 and 20 years RR 2.73 
(95% CI 2.73, 2.94), and follow up duration above 20 years RR 3.50 (95% CI 3.37, 3.63). 
These results confer with other studies, demonstrating an increased risk of mortality from acute 
complications in lower age groups (children and adolescents) and an increased risk of mortality 
from chronic complications in older age groups (Orchard, Costacou, Kretowski, & Nesto, 
2006; Lung et al 2014; Huxley, Peters, Gita., & Woodward, 2015).  The period between 10 and 
20 years duration of follow up has been explained as a period where there is beginning to be a 
greater understanding of the condition and increasingly better coping mechanisms to confront 
the challenges of T1D (Orchard, Costacou, Kretowski, & Nesto, 2006). 
3.5 Strengths and limitations 
The strength of this study lies in the combination of several studies into one thereby increasing 
the population cohort to almost 95,000 participants and increasing the precision of estimates. 
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It provides both all-cause and cause-specific effect estimates for outcomes considered, giving 
a better understanding of mortality and T1D. Although all the studies used in the analysis were 
published data, provisions were made through the search strategy to include unpublished data, 
reducing publication bias. All languages were also considered provided translations into 
English were available reducing bias due to language. A potential source of bias, however, 
relates to the use of cohort studies. The inherent nature of their design may not fully account 
for all confounding variables which can affect the true estimates of the studies included. 
Many of the results showed significant levels of heterogeneity. By exclusion sensitivity 
analysis, this study found that a few studies did contribute to this heterogeneity; but not 
substantially enough to account for the levels found. Major contributors were from factors such 
as baseline characteristics of the populations included for analysis, observed mortality trends 
used to estimate SMRs of the background populations, differential follow up duration of 
participants, participant characteristics such as differences in treatment regimens, and 
variations in glycaemic levels.  
One limitation of this study is the use of standardized mortality ratios (SMR) as the estimates 
used to arrive at the risk ratios (RR) which are based on the assumption that the background 
population are devoid of the diagnosis of T1D. 
3.6 Conclusions 
In summary, this study has provided pooled overall average effect estimates for all-cause 
mortality, cause-specific mortality, and temporal trends for various outcomes as they relate to 
T1D. The study employed the use of a systematic review and meta-analysis to arrive at the 
results obtained. The result highlights the effects of this condition regarding survival from 
childhood, through adolescence and into adulthood. These results show: 
1. Significant improvements in relative mortality attributed to T1D over time which can be 
related to improvements in treatment modalities, pharmacological and non-
pharmacological interventions such as technological and lifestyle modification. This is 
shown in subgroup analysis where there is an increasing reduction in mortality risk over 
time with overall average effect estimate of RR 4.30 (95% CI 3.92, 4.72) before year 2000, 
compared to RR 3.91 (95% CI 3.75, 4.08) between year 2000 to 2010, and RR 3.35 (95% 
CI 3.23, 3.47) after 2010. 
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2. It also highlights the plight of females who get this condition as they are exposed more to 
the effects of vascular complications of T1D such as cardiovascular complications RR 3.48 
(95% CI 3.14, 3.86)] and Accidents and suicides RR2.30 (95% CI 1.31, 4.06)]. 
3. Overall T1D carries increased mortality risk as compared to the general population (RR 
3.73 [95% CI 3.19, 4.36]) with females bearing the burden of this condition (RR 1.17 [95% 
CI 1.06, 1.29]). 
However, identified research gaps which include: 
• Lack of data to fully clarify gender variations for cerebrovascular diseases, nephropathy, 
accidents, suicide. 
• No precise data to clarify how accidents and suicides relate to depression 
• no data on dementia and T1D 
• coping mechanisms for patients 
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Chapter 4: RESULTS OF ANALYSIS OF THE DATA ON T1D IN THE WIRRAL  
This chapter presents the results of analysis of the study on T1D in the Wirral. The results are 
presented in two overarching themes. These themes are sub-divided into two divisions below: 
Division 1: Initial descriptive analysis including multiple regressions for predictors of mortality  
• Summary of results 
• Baseline characteristics 
• Population density and age profile 
• Epidemiology: prevalence and incidence 
• Absolute risk: probability (risks) of mortality and Relative risk 
• Predicting factors and mortality 
• Total mortality 
• Cause of mortality 
Division 2: Mortality analysis, survival analysis, hazard ratio analysis and retinopathy 
assessment 
• Age – and sex-specific mortality rates 
• Age-sex- and calendar-year adjusted mortality rates 
• Standardised mortality ratio 
• Median survival time 
• Hazard ratio 
• Life expectancy 
• Assessment of retinopathy 
To establish incidence and prevalence in T1D for this cohort it was important to estimate the 
baseline characteristics and distribution of the population, which is found in Sections 4.1 to 
4.3. Sections 4.4 and 4.5 highlight one of the findings of this study, they identify significant 
predictor variables for mortality in T1D. They also establish the relationship predicting risk 
factors and mortality in T1D, and cater to Objectives 2 and 3 of this study. This study reveal 
that the predicting risk factors of gender, age at diagnosis, duration of T1D, BMI, serum 
creatinine levels, SBP, total cholesterol, LDL, HDL, TC\HDL, and LDL\HDL showed a linear 
increase in mortality risk (Section 4.5). DBP followed a U-shaped relationship with relative 
and absolute mortality, while HbA1c levels reveal a sinusoidal pattern with the highest risk of 
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mortality at the levels ≤ 5.9mmol/mol (41%) (Figure 4.3.6). The significant predictors of 
mortality in this cohort (p-value <0.05) were the age at diagnosis, duration of diagnosis, 
HbA1c, SBP, DBP, and triglyceride (TG) levels (Table 4.5). Objectives 1 and 4 are addressed 
in Sections 4.7 to 4.13. They highlight the following findings that the significant predictors (p-
value <0.05) of survival for this cohort were duration of diabetes, HbA1c, Serum creatinine, 
BMI, and lipid levels. The main cause of death in this cohort was malignancy-related eight (8) 
deaths (21.6%), this was followed by cardiovascular disease and sepsis, each having six (6) 
deaths (16.2%) respectively. Cerebrovascular disease accounted for five (5) deaths (13.5%). 
Death from diabetes complications (hypoglycaemia) was recorded in one (1) patient (2.7%). 
Life expectancy at 40 years for females was 66.2 years as compared to males 78.3 years. There 
has been improved survival for T1D in this cohort, 77.185 years [95% CI: 75.191 – 79.179] in 
males and 76.011 years [95% CI: 73.169 – 78.000] in females. 
4.1 Baseline characteristics 
The numbers of participants with T1D that met the selection criteria from the Wirral Diabetes 
register were 1458. They were subdivided into baseline characteristics of females, males, 
survivors (alive) and non-survivors (dead); Table 4.1 illustrates this. 
Table 4.1: Distribution of predicting variables according to total, survivors, non-survivors, 
and gender in T1D using Mean (years) ± SD and Median (years) ± IQR, in the Wirral. 
Characteristics Females Males 
Survivors 
(Alive) 
Non-Survivors 
(Dead) 
Total T1DM 
 
Age at Diagnosis 
Mean (years) ± SD 
Median(years) ± IQR 
 
 
17.49 ± 9.60 
15.00 ± 15.00 
 
 
19.06 ± 10.47 
18.00 ± 16.00 
 
 
17.98 ± 10.05 
16.00 ± 16.00 
 
 
22.96 ± 9.82 
23.00 ± 15.00 
 
 
18.37 ± 10.12 
17.00 ± 15.00 
Age at death/Censored 
Mean (years) ± SD 
Median(years) ± IQR 
 
42.43 ± 17.29 
42.00  ± 26.00 
 
41.91 ± 17.54 
42.00  ± 25.00 
 
40.72 ± 16.65 
41.00 ± 25.00 
 
57.95 ± 17.78 
61.00  ± 30.00 
 
42.14 ± 17.40 
42.00  ± 26.00 
Duration of diabetes 
Mean (years) ± SD 
Median(years) ± IQR 
 
25.21 ± 15.26 
23.00 ± 22.00 
 
23.33 ± 15.24 
20.00 ± 22.00 
 
22.62 ± 13.96 
20.00 ± 21.00 
 
41.69 ± 18.44 
43.50 ± 28.00 
 
24.15 ± 15.27 
21.00 ± 22.00 
SBP (mmHg) 
Mean ± SD 
Median ± IQR 
 
127.78 ± 16.27 
125.00 ± 19.00 
 
130.02 ± 14.24 
130.00 ± 18.00 
 
127.57 ± 14.27 
126.00 ± 18.00 
 
142.99 ± 17.47 
141.00 ± 21.00 
 
128.98 ± 15.25 
127.00 ± 18.00 
DBP (mmHg) 
Mean ± SD 
Median ± IQR 
 
75.63 ± 7.26 
75.00 ± 9.00 
 
76.60 ± 7.36 
76.00 ± 10.00 
 
76.06 ± 7.09 
76.00 ± 9.00 
 
77.07 ± 9.40 
76.00 ± 13.00 
 
76.15 ± 7.34 
76.00 ± 10.00 
Creatinine (µmol/l) 
Mean ± SD 
Median ± IQR 
 
97.67 ± 291.46 
80.23 ± 18.01 
 
99.51 ± 61.78 
92.08 ± 19.99 
 
94.90 ± 205.44 
85.74 ± 20.39 
 
139.98 ± 117.00 
99.90 ± 41.49 
 
98.69 ± 199.89 
86.55 ± 21.49 
Total Cholesterol 
Mean (mmol/l) ± SD 
Median (mmol/l) 
 
4.85 ± 0.91 
4.81± 1.16 
 
5.33 ± 17.16 
4.64 ± 0.86 
 
5.12 ± 13.38 
5.10 ± 0.96 
 
5.10 ± 0.96 
5.07  ± 1.20 
 
5.12 ± 12.80 
4.70 ± 1.10 
HDL (mmol/l) 
Mean ± SD 
Median ± IQR 
 
1.62 ± 0.55 
1.56 ± 0.53 
 
1.52 ± 3.50 
1.35 ± 0.42 
 
1.56 ± 2.72 
1.43 ± 0.47 
 
1.60 ± 0.58 
1.46 ± 0.75 
 
1.57 ± 2.62 
1.43 ± 0.48 
TG (mmol/l) 
Mean ± SD 
 
1.54 ± 3.04 
 
1.74 ± 3.20 
 
1.65 ± 3.25 
 
1.68 ± 1.05 
 
1.65 ± 3.13 
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Median ± IQR 1.21 ± 0.80 1.32 ± 0.93 1.27 ± 0.82 1.38 ± 0.98 1.28 ± 0.83 
LDL (mmol/l) 
Mean ± SD 
Median ± IQR 
 
2.73 ± 0.81 
2.69 ± 1.03 
 
3.13 ± 12.13 
2.60 ± 1.01 
 
3.04 ± 9.37 
2.60 ± 1.00 
 
3.11 ± 0.98 
3.21 ± 1.40 
 
3.05 ± 9.02 
2.63 ± 1.05 
TC/HDL ratio 
Mean ± SD 
Median ± IQR 
 
3.22 ± 0.97 
3.03 ± 1.15 
 
4.03 ± 12.49 
3.36 ± 1.14 
 
3.67 ± 9.66 
3.22 ± 1.14 
 
3.60 ± 1.24 
3.44 ± 1.47 
 
3.66 ± 9.30 
3.23 ± 1.16 
LDL/HDL ratio 
Mean ± SD 
Median ± IQR 
 
1.81 ± 0.69 
1.70 ± 0.89 
 
2.52 ± 9.57 
1.90 ± 0.88 
 
2.20 ± 7.39 
1.79 ± 0.86 
 
2.17 ± 1.03 
2.04 ± 1.40 
 
2.20 ± 7.11 
1.81 ± 0.90 
Serum HbA1c (%) 
Mean ± SD 
Median ± IQR 
 
8.84 ± 1.69 
8.73 ± 2.00 
 
9.65 ± 8.57 
8.57 ± 2.00 
 
9.35 ± 21.02 
8.64 ± 2.00 
 
8.66 ± 1.42 
8.48 ± 2.00 
 
9.29 ± 20.12 
8.62 ± 2.00 
Plasma glucose 
Mean (mmol/l) ± SD 
Median(mmol/l) ± IQR 
 
10.69 ± 26.52 
8.82 ± 6.53 
 
12.07 ± 44.71 
9.59 ± 5.90 
 
11.66 ± 39.37 
9.26 ± 6.25 
 
9.26 ± 4.31 
8.84 ± 6.14. 
 
11.45 ± 37.69 
9.22 ± 6.30 
Serum Albumin levels 
Mean ± SD 
Median 
 
3.05 ± 6.51 
2.19 ± 1.45 
 
3.16 ± 8.50 
1.95 ± 1.38 
 
2.94 ± 7.09 
2.01 ± 1.28 
 
5.34 ± 13.01 
3.00  ± 1.74 
 
3.11 ± 7.68 
2.06 ± 1.42 
TSH 
Mean ± SD 
Median ± IQR 
 
2.71 ± 3.14 
2.00 ± 1.60 
 
2.42 ± 5.79 
1.76 ± 1.10 
 
2.54 ± 4.94 
1.84 ± 1.30 
 
2.70 ± 2.46 
1.99 ± 1.90 
 
2.55 ± 4.78 
1.85 ± 1.40 
Body Mass 
Index(kg/m2) 
Mean ± SD 
Median ± IQR 
 
 
26.49 ± 4.86 
25.50 ± 5.60 
 
 
25..94 ± 5.04 
25.50 ± 4.90 
 
 
26.12 ± 4.91 
25.50 ± 5.10 
 
 
27.17 ± 5.34 
25.85 ± 6.10 
 
 
26.19 ± 4.95 
25.50 ± 5.20 
 
4.2 Population density and age profile 
The population profile of those with T1D in the Wirral is observed in Figure 4.1. The age and 
sex distribution revealed a sinusoidal pattern with an initial peak (Figure 4.1) at the age group 
10-14, another peak in the age group 20-24, a plateau between the age groups 30-34 and 35-
39. The proportions of males were higher in all age groups except in one age groups this was 
in the age group 5-9 years. Females were more in the age group 5-9 years. 
 
Figure 4.1: Age and sex distribution of people with T1D in the Wirral 
The Age- and sex-specific mortality and survival distribution in people with T1D in the Wirral 
are reflected in Table 4.2. There were more males 817 (56.04%) than females 641 (43.96%). 
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This observed trend was also reflected in survivors and non-survivors populations with 760 
(52.13%) males, 585 (40.12%) females; and 57 (3.90%) males, 56 (3.84%) females 
respectively. 
In the survivor population, the age groups below the age of 30 accounted for majority of the 
population, the population distribution in this group followed a sinusoidal pattern with a spike 
in the age group 10 – 14 years, and a gradual decline was noticed after the age of 30 years. 
For the non-survivor population, the pattern reflected a sinusoidal pattern with six (6) age 
groups, 10-14, 15-19, 20-24, 25-29, 30-34, and 35-39 accounting for major proportions in this 
subset. Although overall gender differentiation in the non-survivor population revealed a 
higher proportion of males than females, breakdown into age categories showed a mixed 
picture with females having higher proportions in some age groups. This was evident in age 
groups 10-14, 25-29, and 35-39 
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Table 4.2: Age- and sex-specific mortality and survival distribution in people with T1D in the Wirral 
Age group 
(years) 
Survivors Non-Survivors Overall T1DM 
 Females N 
(%) 
Males N 
(%) 
Total N 
(%) 
Females N 
(%) 
Males N 
(%) 
Total N 
(%) 
Females N 
(%) 
Males N 
(%) 
Total N 
0 – 4 49 (8.4) 73 (9.6) 122 (9.1) 1 (1.8) 3 (5.3) 4 (3.5) 50 (7.8) 76 (9.3) 126 (8.6) 
5 – 9  119 (20.3) 108 (14.2) 227 (16.9) 2 (3.6) 5 (8.8) 7 (6.2) 121 (18.9) 113 (13.8) 234 (16.0) 
10 – 14 141 (24.1) 165 (21.7) 306 (22.8) 11 (19.6) 6 (10.5) 17 (15.0) 152 (23.7) 171 (20.9) 323 (22.2) 
15 – 19 72 (12.3) 95 (12.5) 167 (12.4) 5 (8.9) 10 (17.5) 15 (13.3 77 (12.0) 105 (12.9) 182 (12.5) 
20 – 24 86 (14.7) 95 (12.5) 181 (13.5) 12 (21.4) 13 (22.8) 25 (22.1) 98 (15.3) 108 (13.2) 206 (14.1) 
25 – 29 64 (10.9) 101 (13.3) 165 (12.3) 12 (21.4) 6 (10.5) 18 (15.9) 76 (11.9) 107 (13.1) 183 (12.6) 
30 – 34 30 (5.1) 61 (8.0) 91 (6.8) 4   (7.1) 9 (15.8)  13 (11.5) 34 (5.3) 70 (8.6) 104 (7.1) 
35 – 39 24 (4.1) 62 (8.2) 86 (6.4) 9 (16.1) 5 (8.8) 14 (12.4) 33 (5.1) 67 (8.2) 100 (6.9) 
Total 585(40.12) 760(52.13) 1345(92.25) 56(3.84) 57(3.90) 113(7.75) 641(43.96) 817(56.04) 1458 
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4.3 Epidemiology: incidence and prevalence 
The incidence rate for T1D population in the Wirral followed a sinusoidal pattern during the 
follow-up period of 12 years. The lowest incidence was in 2011 which was less than 2.18 per 
1,000,000, and the highest rate was in 2003 was 15.0 per 1,000,000. Table 4.3 and Figure 4.2 
detailed the yearly incidence and prevalence rates with gender differentiation. Although there 
was witnessed fluctuation in the incidence rates, there was a sustained increase in the 
prevalence of T1D. The overall prevalence was 10.9 per 1,000,000 but increased to 113.8 per 
1,000,000 in 2011. A similar trend was noticed in gender differentiation, but the greatest 
increase was noticed in males with an increase in the prevalence of almost 150% from 2000 to 
2011. 
Table 4.3: Annual incidence and prevalence rates per 100000 populations of T1D in the 
Wirral 
Calendar year Incidence rate Prevalence rate 
 Females Males Total Females Males Total 
2000 7.2 23.0 11.0 7.2 15.0 10.9 
2001 8.4 18.0 13.0 15.7 32.5 23.8 
2002 11.4 14.0 13.0 27.1 46.8 36.6 
2003 10.8 20.2 15.0 38.0 67.0 51.9 
2004 10.8 13.0 12.0 48.8 80.0 63.8 
2005 7.8 13.7 10.6 56.6 91.1 74.4 
2006 5.4 11.7 8.4 60.2 105.0 82.9 
2007 9.6 11.1 10.0 69.9 116.0 93.2 
2008 9.6 15.0 12.2 79.5 131.0 99.4 
2009 3.6 9.1 6.25 83.1 140.0 106.0 
2010 6.0 10.4 8.13 89.2 151.0 113.8 
2011 1.8 2.6 2.18 91.0 153.0 116.0 
 
              
Figure 4.2: Annual incidence and prevalence rates per 100000 population of T1D in the 
Wirral 
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4.4 Absolute risk (Probability (risk) of mortality), relative risk and regression analysis 
During the follow-up period, the risk of mortality per calendar of diagnosis (explained by the 
risk of mortality over the entire study duration, given specified entry into a particular calendar 
year and not the risk of death in the certain year) was found to follow a non-linear pattern 
(Table 4.4). The overall risk of mortality for the total population of T1D remained stable within 
the study period. The highest overall risk of mortality was recorded in 2004 which was 0.05 
(5%). There were minimal observed variations with gender, details of the risk of mortality by 
year and differentiated by gender is further reflected in Table 4.4 
Table 4.4: Risk of mortality per the calendar year of diagnosis in females, males and overall 
T1D population in the Wirral 
Calendar Year Risk of Mortality 
 Females Males Total T1DM 
2000 - - - 
2001 - - - 
2002 0.05 0.04 0.04 
2003 0.10 - 0.04 
2004 0.10 - 0.05 
2005 - - - 
2006 - 0.05 0.04 
2007 - - - 
2008 0.06 - 0.03 
2009 - - - 
2010 - - - 
2011 - - - 
2012 - - - 
Total 0.04 0.01 0.02 
 
The summarised risk of mortality and the corresponding relative risk of specific predicting 
factors in T1D population of the Wirral are illustrated in Table 4.5. Relative risk (Risk ratio) in 
this context is defined as a comparison to evaluate the probability of death in each group rather 
than an estimate for the odds ratio. These values are illustrated in Table 4.5  
Running a multiple regression model to evaluate the multiple independent variables against the 
age at death/censoring for this cohort showed that 89.1% (R2=0.891) of the variance of the 
mortality can be explained by the predictor variables evaluated. The result indicate that the 
model was a significant predictor of mortality in this cohort F (19, 747) =331.72, p= <0.0001. 
The multiple regression model showed that the significant predictor variables for mortality in 
this cohort (p-value <0.05) were the age at diagnosis, duration of diagnosis, HbA1c, SBP, DBP, 
and triglyceride (TG) levels (Table 4.5).  
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The risk of mortality by gender differentiation showed that males had a lesser risk of mortality 
than females with values of 0.01 (1%) and 0.04 (4%), females had a high probability of death 
with a relative risk of four (4) times compared to males. 
Table 4.5: Probability (risk) of mortality and relative risk associated with specific predicting 
factors in T1D including multiple regression analysis to determine significant predictors of 
mortality 
Predicting Factors 
Probability 
(risk) of 
mortality 
Relative Risk 
Unstandardized B 
and (P-values) from 
multiple regression 
model 
Sex     -0.80 (0.073) 
Females 0.04 4   
Males 0.01 1   
Age at diagnosis     0.42(<0.0001) 
0 – 4 0.03 1.0 (reference group)   
5 – 9 0.03 1   
10 – 14 0.05 1.7   
15 – 19 0.08 2.7   
20 – 24 0.12 4   
25 - 29 0.1 3.3   
30 – 34 0.13 4.3   
35 – 39 0.14 4.7   
        
Duration of Diabetes (years)     8.25(<0.0001) 
01-10 0.03 1.0  (reference group)   
11-20 0.04 1.3   
21-30 0.05 1.6   
31-40 0.07 2.3   
41-50 0.16 5.3   
BMI (kg/m2)     0.14(0.588) 
≤18.4 - -   
18.5 - 24.9 0.08 1.1   
25.0 - 29.9 0.07 1.0  (reference group)   
30.0 - 34.9 0.08 1.1   
35.0 - 39.9 0.19 2.7   
≥ 40 0.2 2.9   
IMD     0.13(0.35) 
Quintile 1 (most deprived) 0.09 1.5   
Quintile 2 (above average) 0.07 1.2   
Quintile 3 (average) 0.06 1.0 (reference group)   
Quintile 4 (below average) 0.1 1.6   
Quintile 5 (least deprived) 0.08 1.3   
Serum creatinine (µmol/l)     -0.14(0.66) 
< 61 0.03 0.5   
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62-106 0.06 1.0 (reference group)   
107-129 0.18 3   
130-149 0.4 6.7   
≥ 150 0.4 6.7   
HbA1c %(mmol/mol)     -0.19(0.041) 
≤ 5.9 (41) 0.25 8.3   
6.0-6.4(42-46) 0.03 1.0 (reference group)   
6.5-6.9(48-52) 0.06 2   
7.0-7.4(53-57) 0.1 3.3   
7.5-8.0(58-64) 0.06 2   
8.1-8.4(65-68) 0.1 3.3   
8.5-9.0(69-75) 0.07 2.3   
9.1-9.4(76-79) 0.1 3.3   
9.5-10(80-86) 0.07 2.3   
≥ 10.1 0.08 2.6   
SBP (mmHg)     5.16(<0.0001) 
≤ 99 - -   
100 – 119 0.03 1.0  (reference group)   
120 – 139 0.06 2   
140 – 159 0.23 7.7   
≥160 0.35 11.6   
DBP (mmHg)     -2.88(<0.0001) 
≤59 0.38 5.4   
60-69 0.11 1.6   
70 – 79 0.07 1.0 (reference group)   
80 – 89 0.1 1.4   
90- 99 0.18 2.6   
≥100 0.3 4.3   
TSH levels (mU/L)     0.33(0.625) 
≤0.4 0.15 1.9   
0.4-4.0 0.08 1.0 (reference group)   
≥4.0 0.12 1.5   
Total Cholesterol (mmol/l)     0.27(0.421) 
≤3.9 0.06 1   
4.0-4.5 0.07 1.2   
4.6-5.2 0.06 1.0 (reference group)   
5.3-6.1 0.11 1.8   
≥6.2 0.24 4   
LDL (mmol/l)     -0.09(0.817) 
≤ 2.5 0.05 1.0 (reference group)   
2.6-3.3 0.06 1.2   
3.4-4.1 0.14 2.8   
4.2-4.9 0.17 3.4   
≥ 5.0 0.27 5.4   
HDL (mmol/l)     -0.19(0.665) 
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0.4-0.7 - -   
0.8-1.1 0.05 1.0(reference group)   
1.2-1.5 0.07 1.4   
≥ 1.6 0.08 1.6   
TG (mmol/l)     -1.04(0.004) 
≤ 1.6 0.07 1.0 (reference group)   
1.7-2.2 0.12 1.7   
≥2.3 0.1 1.4   
TC/HDL ratio     0.35(0.602) 
≤ 3.5 0.06 1.0 (reference group)   
3.6-5.0 0.09 1.5   
≥ 5.1 0.13 2.2   
LDL: HDL ratio     -0.83(0.196) 
≤1.5 0.05 1.0  (reference group)   
1.6-3.6 0.07 1.4   
≥ 3.7 0.19 2.7   
Smoking status     0.44(0.094) 
Never smoked 0.07 1.0 (reference group)   
Smokes 0.08 1.1   
Ex-smoker 0.14 2   
 
Considering the age of diagnosis, the age groups 0-4, and 5-9 years had the least risk of 
mortality of 0.03 (3%). Below the age of 30 years, the highest risk of mortality was recorded 
in the age group 20-24 years. The highest risk of mortality for this cohort was recorded in the 
age group 35-39 years with a value of 0.14 (14%), there was a gradually increasing trend of 
the risk of mortality up till the age group 20-24 years and then a slight decline in the age group 
25-29 years 0.10 (10%), then a gradual increase in the age groups of 30-34, and 35-39 years. 
This is also reflected in the relative risk as there is an initial gradual increase in the probability 
of death as age increased up to the age group 20-24 years. There was a minor dip in the relative 
risk age group 25-29 years, which had a relative risk of 3.3 times compared to those 0-4 years. 
The highest risk of death was recorded in the age group 35-39 years which was 4.7 times that 
of age group 0-4 years. 
The duration of diabetes had various subgroups that experienced varying degrees in the risk of 
mortality. Those with the condition between 1 and 10 years had the lowest risk of mortality 
0.03 (3%). Increase in the duration of diabetes saw a corresponding increase in the risk of 
mortality with a duration of diabetes between 41-50 years having the highest risk of mortality 
of 0.16 (16%). For the relative risk, there was increase in the probability of death with 
increasing duration of T1D. Having T1D for between 11 and 20 years conferred a relative risk 
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of 1.3 times and having T1D for between 31 and 40 years had a relative risk of 2.4. Above 40 
years’ duration of T1D had a relative risk of 5.3 times was observed as compared to those less 
than 10 years’ duration. 
Being obese (BMI 30 and 39.9) and severely obese (BMI 40 or more) had relative risks of 2.7 
times and 2.9 times the probability of death when compared to the reference group of BMI 25.0 
- 29.9kg/m2. For the index of multiple deprivations (IMD), the risk of mortality was most 
prominent in the group below average for IMD, being 0.10 (10%) followed closely by most 
deprived 0.09 (9%). Those classes as being average had the least risk of mortality of 0.06 (6%). 
Serum creatinine levels of below 61 µmol/l had the lowest risk of mortality 0.03 (3%), in 
comparison, there was a persistent rise in the risk of mortality as serum creatinine levels rose 
with the highest risk of 0.40 (40%) at levels of between 130-149 and above 150 µmol/l. Using 
normal serum creatinine levels (62-106 µmol/l) as the reference, there was a significant 
increase in the relative risk of mortality with increasing serum creatinine levels. This is 
observed in table 5.5, those with serum creatinine levels of 107-129 µmol/l (mild; stage 2 CKI, 
equivalent to GFR 45-89ml/min/1.73m2), 130-149 µmol/l (moderate; stage 3 CKI, equivalent 
to GFR 30-45ml/min/1.73m2), and ≥ 150 µmol/l (severe; stage 4 and 5 CKI, equivalent to GFR 
<30ml/min/1.73m2), had 3 times, 6.7 times and 6.7 times the probability of mortality than those 
within normal creatinine levels. 
For glycaemic control, the reference group was glycaemic values of 6.0-6.4% (42-46) 
mmol/mol. The highest risk of mortality was recorded with values of less than ≤ 5.9% (41) 
mmol/mol having a value of 0.25 (25%). Levels greater or equal to 10.1% (≥87mmol/mol). 
Similar levels of risk of mortality 0.10 (10%) was recorded for levels of 7.0-7.4% (53-57) 
mmol/mol and 8.1-8.4% (65-68) mmol/mol. There was minimal difference in relative risk of 
mortality between the groups as compared to the reference group (6.5-6.9% [48-52 
mmol/mol]). However, there was a significant risk of mortality when glycaemic levels were 
below 5.9% [≤41 mmol/mol]). Values of (8.1-8.4% [65-68 mmol/mol]) and ≥ 10.1% (≥ 
87mmol/mol) respectively had 3.3 times, and 1.6 times the probability of death in comparison 
to the reference value. 
Systolic blood pressure (SBP) of levels between 100 and 119 mmHg were associated with the 
lowest risk of mortality of 0.03 (3%) while values above or equal to 160 mmHg had the highest 
risk of mortality 0.35 (35%). Increase in the values for systolic blood pressures was associated 
with increasing risk of mortality. For diastolic blood pressure (DBP), values less than or equal 
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to 59 mmHg had the highest risk of mortality 0.38 (38%). Values above or equal to 100 mmHg 
also had high risk of mortality 0.30 (30%). The relative risk of death significantly increased 
with rise in systolic blood pressure (SBP), the relative risk of mortality was 2 times, 7 times 
and 11.6 times for those with SBP of 120 – 139 mmHg, 140 – 159 mmHg, and ≥160 mmHg 
respectively as compared to the reference group (100 – 119 mmHg). Conversely, this trend was 
not noted with diastolic blood pressure (DBP); however, the two extremes (≤59 mmHg [RR: 
5.4]) and (≥100 mmHg [RR: 4.3]) of DBP had high relative risk of mortality when compared 
to the reference group (70-79 mmHg).  
TSH levels below or equal to 0.4 mU/L conferred the greatest risk of mortality 0.15 (15%) 
while those with values of 4.0 mU/L or greater had higher risk of mortality 0.12 (12%) than 
with those having values 0.4-4.0 mU/L 0.08 (8%). 
Lipid profiles illustrated varying degrees for risk of mortality. Total cholesterol levels of ≥ 6.2 
mmol/l had the highest risk of mortality 0.24 (24%). Higher risk of mortality 0.11 (11%) was 
also found for values between 5.3-6.1mmol/l. There was minimal difference between the other 
subgroups. The relative risks for total cholesterol levels were similar for lower levels of total 
serum cholesterol (≤3.9 mmol/l, 4.0-4.5 mmol/l, and 4.6-5.2 mmol/l [reference group]), 
however, higher levels of total cholesterol (5.3-6.1 mmol/l and ≥6.2 mmol/l) reflected increased 
relative risk of 1.8 and 4.0 respectively.  
LDL level reflected an increase in the risk of mortality with rising LDL levels. The lowest risk 
of mortality 0.05 (5%) was found with levels ≤ 2.5 mmol/l while the highest risk of mortality 
was identified in those who had LDL levels ≥ 5.0 mmol/l. There was little or no differentiation 
between the various grouping of HDL levels and the greatest risk of mortality 0.08 (8%) was 
found in those with HDL levels between ≥ 1.6 mmol/l. Reduced levels of serum triglycerides 
(≤ 1.6 mmol/l) conferred low risk of mortality 0.07 (7%) as compared to the other subgroups. 
The other subgroups with levels of 1.7-2.2 mmol/l and ≥ 2.3 mmol/l had higher risk of mortality 
0.12 (12%) and 0.10 (10%) respectively. TC/HDL ratios reflected increasing risk of mortality 
with increasing values for ratio. The risk of mortality was highest 0.13 (13%) when the ratio 
was ≥ 5.1. A similar trend was also noticed with LDL/HDL ratios. The risk of mortality was 
highest 0.19 (19%) for values greater or equal to 3.7. For smoking status, being an ex-smoker 
conferred the highest risk of mortality 0.14 (14%). However, current smokers when compared 
to non-smokers had higher risk of mortality. 
96 
 
4.5 Graphical representation of the relationship of the predictor variables and mortality 
risk using RR  
                     
                (a) : Age group at diagnosis 
                    
                      (b): Duration of diabetes (years) 
                          
                    (c) : BMI and relative risk 
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             (d): Index of multiple deprivations. 
                 
            (e): Figure Serum creatinine 
               
            (f): HBA1c 
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            (g): Systolic blood pressure (SBP)mmHg 
  
(h): DBP (mmHg) 
  
(i): Total Cholesterol (mmol/l) 
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(j): LDL cholesterol (mmol/l) 
 
(k): HDL cholesterol (mmol/l) 
 
(l): Triglycerides (mmol/l) 
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(m): TC:HDL ratio 
 
(n): LDL\HDL Ratio 
Figure 4.3(a-n): Representation of the relationship of the predictor variables and mortality 
risk using RR  
4.6 Predicting factors and mortality distribution 
4.6.1 Gender 
Overall males and females accounted for 817 (56.04%) and 641 (43.96%) respectively. Over 
the follow-up period, survivors accounted for 1345 (92.25%) of the total T1D population while 
non-survivors accounted for 113 (7.75%) of the total T1D population. Figure 4.4 illustrates the 
age and sex stratification of survivors and non-survivors in T1DM population. Chi-squared test 
was used to determine any significant relationship between the survivors and non-survivors. 
Of the survivor population (1345), males were more with 760 (52.13%) as compared to females 
585 (40.12%). There were 113 non-survivors, 56 (3.84%) were females and 57 (3.90%) were 
males (p-value <0.0001). 
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Figure 4.4: Age and sex stratification of survivors and non-survivors in T1D population 
Table 4.6 shows the age – and sex-specific distribution among survivors and non-survivors in 
people with T1D. For those that survived, males were more in all age groups except in the age 
group 5-9 years, for the non-survivor group, males were more in all groups except age groups 
10-14, 25-29, and 35-39 years. In this non-survivor category, females accounted for greater 
proportions than males 10-14 (19.6:10.5%), 25-29 (21.4%:10.5%), and 35-39 (16.1%:8.8%). 
Table 4.6: Age – and sex-specific distribution among survivors, and non-survivors in people 
with T1D, in the Wirral including chi square test for statistically significant association 
between survivors and non-survivors. 
 
4.6.2 Age at diagnosis 
Table 4.7 illustrates the categories of the age at diagnosis into various subgroups, and their 
percentages for survivors, non-survivors, and total T1D population (p-value <0.0001, df =7, 
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 Females Males  
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Survivors 
N (%) 
Non-
survivors 
N (%) 
Survivors 
N (%) 
Non-survivors 
N (%) 
 
0 – 4 49 (7.6) 1 (0.2) 73 (9.6) 3 (5.3) 126 (8.6) 
5 – 9 119 (18.6) 2 (3.6) 108 (14.2) 5 (8.8) 234 (16.0) 
10 – 14 141 (24.1) 11 (19.6) 165 (21.7) 6 (10.5) 323 (22.2) 
15 – 19 72 (12.3) 5 (8.9) 95 (12.5) 10 (17.5) 182 (12.5) 
20 – 24 86 (14.7) 12 (21.4) 95 (12.5) 13 (22.8) 206 (14.1) 
25 – 29 64 (10.9) 12 (21.4) 101 (13.3) 6 (10.5) 183 (12.6) 
30 – 34 30 (5.1) 4 (7.1) 61 (8.0) 9 (15.8) 104 (7.1) 
35 – 39 24 (4.1) 9 (16.1) 62 (8.2) 5 (8.8) 100 (6.9) 
Total 585 56 760 57 1458 (100) 
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X2=29.358). Among the survivors, the age group 10-14 years had the highest frequency and 
then subsequently by the age group 5-9 years. These two age groups jointly accounted for over 
one-third (36.6%) of the survivor population. Conversely, in the non-survivor group, the 20-24 
years’ age group had the highest frequency, followed closely by four age groups 25-29 and 10-
14 age groups.  
Figure 4.5 highlights the age-specific relative risk and risk of mortality in people with T1D in 
the Wirral. Overall, there was an increase in the relative risk and the risk of mortality as the 
age of diagnosis (entry into the study) increased. 
 
           
Figure 4.5: Age-specific relative risk and risk of mortality in people with T1D in the Wirral 
The risk of mortality followed a linear pattern in increase from 3% in the 0-4 year age group 
to 14% in the 35-39 year age group. However, for the relative risk, there was an exponential 
increase in RR from 1 in the 0-4 age group to 4.7 in the 35-39 year age group. This followed a 
sinusoidal pattern with peaks for the following age groups; 20-24, 30-34, and 35-39 years with 
corresponding RRs of 4.0, 4.3, and 4.7. 
 
 
 
 
Table 4.7: Basic distribution characteristics for survivors and non-survivors according to age 
at diagnosis, duration of diagnosis and smoking status including chi square test for statistical 
significant association between survivors and non-survivors 
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Characteristics Survivors N (%) Non-Survivors N (%) Total T1DM p-values 
Age at diagnosis (years)                                                                                                                <0.0001 
0 – 4 122 (8.4) 4 (0.3) 126 (8.6)  
5 – 9  227 (15.6) 7 (0.5) 234 (16.0)  
10 – 14 306 (21.0) 17 (1.2) 323 (22.2)  
15 – 19 167 (11.5) 15 (1.0) 182 (12.5)  
20 – 24 181 (12.4) 25 (1.7) 206 (14.1)  
25 – 29 165 (11.3) 18 (1.2) 183 (12.6)  
30 – 34 91 (6.2) 13 (0.9) 104 (7.1)  
35 – 39 86 (5.9) 14 (1.0) 100 (6.9)  
Total 1345 (92.2) 113 (7.8) 1458 (100)  
Duration of diabetes (years)                                                                                                          <0.0001 
1-10 306 (22.4) 8 (0.6) 314 (23.0)  
11-20 382 (28.0) 14 (1.0) 396 (29.0)  
21-30 275 (20.2) 13 (1.0) 288 (21.1)  
31-40 222 (16.3) 16 (1.2) 238 (17.4)  
41-50 108 (7.9) 20 (1.5) 128 (9.4)  
Total 1293 (94.8) 71 (5.2) 1364 (100)  
Smoking status                                                                                                                                  0.015 
Never smoked 542 (54.4) 43 (4.3) 585 (58.7)  
Ex-smoker 205 (20.6) 32 (3.2) 237 (23.8)  
Current smoker 162 (16.2) 13 (1.3) 175 (17.6)  
Total 909 (91.2) 88 (8.8) 997 (100)  
4.6.3 Smoking 
Table 4.7 and Figure 4.6 show the overall distribution of T1D population according to their 
smoking status, 23.8% and 17.6% were ex-smokers and current smokers respectively. 
However, considering the non-survivor population, 1.3% were still smoking at the time of their 
demise, while 3.2% had stopped smoking at the time of death (p-value 0.015, df =2, X2=8447). 
 
Figure 4.6: Distribution of T1D population according to their smoking status. 
3.4.9 Body Mass Index (BMI): Measure of obesity 
With the body mass index (BMI), there was increased potential probability (risk) of death 
found in those in higher categories of BMI 35-39, and ≥ 40 kg/m2 with values of 0.19 (19%) 
and 0.20 (20%) respectively.  
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Figure 4.7: Distribution of survivors and nom-survivors among T1D in the Wirral according 
to their BMI 
The distribution of BMI into survivor and non-survivor categories among T1D in the Wirral as 
reflected in Figure 4.7 and Table 4.8. Majority of the non-survivors (38 [3.6%]) were found to 
have normal BMI range. This was followed by those who were overweight (33 [3.1%]) with 
BMI range 25.0 - 29.9, and then those with class 1 obesity of BMI 30.0-34.9 (10 [0.9 %]). The 
survivor group showed similar trend as the non-survivors in terms of distribution. 
 
 
 
 
 
 
 
Table 4.8: The characteristics of BMI, HbA1c, and IMD among survivors, non-survivors and 
total T1D population including chi-square test for statistical significant association between 
survivors and non-survivors 
Characteristics Survivors N 
(%) 
Non-Survivors N (%) Total T1DM p-values 
BMI (kg/m2)                                                                                                                               
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18.5-24.9 411 (38.5) 38 (3.6) 449 (42.0)  
25.0-29.9 394 (36.9) 33 (3.1) 427 (40.0)  
30.0-34.9 109 (10.2) 10 (0.9) 119 (11.1)  
35.0-39.9 38 (3.6) 9 (0.8) 47 (4.4)  
>40 8 (0.7) 2 (0.2) 10 (0.9)  
Total 976 (91.4) 92 (8.6) 1068 (100)  
HbA1c % (mmol/mol)                                                                                               0.295 
≤ 5.9  (41) 12 (1.0) 4 (0.3) 16 (1.3)  
6.0-6.4 (42-46) 29 (2.3) 1 (0.1) 30 (2.4)  
6.5-6.9 (48-52) 60 (4.8) 4 (0.3) 64 (5.2)  
7.0-7.4 (53-57) 85 (6.8) 9 (0.7) 94 (7.6)  
7.5-8.0 (58-64) 180 (14.5) 12 (1.0) 192 (15.5)  
8.1-8.4 (65-68) 113 (9.1) 13 (1.0) 126 (10.2)  
8.5-9.0 (69-75) 212 (17.1) 16 (1.3) 228 (18.4)  
9.1-9.4 (76-79) 94 (7.6) 10 (0.8) 104 (8.4)  
9.5-10 (80-86) 140 (11.3) 10 (0.8) 150 (12.1)  
≥ 10.1 (87) 219 (17.6) 18 (1.5) 237 (19.1)  
Total 1144 (92.2) 97 (7.8) 1241 (100)  
IMD (Quintiles)                                                                                                        0.328      
1 (most deprived) 415 (27.8) 39 (2.6) 454 (30.4)  
2 (below average) 283 (18.9) 20 (1.3) 303 (20.3)  
3 (average) 192 (12.8) 13 (0.9) 205 (13.7)  
4 (above average) 256 (17.1) 31 (2.1) 287 (19.2)  
5 (least deprived) 226 (15.1) 20 (1.3) 246 (16.5)  
Total 1372 (91.8) 123 (8.2) 1495 (100)  
 
4.6.4 Glycaemic control 
Although the result highlighted no statistical significance of the various deciles for HbA1c (p-
value 0.295, df =9, x2=10.723). The results as illustrated in Table 4.8, with the distribution of 
survivors and non-survivors in Figure 4.8 indicate that only 11.6% of the survivors, 1% of the 
non-survivors and 12.8% of the overall population with T1D attained satisfactory levels of 
control of between 6.0-7.4%. 
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Figure 4.8: Distribution of HbA1c (%) among survivors and non-survivors in T1D 
For levels of HbA1c ≤ 5.9% in survivors, non-survivors, and total participants with T1D, were 
1.0%, 0.3% and 1.3% respectively. The highest distribution of survivors (17.1%), non-
survivors (1.3%), and total cohort (18.4%) attained glycaemic levels of 8.5-9.0%. Also, HbA1c 
levels ≥ 7.5% was recorded in 77.6%, 6.4%, and 83.7% of survivors, non-survivors, and total 
T1D population respectively. 
4.6.5 IMD (social deprivation) 
The results highlighted in table 4.8 indicate that a proportionate number of people with T1D 
was found in the most deprived quintile (30.4%). A similar trend in distribution was noted in 
both survivors and non-survivor subgroups with 27.8% and 2.6% respectively. 15.1%, 1.3%, 
and 16.5% of survivors, non-survivors and total T1D population were noted to be in the least 
deprived quintile. Figure 4.9 highlights the distribution of survivors and non-survivors in T1D. 
Almost twice the number of people lived in the most deprived areas as compared to the least 
deprived areas. 
       
Figure 4.9: Distribution of survivors and non-survivors in T1D according to IMD 
4.6.6 Systolic blood pressure (SBP) 
Table 4.9 highlights significant statistical relationship between survivors, non-survivors and 
SBP (p-value <0.0001, df =4, X2=99.879). More participants in the survivors, non-survivors 
and total T1D population were found to have higher levels of SBP in the quintile 120-139 
mmHg, having 49.7%, 3.2%, and 52.9% respectively. Only 25.4% of survivors, 0.8% of non-
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survivors and 26.2% of the total T1D population have normal range of SBP (100-119mmHg). 
Those noted to be in the hypertensive stage (≥ 140 mmHg) were 15.1% of the survivors, 5.1% 
of non-survivors, and 20.2% of the total T1D population. Figure 4.10 highlights the distribution 
of the survivors and non-survivors with T1D in the Wirral according to their SBP (mmHg).  
 
 
 
 
 
 
Table 4.9: Distribution of serum creatinine, SBP and DBP amongst the survivors and non-
survivors and total T1D including chi square test for statistical significant association between 
survivors and non-survivors 
Characteristics Survivors N (%) Non-Survivors N (%) Total T1DM p-values 
SBP (mmHg)                                                                                                              <0.001 
≤ 99 8 (0.7) 0 (0) 8 (0.7)  
100–119 279 (25.4) 9 (0.8) 288 (26.2)  
120–139 547 (49.7) 35 (3.2) 582 (52.9)  
140–159 134 (12.2) 40 (3.6) 174 (15.8)  
≥160 31 (2.8) 17 (1.5) 48 (4.4)  
Total 999 (90.8) 101(9.2) 1100 (100)  
DBP (mmHg)                                                                                                             0.001 
≤59 5 (0.5) 3 (0.3) 8 (0.7)  
60-69 147 (13.4) 18 (1.6) 165 (15.0)  
70 – 79 555 (50.5) 41 (3.7) 598 (54.2)  
80 – 89 251 (22.8) 29 (2.6) 280 (25.5)  
90- 99 37 (3.4) 8 (0.7) 45 (4.1)  
≥100 4 (0.4) 2 (0.2) 6 (0.5)  
Total 999 (90.8) 101 (9.2) 1100 (100)  
Serum creatinine (µmol/l)                                                                                          <0.0001 
< 61 96 (6.8) 3 (0.2) 99 (7.0)  
62-106 1066 (75.1) 65 (4.6) 1131 (79.6)  
107-129 98 (6.9) 21 (1.5) 119 (8.4)  
130-149 12 (0.8) 8 (0.6) 20 (1.4)  
≥ 150 30 (2.1) 21 (1.5) 51 (3.6)  
Total 1302 (91.7) 118 (8.3) 1420 (100)  
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Figure 4.10: Distribution of the survivors and non-survivors with T1D in the Wirral 
according to their SBP (mmHg) 
The quintiles above the normal range for systolic blood pressure (≥ 120mmHg) accounted for 
most of the participants in the various subgroups of survivors, non-survivor and overall T1D 
population. 
4.6.7 Diastolic blood pressure (DBP) 
The distribution of the survivors and non-survivors with T1D in the Wirral according to their 
DBP (mmHg) is illustrated in Figure 4.11. Table 4.9 shows that the largest cohort of 
participants had their DBP within 70-79 mmHg range; this is reflected as 50.7% of survivors, 
3.7% of non-survivors and 54.2% of the total population of T1D. Slightly lower proportions of 
survivors, non-survivors, and total T1D population had their DBP within the range 80-89 
mmHg. The relationship between DBP and mortality status was statistically significant (p-
value: 0.001, df = 5, X2 = 20.72). 
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Figure 4.11: Distribution of the survivors and non-survivors with T1D in the Wirral 
according to their DBP (mmHg) 
Majority of the participants in the study had normal diastolic blood pressures. 
4.6.8 Serum creatinine and renal status 
Figure 4.12 shows the distribution of the survivors and non-survivors with T1D in the Wirral 
according to their serum creatinine levels (µmol/l). The association between the various 
subgroups were statistically significant (p-value: <0.001, df = 4, X2 = 125.65). The largest 
cohort of T1D had their creatinine levels within the normal range of 62-106 µmol/l; this was 
reflected as 75.1% of survivors, 4.6% of non-survivors and 79.6% of T1D population. 
                 
Figure 4.12: Distribution of the survivors and non-survivors with T1D in the Wirral 
according to their serum creatinine levels (µmol/l) 
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4.6.9 Total Cholesterol levels (TC) 
Figure 4.13 shows the distribution of the survivors and non-survivors with T1D in the Wirral, 
according to their serum total Cholesterol levels (mmol/l). Those that had serum cholesterol 
levels ≤ 3.9 mmol/l in the survivor, non-survivor, and total T1D population were 14.6%, 0.9%, 
and 15.5% respectively. Conversely, Table 4.10 also shows that those who had serum 
cholesterol levels ≥ 6.2mmol/l in the various subgroups were 4.3% for survivors, 1.3% for non-
survivors, and 5.6% for total T1D population. The correlation between the various subgroups 
and mortality status was also statistically significant (p-value: <0.0001, df = 4, X2 = 28.66). 
               
Figure 4.13: Distribution of the survivors and non-survivors with T1D in the Wirral, 
according to their serum Total Cholesterol levels (mmol/l). 
4.6.10 Total Triglycerides (TG) 
The distribution of the survivors and non-survivors with T1D in the Wirral, according to their 
serum Triglyceride (mmol/l) is reflected in Figure 4.14. Table 4.10 shows that the largest 
cohorts of survivors (66.8%), non-survivors (5.2%) and total T1D populations (72%) had TG 
levels ≤ 1.6 mmol/l. Correlation between survivors and non-survivors were not statistically 
significant (p-value:< 0.063, df = 2, X2 = 5.54) 
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Figure 4.14: Distribution of the survivors and non-survivors with T1D in the Wirral, 
according to their serum Triglyceride (mmol/l). 
Table 4.10: Distribution of TC, TG, HDL, LDL, TC/HDL, LDL/HDL, and TSH amongst 
survivors, non-survivors, and total T1D population including chi square test for statistical 
significant association between survivors and non-survivors 
Characteristics Survivors N (%) Non-Survivors N (%) Total T1D p-values 
Total Cholesterol (mmol/l)                                                                                           < 0.001 
≤3.9 188 (14.6) 12 (0.9) 200  (15.5)  
4.0-4.5 316 (24.5) 25 (1.9) 341 (25.4)  
4.6-5.2 378 (29.3) 24 (1.9) 402 (31.1)  
5.3-6.1 247 (19.1) 29 (2.2) 276 (21.4)  
≥6.2 55 (4.3) 17 (1.3) 72 (5.6)  
Total 1184 (91.7) 107 (8.3) 1291 (100)  
TG (mmol/l)                                                                                                                  0.063 
≤ 1.6 899 (66.8) 70 (5.2) 969 (72.0)  
1.7-2.2 159 (11.8) 22 (1.6) 181 (13.4)  
≥ 2.3 177 (13.2) 19 (1.4) 196 (14.6)  
Total 1235 (91.8) 111 (8.2) 1346 (100)  
HDL (mmol/l)                                                                                                              0.573 
0.4-0.7 5 (0.5) 0 (0) 5 (0.5)  
0.8-1.1 173 (15.6) 10 (0.9) 183 (16.5)  
1.2-1.5 436 (39.4) 32 (2.9) 468 (42.3)  
≥ 1.6 414 (37.4) 37 (3.3) 451 (40.7)  
Total 1028 (92.9) 79 (7.1) 1107 (100)  
LDL (mmol/l)                                                                                                               <0.001 
≤ 2.5 567 (45.5) 30 (2.4) 297 (47.9)  
2.6-3.3 406 (32.6) 24 (1.9) 430 (34.5)  
3.4-4.1 156 (12.5) 25 (2.0) 181 (14.5)  
4.2-4.9 20 (1.6) 4 (0.3) 24 (1.9)  
≥ 5.0 11 (0.9) 4 (0.3) 15 (1.2)  
Total 1160 (93.0) 87 (7.0) 1247 (100)  
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TC/HDL ratio                                                                                                               0.044 
≤ 3.5 790 (60.9) 53 (4.1) 843 (64.9)  
3.6-5.0 343 (26.4) 34 (2.6) 377 (29.0)  
≥ 5.1 68 (5.2) 10 (0.8) 78 (6.0)  
Total 1201 (92.5) 97 (7.5) 1298 (100)  
LDL: HDL ratio                                                                                                            0.022 
≤1.5 379 (30.4) 28 (2.2) 407 (32.6)  
1.6-3.6 746 (59.8) 59 (4.7) 805 (64.5)  
≥ 3.7 29 (2.3) 7 (0.6) 36 (2.9)  
Total 1154 (92.5) 94 (7.5) 1248 (100)  
TSH (mU/L)                                                                                                                  0.014 
≤ 0.4 11 (0.8) 2 (0.1) 13 (1.0)  
0.4-4.0 1124 (82.7) 92 (6.8) 1216 (89.5)  
≥ 4.0 111 (1246) 19 (1.4) 130 (9.6)  
Total  1246 (91.7) 113 (8.3) 1359 (100)  
4.6.11 High-density lipoprotein levels (HDL) levels 
Table 4.10 shows the distribution of the survivors, non-survivors, and total T1D population in 
the Wirral, according to their serum HDL levels. The largest cohort of survivors (39.4%), non-
survivors (2.9%) and total T1D population (42.3%) had HDL levels between 1.2-1.5 mmol/l. 
The smallest proportion of survivors (0.5%), non-survivors (0%) and total T1D population 
(0.5%) had HDL levels between 0.4-0.7mmol/l. Figure 4.15 highlights the distribution of the 
survivors and non-survivors with T1D in the Wirral, according to their serum HDL levels 
(mmol/l). 
                  
Figure 4.15: Distribution of the survivors and non-survivors with T1D in the Wirral, 
according to their serum HDL levels (mmol/l). 
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4.6.12 Low-density lipoprotein levels (LDL) levels 
Figure 4.16 shows the distribution of the survivors and non-survivors with T1D in the Wirral, 
according to their serum LDL levels (mmol/l). It shows a gradual decline in the distribution 
pattern for non-survivors. 
                   
Figure 4.16: Distribution of the survivors and non-survivors with T1D in the Wirral, 
according to their serum LDL levels (mmol/l) 
Table 4.10 shows the distribution of the survivors, non-survivors, and total T1D population in 
the Wirral, according to their serum LDL levels. The largest cohort of survivors (45.5%), non-
survivors (2.4%) and total T1D population (47.9%) had LDL levels ≤ 2.5 mmol/l. Although 
very small proportions of the survivors (0.9%), non-survivors (0.3%), and total T1D population 
(1.2%) had LDL levels ≥5.0 mmol/l. 
4.6.13 Total Cholesterol to HDL ratio 
Figure 4.17 shows the distribution of the survivors and non-survivors with T1D in the Wirral, 
according to their TC/HDL ratio. Table 4.14 illustrates that 4.1%, 2.6%, and 0.8% of non-
survivors had TC/HDL ratios of ≤ 3.5, 3.6-5.0, and ≥ 5.1 respectively. 
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Figure 4.17: Distribution of the survivors and non-survivors with T1D in the Wirral, 
according to their TC/HDL ratio 
4.6.14 Total HDL to LDL ratio 
Figure 4.18 shows the distribution of the survivors and non-survivors with T1D in the Wirral, 
according to their LDL/HDL ratio. Table 4.10 illustrates that 2.2%, 4.7%, and 0.6% of non-
survivors had TC/HDL ratios of ≤ 1.5, 1.6-3.6, and ≥ 3.7 respectively.  
                      
Figure 4.18: Distribution of the survivors and non-survivors with T1D in the Wirral, 
according to their LDL: HDL ratio 
4.6.15 TSH levels (mU/L 
Figure 4.19 shows the distribution of the survivors and non-survivors with T1D in the Wirral, 
according to their LDL: HDL ratio. Table 4.10 shows that the largest cohort of the survivors 
(82.7%), non-survivors (6.8%), and total T1D (89.5%) had normal TSH levels (0.4-4.0 mU/L). 
For non-survivors, 0.1% and 1.4% had TSH level of ≤ 0.4 mU/L and ≥ 4.0 mU/L respectively. 
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Figure 4.19: Distribution of the survivors and non-survivors with T1D in the Wirral, 
according to their TSH levels 
4.6.16 Calendar year of diagnosis 
Table 4.11 illustrates the distribution of amongst survivors, non-survivors, and total T1D 
population, according to calendar year of diagnosis. Figure 4.20 shows the distribution of the 
survivors and non-survivors with T1D in the Wirral, according to their calendar year of 
diagnosis. The subsequent diagnosis of T1D over the 12 years followed a sinusoidal pattern 
but overall a declining trend from 2.4% in 2000 to 0.5% in 2011. Most of the individuals in 
this cohort were diagnosed before the year 2000 (65.9%). During the follow up period, the peak 
period of diagnosis was noticed in the year 2003 (3.3%), however, before this peak, levels of 
diagnosis were 2.4% in 2000, 2.8% in 2001, 2.8% in 2002 and then a gradual decline over the 
next three years to 1.8% in 2006. In 2007, there a minor surge in diagnosis to 2.3%, with a 
further increase in 2008 to 2.7%. 
 
 
Table 4.11: Distribution of amongst survivors, non-survivors, and total T1D population, 
according to calendar year of diagnosis including chi square test for statistical significant 
association between survivors and non-survivor 
Characteristics Survivors N (%) Non-Survivors N (%) Total T1DM p-values 
Calendar year of diagnosis                                                                                             0.005 
≤ 1999 965 (65.9) 110 (7.5) 1075 (73.4)  
2000 35 (2.4) 0 (0) 35 (2.4) 
2001 41 (2.8) 0 (0) 41 (2.8) 
2002 39 (2.7) 2 (0.1) 41 (2.8) 
2003 47 (3.2) 2 (0.1) 49 (3.3) 
2004 36 (2.5) 2 (0.1) 38 (2.6) 
2005 34 (2.3) 0 (0) 34 (2.3) 
2006 26 (1.8) 1 (0.1) 27 (1.8) 
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2007 33 (2.3) 0 (0) 33 (2.3) 
2008 38 (2.6) 1 (0.1) 39 (2.7) 
2009 20 (1.4) 0 (0) 20 (1.4) 
2010 26 (1.8) 0 (0) 26 (1.8) 
2011 7 (0.5) 0 (0) 7 (0.5) 
Total 1347 (91.9) 118 (8.1) 1465 (100) 
 
           
Figure 4.20: Distribution of the survivors and non-survivors with T1D in the Wirral, 
according to their calendar year of diagnosis 
A decline to 1.4% was noted in 2009, and then rise to 1.8% in 2010. The lowest level of 
diagnosis was recorded in 2011 (0.5%). The largest cohorts of survivors were recorded in 2003 
(3.2%), but in the non-survivors group, 3 consecutive years recorded similar proportions of 
non-survivors, these were 2002 (0.1%), 2003 (0.1%), 2004 (0.1%). Following 2004, there was 
a decline in the number of non-survivors. The association between survivors and non-survivors 
considering the calendar of diagnosis was statistically significant (p-value=0.005, df =12, 
X2=28.34). 
Table 4.12: Year of death, number of deaths and rates of change in non-survivors with T1D 
in the Wirral 
Year of death No. of Death Rate of change (%) 
≤ 1999 110 - 
2000 0 - 
2001 0 - 
2002 2 1.79 
2003 2 1.75 
2004 2 1.72 
2005 0 0 
2006 1 0.85 
2007 0 0 
2008 1 0.85 
2009 0 0 
2010 0 0 
0
10
20
30
40
50
2
0
0
0
2
0
0
1
2
0
0
2
2
0
0
3
2
0
0
4
2
0
0
5
2
0
0
6
2
0
0
7
2
0
0
8
2
0
0
9
2
0
1
0
2
0
1
1
Non-Survivors (n)
Survivors (n)
117 
 
2011 0 0 
 
4.7 Cause of mortality 
Of the 113 deaths recorded for the cohort that indicated a proportion of 7.75% of the total T1D 
patients, records for only 37 participants were retrieved. The principal cause of death in this 
cohort was malignancy-related 8 deaths (21.6%), this was followed by cardiovascular disease 
and sepsis, each having 6 deaths (16.2%) respectively. Cerebrovascular disease accounted for 
5 deaths (13.5%). These four conditions accounted for over 60% of all-cause mortality in this 
cohort of T1D patients. Death from diabetes complications (hypoglycaemia) was recorded in 
1 patient (2.7%). Table 4.13 below further illustrated the cause of mortality in this cohort. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.13: Cause of mortality 
Cause of death Males N (%) Females N (%) Total N (%) ICD-10th revision block 
Cardiovascular 
disease 
3 (8.1) 3 (8.1) 6 (16.2) I00 - I09, I11, I13, I20 - 
I51, I21 - I22, I71 - I78 
Cerebrovascular 
disease 
5 (13.5)  5 (13.5) I60 - I69 
Malignancy related 6 (16.2) 2 (5.4) 8 (21.6) C00-C97 
Renal disease  1 (2.7) 1 (2.7) N17 - N19 
Hepatic and 
Gastrointestinal 
3 (8.1) 1 (2.7) 1 (2.7) K70, K73 - K74 
Sepsis 3 (8.1) 3 (8.1) 6 (16.2) A40-A41, A00-A09, 
A20-A39, A42-A49, 
A54-A99, B00-B19, B25-
B99 
Respiratory disease  2 (5.4) 2 (5.4) J40 - J47 
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Diabetes 
complications 
 1 (2.7) 1 (2.7) E10 - E14 
Dementia 2 (2.7) 1 (2.7) 3 (8.1) G30 
Others (obesity, 
external cause 
 1 (2.7) 1 (2.7) V01, V05 - V06, V091, 
V093 - V099, V10 - V11, 
V15 - V18, V193, V198 - 
V199, V800 - V802, 
V806 - V809, V812 - 
V819, V822 - V829, 
V879, V889, V891, 
V893, V899, V90 - X599, 
Y85 - Y869 
Total 22 (59.5) 15 (40.5) 37 (100)  
 
4.8 Mortality analysis and competing risk 
4.8.1. Age- and sex-specific mortality 
Figure 4.21 and Table 4.14 illustrates the Age- and sex-specific mortality rates in both sexes 
with T1D in the Wirral. This reflects a fluctuating but rising trend with age groups. For both 
sexes, the age-specific mortality rates were least in the age 0-4 years, in males and females, the 
age-specific mortality rates were 0.039 (39 deaths per 1000 person-years) and 0.020 (20 deaths 
per 1000 person-years). In the pre-pubertal age group (10-14 years) there was a reversal of 
trend with females having higher age-specific mortality (0.072 [72 per 1000 person years]) as 
compared to males (0.035 [35 per 1000 person-years). In the 15 -19 years age group there was 
a reversal of trend as males had higher age-specific mortality rates than females. The age-
specific mortality rates for the age-group 20-24 year were similar, but the rates in the 25-29 
age group were more than doubles for females (0.158 [158 per 1000 person years]) as compared 
to males (0.056 [56 per 1000 person years]). In the age group, 30-34 years the age-specific 
mortality rates for males was slightly higher than females 0.1286 (128.6 per 1000) and 0.1176 
(117.6 per 1000) respectively. However, in there was a reversal in the trend for the age group 
35-39 were females had a marked increase in the age-specific mortality rate than males having 
values of 0.2727 (272 per 1000) and 0.0746 (74.6 per 1000). This indicates almost a fourfold 
increase age-specific mortality rate between females and males in this age group. The total 
observation time was 17,496 person-years with an overall age-specific mortality rate of 0.0775 
(77.5 per 1000 person-years). Figure 4.22 Age- and sex-adjusted mortality rates in both sexes 
with T1D in the Wirral. After initial adjustment, the age-adjusted mortality rates according to 
gender followed a similar pattern to age-specific mortality rates. The age-adjusted mortality 
rate was lowest in the age group 0-4 years in both sexes, having age-adjusted mortality rates of 
0.0034 (3.4 per 1000 person-years) and 0.0017 (1.7 per 1000 person-years) in males and 
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females respectively. For males, the age group with the highest age-adjusted mortality rate was 
in the age group 20-24 years having an age-adjusted mortality rate of 0.0170 (17 per 1000 
person-years) followed by age group 15-19 years with an age-adjusted mortality rate of 0.0119 
(11.9 per 1000 person-years). In females, the highest recorded age-adjusted mortality rate was 
in the 25-29 year age group 0.0198 (19.8 per 1000 person-years, followed closely by age group 
35-39 with an age-adjusted mortality rate of 0.0187 (18.7 per 1000 person-years). 
Table 4.14: Age- and sex-specific, age- and sex-adjusted mortality rates in T1D and the 
Wirral standard population (per 1000) 
Age 
group 
T1DM population in the Wirral Wirral standard 
population 
 
 Age-specific mortality Age-adjusted mortality Standardised 
Age-adjusted 
mortality 
 
 Males Females Total 
T1D 
Males Females Total 
T1D 
Males Females Total 
0 – 4 0.0395 0.0200 0.0317 0.0034 0.0017 0.0021 0.0050 0.0025 0.0041 
5 – 9  0.0442 0.0165 0.0299 0.0071 0.0026 0.0049 0.0053 0.0020 0.0037 
10 – 14 0.0351 0.0724 0.0526 0.0078 0.0160 0.0123 0.0045 0.0093 0.0071 
15 – 19 0.0952 0.0649 0.0824 0.0119 0.0081 0.0112 0.0129 0.0088 0.0122 
20 – 24 0.1204 0.1222 0.1214 0.0170 0.0173 0.0195 0.0147 0.0150 0.0169 
25 – 29 0.0561 0.1579 0.0984 0.0070 0.0198 0.0137 0.0068 0.0192 0.0132 
30 – 34 0.1286 0.1176 0.1250 0.0092 0.0084 0.0102 0.0149 0.0137 0.0166 
35 – 39 0.0746 0.2727 0.1400 0.0051 0.0187 0.0112 0.0095 0.0349 0.0208 
Total 0.0698 0.0874 0.0775 0.0698 0.0874 0.0775 0.0698 0.0874 0.0775 
 
 
                
Figure 4.21: Age- and sex-specific mortality rates in both sexes with T1D in the Wirral. 
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Figure 4.22: Age- and sex-adjusted mortality rates in both sexes with T1D in the Wirral. 
Females had higher age-adjusted mortality than males in the following age groups 10-14, 20-
24, 25-29, and 35-39. In the 15-19 year age groups, the age-adjusted mortality rate for males 
was almost 2 times the females’ age-adjusted mortality rate, having 0.0119 (11.9 per 1000 
person-years) and 0.0081 (8.1 per 1000 person-years) respectively.    
 
Figure 4.23: Age- and sex-adjusted mortality rates compared to Standardised to Age- and 
sex-adjusted mortality rates in both sexes with T1D in the Wirral. 
Figure 4.23 reflects standardised Age- and sex-adjusted mortality rates in both sexes with T1D 
in the Wirral. This was then standardised to the local Wirral population. A comparison between 
the Age- and sex-adjusted mortality rates and the standardised to Age- and sex-adjusted 
mortality rates reflected a sinusoidal pattern but gradually rising trend. The age groups with 
the highest standardised age-adjusted mortality rates were 30-34 (0.0149 [14.9 per 1000 person 
years]) in males and 35-39 (0.0349 [34.9 per 1000 person years]) in females. Predominantly, 
males had higher standardised age-adjusted mortality rates in the following four age groups, 0-
4, 5-9, 15-19, and 30-34.  
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Figure 4.24 shows age- and sex-specific mortality rates compared to age- and sex-adjusted 
mortality rates in both sexes with T1D in the Wirral. While the age- and sex-specific mortality 
rates for a sinusoidal pattern, the age-adjusted mortality rates follow a linear trend. 
 
 
Figure 4.24: Age- and sex-specific mortality rates compared to the age- and sex-adjusted 
mortality in T1D in the Wirral 
Table 4.15 shows a comparison of the age- and sex-specific rate difference, rate ratio and 
percentage change in adjusted and specific mortality rates in T1D in the Wirral. The mortality 
rate ratios were higher in males than females in three age groups 5-9, 30-34 and 35-39 years. 
For the females, the rate ratios followed a sinusoidal pattern with the highest rate ratio in the 
age group 35-39 years. The male cohort showed a similar sinusoidal pattern with the highest 
rate ratio also in the age group 35-39 years. 
 
Table 4.15: Age- and sex-specific rate difference, rate ratio and percentage change in adjusted 
and specific mortality rates in T1D in the Wirral. 
Age 
group 
Mortality rate 
difference 
Mortality rate 
ratio 
Mortality rate per cent 
change (%) 
 Males Females Males Females Males Females 
0 – 4 -0.0012 -0.0006 0.67 0.67 47.1 47.1 
5 – 9  -0.0048 --0.0018 0.35 0.33 -25.4 -23.1 
10 – 14 -0.0060 -0.0127 0.26 0.27 42.3 -41.9 
15 – 19 -0.0065 -0.0043 0.50 0.51 8.4 8.6 
20 – 24 -0.0167 -0.0119 0.13 0.40 -13.5 -13.3 
25 – 29 -0.0042 -0.0130 0.44 0.45 -2.9 3.0 
30 – 34 -0.0027 -0.0024 0.74 0.11 62.0 63.1 
35 – 39 -0.0007 -0.0036 0.87 0.86 86.3 86.6 
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Considering mortality rate difference, for males, there was a gradual initial increase in the rate 
difference up to the 20-24 age groups, and then a gradual decline onwards to the age group 35-
39 years. Conversely, females a more varying pattern for mortality rate difference. The 
mortality rates per cent change were almost similar in both groups. Before the year 2000, the 
mortality rate ratio was similar for males and females respectively 0.11 for both genders. 
Considering the period 2000 to 2012, the highest risk ratio was in 2006 for females (4.40) and 
2004 for males (3.07). 
Table 4.16: Calendar year- and sex-specific rate difference, rate ratio and percentage change in 
adjusted mortality rates, and absolute excess risk in T1D in the Wirral 
Calendar 
year 
Mortality rate 
difference 
Mortality rate  
ratio 
Mortality rate change 
(%) 
 Males Females Males Females Males Females 
≤1999 -
0.0647 
-0.0683 0.11 0.11 -89.0 -89.0 
2000 - - - - - - 
2001 - - - - - - 
2002 0.0023 0.0027 2.77 2.80 176.9 180.0 
2003 - 0.0052 - 2.41 - 140.5 
2004 - 0.0060 - 3.07 - 206.9 
2005 - - - - - - 
2006 0.0034 - 4.40 - 340 - 
2007 - - - - - - 
2008 - 0.0033 - 2.94 - 194.1 
2009 - - - - - - 
2010 - - - - - - 
2011 - - - - - - 
 
4.8.2. Age-, sex-specific and Age-, sex-adjusted mortality rates, according to 
calendar-year 
Age-, sex- and calendar-year adjusted mortality rates are illustrated in table 4.17. Considering 
the period between 2000 and 2012, the maximal specific mortality rates for this cohort occurred 
in 2004 having a specific mortality rate of 0.0526 (52 per 1000 person-years). Considering 
gender differentiation, males and females had their maximal specific mortality rates in 2006, 
0.0556 (55.6 per 1000 person-years), and 2004, 0.1111 (111 per 1000) respectively. The total 
T1D population had an overall specific mortality rate of 0.0.0805 (80.5 per 1000 person-years). 
By gender differentiation, the specific mortality rate by calendar year followed a sinusoidal 
pattern. Females had higher specific mortality rates than males in all years except. The total 
T1D population also followed a similar sinusoidal pattern. After adjustment and 
standardisation to the Wirral population, the adjusted mortality rate for this cohort had minimal 
variations, while the standardised adjusted mortality rates showed a sinusoidal pattern.  
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Table 4.17: Calendar year- and sex-specific and calendar year- and sex-adjusted mortality rates 
in T1D and the Wirral standard population 
Calendar 
year 
Wirral T1D specific 
mortality rate 
Wirral adjusted 
mortality rate T1D 
Standardised Wirral 
adjusted mortality rate  
 Males Females Total 
T1D 
Males Females Total 
T1D 
Males Females Total 
T1D 
≤1999 0.1005 0.1045 0.1023 0.0727 0.0767 0.0751 0.0080 0.0084 0.0082 
2000 - - - - - - - - - 
2001 - - - - - - - - - 
2002 0.0455 0.0526 0.0488 0.0013 0.0015 0.0014 0.0036 0.0042 0.0039 
2003 - 0.1111 0.0408 - 0.0037 0.0014 - 0.0089 0.0033 
2004 - 0.1111 0.0526 - 0.0029 0.0014 - 0.0089 0.0042 
2005 - - - - - - - - - 
2006 0.0556 - 0.0370 0.0010 - 0.0007 0.0044 - 0.0030 
2007 - - - - - - - - - 
2008 - 0.0625 0.0256 - 0.0017 0.0007 - 0.0050 0.0020 
2009 - - - - - - - - - 
2010 - - - - - - - - - 
2011 - - - - - - - - - 
Total 0.0741 0.0888 0.0805 0.0741 0.0888 0.0805 0.0741 0.0888 0.0805 
 
4.8.3. Standardised mortality ratio (SMR) 
Standardized Mortality Ratio (SMR) is defined as the ratio between the observed numbers of 
deaths to the number of deaths that would be expected in a study population expressed as a 
comparison to the Wirral standard population (per 1000). 
 
 
 
Table 4.18: Age- and sex-specific SMR with their corresponding 95% CI in T1D in the 
Wirral 
Age 
group 
SMR (95% CI) 
 Males Females Total 
0 – 4 7.89 [(-1.28) – 17.06] 8 [(-7.7) – 15.7] 7.96 [0.15 – 15.23] 
5 – 9  8.33 [1.02 – 15.64] 8.26 [(-3.1) – 19.4] 8.05 [2.07 -14.03] 
10 – 14 7.79 [1.56 – 14.02] 7.76 [3.9 – 11.6] 7.42 [3.95 – 10.89] 
15 – 19 7.41 [2.82 – 12] 7.37 [ (-0.4) -15.17] 6.76 [3.35 – 10.17] 
20 – 24 8.18 [3.73 – 11.91] 8.16 [4.34 – 11.94] 7.18 [4.36 – 10] 
25 – 29 8.22 [1.63 – 14.81] 8.21 [3.56 – 12.86] 7.43 [4 – 10.86] 
30 – 34 8.65 [3.01 – 14.29] 8.51 [0.16 -16.86] 7.51 [3.41 – 11.61] 
35 – 39 7.81 [0.95 – 14.67] 7.83 [2.71 – 12.95] 6.73 [3.2 – 10.26] 
Total 1 [0.96 – 1.04] 1 [0.96 -1.04] 1 [0.96 -1.04] 
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The respective distribution of age- and sex-specific SMRs including their corresponding 95% 
CI in the total T1D population, males and females respectively are reflected in Figures 4.25 
4.26, and 4.27. The highest SMRs for both sexes was recorded in the age group 30-34 having 
SMRs of 8.65 [95% CI: 3.01 – 14.29], 8.51 [95 % CI: 0.16 -16.86] in males and females 
respectively. The highest value for SMR in total T1D population was 8.05 [95% CI: 2.07 -
14.03] in the age group 5-9 years. The broadened CI reflect that the exact value for the SMR 
remains uncertain, this is due to the influence of the effect sizes in the age groups. Males had 
higher SMRs than females for all but three age groups 0-4, 5-9, and 35-39 years.  
                 
Figure 4.25: Age- and sex-specific SMR [95%CI] in total T1D population 
 
                    
Figure 4.26: Age- and sex-specific SMR [95% CI] in females 
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Figure 4.27: Age- and sex-specific SMR [95% CI] in males 
Table 4.19 reflects the SMRs according to the calendar year of diagnosis. The overall trend 
reflects no change SMR within the follow-up period. There were no deduced values for SMRs 
in the years 2000, 2001, 2005, 2007, 2009, 2010, 2011. This was because they estimated zero 
person-years. These values can be attributed to the small numbers in this cohort. Further 
illustration is reflected in Figure 4.28. There were no variations in SMRs according to gender 
reflected in Figures 4.29 and 4.30. 
 
 
 
 
 
Table 4.19: Calendar year SMR [95%CI] in T1D in the Wirral 
Calendar year SMR [95% CI] 
 Males Females Total 
≤1999 12.6 [(-2.5) – 27.7] 12.4 [4.95 – 19.85] 12.5 [10.2 -14.8] 
2000  - - 
2001  - - 
2002 12.5 [(-12) – 37] 12.5 [(-12) – 37] 12.5 [(-4.8) – 29.8] 
2003  12.5 [(-4.8) – 29.8]  12.5 [(-4.8) – 29.8] 
2004  12.5 [(-4.8) – 29.8]  12.5 [(-4.8) – 29.8] 
2005  - - 
2006 12.5 [(-12) – 37] - 12.5 [(-12) – 37] 
2007  - - 
2008  12.5 [(-12) – 37] 12.5 [(-12) – 37] 
2009  - - 
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2010  - - 
2011  - - 
Total 1 [0.74 – 1.26] 1 [0.96 – 1.04] 1 [0.82 – 1.18]] 
 
               
Figure 4.28: SMR per calendar- year in people with T1D 
 
Figure 4.29: SMR [95%CI] according to calendar year in males with T1D in the Wirral 
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Figure 4.30: SMR [95% CI] according to the calendar year in females with T1D in the Wirral 
4.9 Median survival 
Median survival in this population subset (T1D population), relates to a statistical measure that 
determines how long patients survive with disease in general, estimated in years. Table 4.20 
reflects estimates of comparative measures of the median survival times in years for the T1D 
population, using the predictors of mortality and estimating the p-values for males and females. 
Analysis of the median survival showed that significant predictors (p-value <0.05) of survival 
for this cohort were duration of diabetes, HbA1c, Serum creatinine, BMI, and lipid levels.  
4.9.1. Gender and survival time 
The overall median survival time for T1D population was 76.906 years [95% CI: 75.041 – 78. 
771]. Males had a median survival period of 77.185 years [75.191 – 79.179], which was slightly 
higher than females with median survival of 76.011 years [73.169 – 78.000].  Figure 4.31 
illustrates the survival curve according to gender in people with T1D in the Wirral, the 
relationship between both sexes was not statistically significant (p-value= 0.226).  
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Figure 4.31: Survival curve according to gender in people with T1D in the Wirral 
Table 4.20: Comparative median survival of the various predictors of mortality in T1D 
including p-values from log-rank test for statistical significance 
Predictors  
of  
mortality 
Median survival (years) P-
values 
 Males [95%CI] Females [95%CI] Total [95% CI]  
Gender 77.185 [75.191 – 79.179] 76.011 [73.169 – 78.000] 76.906 [75.041 – 78. 771] 0.226 
Age of 
diagnosis 
(years) 
   0.625 
0 – 4 62.115 [56.308 – 67.922] 63.348 [60.181 – 66.515] 62.980 [59.151 – 66.810]  
5 – 9 69.973 [64.633 – 75.313] 68.550 [65.036 – 72.063] 71.626 [68.197 – 75.055]  
10 – 14 71.423 [65.729 – 77.117] 73.948 [65.882 – 82.013] 75.513 [68.989 – 82.037]  
15 – 19 73.058 [68.965 – 77.150] 72.917 [66.767 – 77.626] 72.923 [69.751 – 76.096]  
20 – 24 76.318 [72.826 – 79.809] 72.947 [69.579 – 76.315] 75.328 [72.612 – 78.043]  
25 – 29 77.576 [73.550 – 81.603] 76.309 [71.682 – 80.935] 77.527 [74.099 – 80.955]  
30 – 34 78.799 [73.942 – 83.655] 68.656 [64.728 – 72.584] 77.586 [73.117 – 82.054]  
35 – 39 81.893 [76.921 – 86.866] 75.729 [67.229 – 84.228] 79.223 [74.079 – 84.366]  
Total 77.192 [75.075 – 79.309] 76.634 [73.505 – 79.762] 77.228 [75.191 – 79.265]  
Duration of 
Diabetes 
   0.004 
1-10 48.416 [47.625 – 49.207] 45.527 [42.961 – 48.094] 47.396 [46.334 – 48.457]  
11-20 72.781 [70.370 – 75.193] 55.189 [53.635 – 56.744] 72.168 [69.729 – 74.607]  
21-30 65.918 [64.402 – 67.433]  73.792 [68.679 – 78.904]  75.221 [72.891 – 77.551]  
31-40 77.667 [75.847 – 79.487] 68.555 [66.423 – 70.687]  74.279 [70.933 – 77.626]  
41-50 78.276 [73.993 – 82.559] 76.666 [72.746 – 80.586] 78.677 [75.427 – 81.928]  
Total 79.020 [76.058 – 81.982] 73.434 [72.746 – 80.586] 76.936 [74.358 – 79.514]  
Index of 
Multiple 
Deprivation 
   0.607 
Quintile 
1(most 
deprived) 
76.109 [72.251 – 79.968] 73.820 [68.684 – 78.957] 75.490 [72.050 – 78.929]  
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Quintile 
2(above 
average) 
76.678 [70.274 – 83.081] 80.179 [74.081 – 86.277] 79.409 [74.452 – 84.367]  
Quintile 
3(average) 
78.940 [74.958 – 82.922] 77.483 [73.773 – 81.193] 78.004 [74.999 – 81.010]  
Quintile 
4(below 
average) 
77.910 [75.068 – 80.753]  70.117 [66.389 – 73.845] 74.356 [71.895 – 76.817]  
Quintile 5 
(least 
deprived) 
76.796 [73.188 – 80.404] 78.065 [72.537 – 83.594] 77.099 [73.755 – 80.422]  
Total 77.185 [75.191 – 79.179] 76.011 [73.169 – 78.854] 76.906 [75.041 – 78.771]  
HbA1c 
%(mmol/mol) 
   0.034 
≤ 5.9 (41) 59.415 [44.180 - 79.649] 58.286 [45.040 - 93.531] 59.101 [45.607 – 72.595]  
6.0-6.4(42-46) 77.873 [72.679 - 83.066] 80.000 [67.005 - 85.928] 82.478 [77.644 – 87.312]  
6.5-6.9(48-52) 73.000 [71.573 - 90.427] 74.000 [76.272 - 91.728] 72.931 [68.394 – 77.469]  
7.0-7.4(53-57) 79.600 [77.009 - 86.191] 73.379 [67.106 - 79.652] 76.595 [69.380 – 83.810]  
7.5-8.0(58-64) 77.000 [74.023 - 85.977] 75.000 [70.214 - 95.786] 76.633 [73.697 – 79.569]  
8.1-8.4(65-68) 78.000 [70.383 - 85.617] 75.000 [71.554 - 92.446] 77.815 [72.236 – 83.394]  
8.5-9.0(69-75) 82.000 [80.519 - 83.481] 78.000 [72.051 - 83.949] 77.214 [74.726 – 79.703]  
9.1-9.4(76-79) 74.000 [62.585 - 85.415] 78.254 [71.696 - 84.813] 68.493 [64.895 – 72.092]  
9.5-10(80-86) 81.000 [71.930 - 96.070] 78.000 [67.630 - 88.370] 74.913 [70.375 – 79.451]  
≥ 10.1 71.000 [67.020 - 74.980] 75.217 [70.903 - 79.531] 73.620 [69.727 – 77.512]  
Total 75.000 [75.777 - 84.223] 77.000 [77.122 - 82.878] 76.542 [74.508 – 78.576]  
Smoking 
status 
   0.382 
Never smoked 77.750 [75.341 – 80.159] 77.768 [74.018 – 81.519] 78.518 [75.634 – 81.401]  
Smokes 75.338 [71.689 – 78.987] 69.159 [62.732 – 75.589] 73.104 [69.584 – 76.625]  
Ex-smoker 76.339 [75.192 – 81.459] 73.580 [69.910 – 77.251] 77.223 [74.557 – 79.889]  
Total 78.617 [76.491 – 80.743] 76.802 [73.706 – 79.899] 78.121 [76.025 – 80.216]  
BMI (kg/m2)    0.023 
≤ 18.4 77.000 [76.282 - 85.718] 78.000 [75.000 - 82.000] 77.667 [72.533 - 86.800]  
18.5 - 24.9 68.000 [52.177 - 83.823] 66.000 [55.451 - 76.549] 67.000 [52.282 - 85.718]  
25.0 - 29.9 64.000 [57.337 - 70.663] 69.000 [64.836 - 73.164] 79.000 [78.801 - 85.199]  
30.0 - 34.9 70.000 [67.078 - 72.922] 69.000 [57.313 - 80.687] 78.000 [76.069 - 95.931]  
35.0 - 39.9 40.000 [22.396 - 57.604] 61.000 [48.998 - 73.002] 60.000 [45.075 - 79.925]  
≥ 40 - 59.000 [33.520 - 84.480] 66.000 [63.390 - 75.883]  
Total 68.000 [62.534 - 73.466] 69.000 [65.102 - 72.898] 73.000 [65.562 - 84.438]  
Serum 
creatinine 
(µmol/l) 
   <0.001 
< 61 65.500 [63.421 – 67.579] 51.400 [49.912 – 52.888] 60.250[54.128 –  66.372]  
62-106 78.723 [75.711 – 81.735] 77.991 [74.287 – 81.695] 78.522 [75.763 – 81.281]  
107-129 78.889 [75.090 – 82.688] 79.679 [72.013 – 87.344] 79.734 [75.687 – 83.782]  
130-149 73.000 [61.440 – 74.470] 74.133 [66.147 – 82.210] 73.472 [68.134 – 78.810]  
≥ 150 67.955 [61.440 – 74.470] 64.756 [57.052 – 72.461] 66.462 [61.569 – 71.354]  
Total 77.108 [75.059 – 78.930] 76.453 [73.498 – 79.409] 76.995 [75.060 – 78.930]  
Systolic BP 
(mmHg) 
   0.687 
≤ 99 - - -  
100 – 119 57.000 [13.374 - 
100.626] 
57.000 [33.626 - 80.374] 57.000 [41.443 - 72.557]  
120 – 139 59.000 [50.412 - 67.588] 66.000 [61.003 - 70.997] 65.000 [61.859 - 68.141]  
140 – 159 76.000 [74.243 - 77.757] 73.000 [67.325 - 78.675] 73.000 [70.106 - 75.894]  
≥160 71.000 [61.703 - 80.297] 67.000 [57.947 - 76.053] 70.000 [65.403 - 74.597]  
Total 70.000 [64.781 - 75.219] 69.000 [64.937 - 73.063] 69.000 [65.329 - 72.671]  
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Diastolic BP 
(mmHg) 
   0.008 
≤59 87.000 [87.000 – 87.000] 76.000 [70.120 – 81.880] 79.000 [69.398 – 88.602]  
60-69 76.167 [71.838 – 80.496] 74.100 [70.221 – 77.980] 76.000 [74.091 – 77.909]  
70 – 79 79.741 [76.762 – 82.719] 79.130 [74.446 – 83.814] 82.000 [78.688 – 85.312]  
80 – 89 75.785 [72.954 – 78.616] 72.353 [68.716 – 75.990] 78.000 [76.111 – 79.289]  
90- 99 71.320 [67.124 – 75.516] 63.500 [57.400 – 69.600] 71.000 [66.756 – 75.244]  
≥100 46.667 [38.132 – 55.202] 65.000 [60.842 – 69.158] 62.000 [24.207 – 99.793]  
Total 77.806 [75.493 – 79.452] 76.225 [73.245 – 79.206] 79.000 [76.284 – 81.716]  
Total 
Cholesterol 
(mmol/l) 
   0.002 
≤3.9 78.067 [72.011 – 84.122] 68.244 [63.272 – 73.215] 76.000 [71.184 – 81.844]  
4.0-4.5 75.231 [72.073 – 78.390] 74.629 [70.364 – 78.895] 82.000 [76.565 – 87.435]  
4.6-5.2 79.269 [76.907 – 81.631] 75.312 [71.735 – 78.889] 79.000 [71.523 – 86.477]  
5.3-6.1 75.643 [69.501 – 81.784] 74.647 [68.839 – 79.355] 70.000 [63.128 – 76.872]  
≥6.2 64.239 [58.415 – 70.063] 69.812 [62.839 – 76.785] 79.000 [75.895 – 82.105]  
Total 77.191 [74.962 – 79.412] 76.062 [72.941 – 79.184]   
High density 
lipoproteins 
[HDL] 
(mmol/l) 
   <0.001 
0.4-0.7 69.000 [58.043 - 79.957] 73.000 [62.837 - 83.163] 71.000 [62.000 - 86.000]  
0.8-1.1 74.000 [53.808 - 94.192] 65.000 [59.814 - 70.186] 70.000 [59.010 - 82.990]  
1.2-1.5 64.000 [46.937 - 81.063] 67.000 [63.477 - 70.523] 65.000 [44.929 - 85.071]  
≥ 1.6 69.000 [62.195 - 75.805] 67.000 [63.675 - 70.325] 68.000 [62.045 - 89.955]  
Total - - -  
Triglycerides 
[TG] (mmol/l) 
   <0.001 
≤ 1.6 81.000 [78.152 – 83.848] 78.000 [71.840 – 84.160] 81.000 [77.007 – 84.993]  
1.7-2.2 77.000 [65.451 – 88.848] 74.000 [65.068 – 82.932] 77.000 [73.955 – 80.045]  
≥ 2.3 70.000 [60.933 – 79.067] 72.000 [62.015 – 81.985] 70.000 [64.220 – 75.780]  
Total 81.000 [77.898 – 74.102] 77.000 [71.319 – 82.681] 79.000 [76.061 – 81.939]  
Low density 
lipoprotein 
[LDL] 
(mmol/l) 
   <0.001 
≤ 2.5 81.044 [77.745 – 84.343] 74.994 [71.905 – 78.083] 79.417 [76.711 – 82.063]  
2.6 - 3.3 78.738 [75.829 – 81.647] 79.054 [73.373 – 84.735] 82.000 [77.077 – 86.923]  
3.4 - 4.1 78.145 [73.426 – 82.864] 72.735 [67.902 – 77.568] 78.000 [76.550 – 79.450]  
4.2 - 4.9 49.857 [47.783 – 51.931] 58.857 [50.061 – 67.653] 58.857 [51.547 – 66.167]  
≥ 5.0 45.000 [37.031 – 52.969] 70.800 [45.512 – 96.088] 67.563 [52.433 – 82.692]  
Total 79.512 [77.262 – 81.762] 76.804 [73.703 – 79.906] 78.611 [76.424 – 80.797]  
Total 
Cholesterol : 
HDL ratio 
   <0.001 
≤ 3.5 82.000 [79.317 – 84.683] 78.000 [73.539 – 82.461] 81.000 [77.205 – 84.795]  
3.6-5.0 77.000 [72.142 – 81.858] 74.000 [64.528 – 83.472] 77.000 [73.327 – 80.673]  
≥ 5.1 58.000 [49.826 – 66.174] 73.000 [61.078 – 75.783] 70.000 [52.128 – 87.872]  
Total 81.000 [79.101 – 82.899] 78.000 [74.228 – 81.772] 79.000 [76.698 – 81.302]  
Low Density 
Lipoproteins : 
HDL ratio 
   <0.001 
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≤ 1.5 81.000 [76.755 – 85.245] 77.000 [71.768 – 82.232] 80.808 [76.929 – 84.688]  
1.6-3.6 61.141 [53.151 – 69.670] 78.000 [70.058 – 85.942] 76.030 [73.974 – 78.086]  
≥ 3.7 81.000 [78.213 – 83.783] 73.000 [51.093 – 82.621] 63.823 [57.075 – 70.571]  
Total 79.000 [76.681 – 81.313] 77.000 [72.648 – 81.352] 77.750 [75.571 – 79.930]  
 
4.9.2. Age at diagnosis and survival time 
Table 4.20 highlights that early age at diagnosis (≤ 10 years) accounted for reduced median 
survival time, in males and females. The overall trend for the total T1D cohort follows a 
sinusoidal pattern but with a gradually increasing trend. The lowest median survival time from 
diagnosis was found in the age group 0-4 years while highest median survival time was found 
in the age group 35-39 years. The overall median survival for the T1D population was  
77.228 years [95% CI: 75.191 – 79.265], females 76.634 years [95% CI: 73.505 – 79.762], and 
males 77.192 years [95% CI: 75.075 – 79.309]. For the total T1D population, there was a 
gradual increased up the age 10-14 years then a minor drop in age 15-19 years, then a gradual 
increase up to the age 35-39 years. For diagnosis at the pubertal years (10-14 years), females 
fared better than males having a median survival time of 73.948 years [95 % CI: 65.882 – 
82.013] as compared to 71.423 years [95% CI: 65.729 – 77.117]. The general trend shows that 
males had better survival in the following age groups 5-9, 15-19, 20-24, 25-29, 30-34, and 35-
39 years. Females had better survival if they were diagnosed in the following age groups 0-4, 
and 10-14 years. There was a marked difference in median survival time of almost 10 years 
between males and females in the age group 30-34 years, having median survival times of 
78.799 years [95% CI: 73.942 – 83.655] and 68.656 years [95% CI: 64.728 – 72.584] 
respectively. This difference dropped to 6 years in the age group 35-39 year, having median 
survival periods of 81.893 years [95% CI:76.921 – 86.866], and 75.729 years [95% CI: 67.229 
– 84.228] in males and females respectively. 
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Figure 4.32: Survival curve according to the age at diagnosis (years) in people with T1D 
Figure 4.32 shows the survival curve according to the age at diagnosis (years) in people with 
T1D. The relationship between the groups was not statistically significant (p-value= 0.625). 
4.9.3. Duration of diabetes and survival time 
Figure 4.33 shows the survival curve according to the duration of diabetes (years) in people 
with T1D in the Wirral. According to the duration of diabetes, the optimum median survival 
time was noted to be in those who had duration of diabetes between 41-50 years, 78.276 years 
[95% CI: 73.993 – 82.559] for males, females 76.666 years [95% CI: 72.746 – 80.586], and 
overall T1D population 78.677 years [95% CI: 75.427 – 81.928]. The overall values for median 
survival according to the duration of diabetes was 79.020 years [95% CI: 76.058 – 81.982] in 
males, 73.434 years [95% CI: 72.746 – 80.586] in females, and 76.936 years [95% CI: 74.358 
– 79.514] in the total population 
               
 
Figure 4.33: Survival curve according to the duration of diabetes (years) in people with T1D 
in the Wirral. 
4.9.4. Year of diagnosis and survival time 
Figure 4.34 shows the survival curve according to the year of diagnosis in people with T1D in 
the Wirral. 
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Figure 4.34: Survival curve according to the year of diagnosis in people with T1D 
4.9.5. Index of multiple deprivations (IMD) and survival time 
The optimum median survival period for males, was found in the third quintile (average) with 
median survival times of 78.940 years [95% CI: 74.958 – 82.922], and in quintile 2 (above 
average) for females and T1D population having a median survival of 80.179 years [95% CI: 
74.081 – 86.277], and 79.409 years [95% CI: 74.452 – 84.367] respectively. 
                  
Figure 4.35: Survival curve according to the IMD (quintiles) in people with T1D 
For the most deprived, males had longer median survival time 76.109 years [95% CI: 72.251 
– 79.968] as compared to females 73.820 years [95% CI: 68.684 – 78.957]. The difference in 
median survival time for this group was 3 years.  Figure 4.35 illustrates the survival curve 
according to the IMD (quintiles) in people with T1D. 
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4.9.6. HbA1c and survival time 
The relationship between the various subgroups and HbA1c was not statistically significant (p-
value=0.607). For those with levels of HbA1c ≤ 5.9% (41mmol/mol), the average age at death 
was 59.101 years [95% CI: 45.607 – 72.595]. As illustrated in Table 4.20 and Figure 4.36. 
                       
Figure 4.36: Survival curve according to serum HbA1c (%) in people with T1D in the Wirral. 
The overall trend follows a sinusoidal pattern with the optimum survival time noted with those 
having HbA1c
 values of 6.0-6.4(42-46) mmol/mol with median survival of 82.478 years [95% 
CI: 77.644 – 87.312]. 
4.9.7. Smoking status and survival time 
The survival curve according to smoking status is illustrated in Figure 4.37. Overall, those that 
never smoked survived longer than those who smoked had a median survival time of 78.518 
years [95% CI: 75.634 – 81.401] and 73.104 years [95% CI: 69.584 – 76.625] respectively.  
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Figure 4.37: Survival curve according to the smoking status in people with T1D in the Wirral 
However, the difference between smokers and no-smokers was more apparent in the female 
cohort where there was the 8-year difference in median survival times. 
4.9.8. Body mass index (BMI) and survival time 
Figure 4.38 illustrates the survival curve associated with the various categories of BMI. The 
median survival time for overall T1D population was 73.000 years [95% CI: 65.562 - 84.438]. 
BMI categories of 35.0 - 39.9 and ≥ 40 (kg/m2) are noted to have reduced survival times of 
40.000 years [95% CI; 22.396 - 57.604] in males, 61.000 years [95% CI: 48.998 - 73.002] in 
females, and 61.000 years [95% CI: 48.998 - 73.002] in the total T1D population. 
                             
Figure 4.38: Survival curve according to the BMI (kg/m2) in people with T1D in the Wirral 
Those with normal BMI range had median survival times of 68.000 years [95% CI: 52.177 - 
83.823] for males, 66.000 years [95% CI: 55.451 - 76.549] for females, and 67.000 years [95% 
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CI: 52.282 - 85.718]. Incidentally, those with BMI ≤ 18.4 kg/m2 had higher survival times than 
those with normal BMI. This is probably due to the skewness of the population, as a large 
proportion of participants in this cohort were in their pre-teen and teenage years. 
Serum creatinine and survival time 
The median survival times found in those with normal serum creatinine levels, were median 
survival of 78.723 years [95% CI: 75.711 – 81.735] for males, 77.991 years [95% CI: 74.287 
– 81.695] for females and 78.522 years [95% CI: 75.763 – 81.281] for T1D.  
                    
 
Figure 4.39: Survival curve according to serum creatinine levels (µmol/l) in people with T1D 
in the Wirral 
A gradual decrease in median survival was noted as serum creatinine levels increased above 
the normal levels. The overall median survival for T1D according to serum creatinine levels 
was 76.995 years [95% CI: 75.060 – 78.930]. Overall, men and women had almost similar 
median survival times with statistically relevant relationship (p-value = <0.001). Figure 4.39 
shows the survival curves for the various serum creatinine levels. 
4.9.9. Systolic blood pressures and survival time 
Median survival time for various systolic blood pressure ranges reveals a sinusoidal pattern. 
The overall average survival time for T1D population is 69 years [95%CI: 65.329 - 72.671]. 
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Figure 4.40: Survival curve according to systolic blood pressure (mmHg) in people with 
T1D. 
The lowest median survival period in this cohort was identified in those who had SBP range of 
100-119, having a survival period of 57 years in males, females and the overall T1D population. 
The relationship of the various subgroups was not statistically significant (p-value=0.483). 
Figure 4.40 illustrates the survival curve for SBP. 
4.9.10. Diastolic blood pressure and survival time 
Table 4.20 shows the various categories of DBP and their median survival rates. The trend 
showed a reduction in survival time as the DBP increased. The lowest median survival was 
recorded in those who had DBP ≥100mmHg, having median survival times of 46.667 years 
46.667 [95%CI: 38.132 - 38.132] for males, 65 years [95%CI: 60.842 - 69.158] for females 
and 62 years [95%CI: 24.207 - 99.793] for T1D. 
                  
 
Figure 4.41: Survival curve according to the diastolic blood pressure (mmHg) in people with 
T1D, in the Wirral 
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There was a difference of 19 years in survival time between females and males in those with 
DBP ≥100mmHg. The overall the median survival for DBP was 77.806 years [95% CI: 75.493 
– 79.452] in males, 76.225 years [95% CI: 73.245 – 79.206] in females and 79.000 years [95% 
CI: 76.284 – 81.716] for the overall T1D population. The relationships between the various 
groups were statistically significant (P-value= 0.008). Figure 4.41 illustrates the survival curve 
for DBP. 
4.9.11. Total Cholesterol and survival time 
The survival curve according to the various categories of cholesterol levels is illustrated by 
figure 4.42.  Overall, males, females and T1D population had median survival times of 77.191 
years [95% CI: 74.962 – 79.412], 76.062 years [95% CI: 72.941 – 79.184], and 76.000 [72.184 
– 82.844]. 
     
 
Figure 4.42: Survival curve according to the total Cholesterol (mmol/l) in people with T1D 
For the overall population, higher levels of cholesterol resulted in reduced survival times. 
Those with levels of cholesterol of 5.3-6.1 and ≥6.2 mmol/l had median survival times of 
70.000 years [95% CI: 63.128 – 76.872] and 66.000 years [95% CI: 60.895 – 82.105] 
respectively as compared to 76.000 years [95% CI: 71.184 – 81.844] in those with levels of 
≤3.9mmol/l. The association between the various groups was statically relevant (p-
value<0.002). 
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4.9.12. High-density lipoproteins [HDL] and survival time 
Although there was little differentiation between the various subgroups, those who with HDL 
levels of 0.4-0.7 mmol/l had an average survival time of 71.000 years [95% CI: 62.000 - 
86.000] as compared to 68.000 years [95% CI: 62.045 - 89.955] in those with HDL levels ≥ 
1.6 mmol/l. 
                 
 
Figure 4.43: Survival curve according to HDL (mmol/l) in people with T1D in the Wirral 
The was a gradual decrease in median survival with increase in HDL levels. In the subgroup 
that had HDL levels of 0.4-0.7 mmol/l, females had higher median survival than males with a 
difference of 4 years, while for those having HDL levels ≥ 1.6 mmol/l males had higher median 
survival than females with a difference of 2 years.  The survival curve showing the interaction 
of the various subgroups is illustrated in Figure 4.43. 
4.9.13. Triglycerides [TG] (mmol/l) and survival time 
Values of TG levels of ≤ 1.6 mmol/l had the best median survival times, having median survival 
of 81.000 years [95% CI: 78.152 – 83.848] for males, 78.000 years [95% CI: 71.840 – 84.160] 
for females and 81.000 years [95% CI: 77.007 – 84.993] in T1D population. For TG levels ≥ 
2.3mmol/l, median survival times for males, females and T1D were 70.000 years [95% CI: 
60.933 – 79.067], 72.000 years [95% CI: 62.015 – 81.985], and 70.000 years [95% CI: 64.220 
– 75.780] respectively. 
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Figure 4.44: Survival curve according to serum Triglyceride level (mmol/l) in people with 
T1D, in the Wirral 
This represented a minimum difference of 3 years between those with values ≤ 1.6 mmol/l and 
those with values ≥ 2.3mmol/l. The overall median survival for this cohort was 79.000 years 
[95% CI: 76.061 – 81.939]. The association between the various subgroups was statistically 
significant (p-value <0.001). The survival curve showing the associations of the various groups 
is illustrated in figure 4.44. 
4.9.14. Low-density lipoprotein [LDL] (mmol/l) and survival time 
In males, there was a definite trend to indicate reduced survival as levels of LDL increased; 
this trend was also replicated in females and total T1D population except in those with levels 
of ≥ 5.0 mmol/l. 
                 
 
Figure 4.45: Survival curve according to the serum LDL (mmol/l) in people with T1D, in the 
Wirral 
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The differences between those having LDL levels of ≤ 2.5 mmol/l and 4.2 - 4.9 mmol/l was 31 
years in males, 16 years in females and 21 years in T1D population. The median survival for 
this cohort was 78.611 years [95% CI: 76.424 – 80.797]. The relationship between the various 
subgroups was statistically significant (p-value <0.001). This relationship is illustrated by the 
survival curve Figure 4.45. 
4.9.15. Total Cholesterol: HDL ratio and survival times 
Reduce median survival times were observed with increasing values for TC: HDL ratios. Those 
who had ratios of ≤ 3.5 had median survival times of 82.000 years [95% CI: 79.317 – 84.683] 
in males, 78.000 years [95% CI: 73.539 – 82.461] in females and 81.000 years [95% CI: 77.205 
– 84.795] in T1D. 
                     
 
Figure 4.46: Survival curve according to the total Cholesterol-to-HDL ratio in people with 
T1D 
In contrast, those with ratios ≥ 5.1 had median survival times of 58.000 years [95% CI: 49.826 
– 66.174] for males, 73.000 years [95% CI: 61.078 – 75.783] for females, and 70.000 years 
[95% CI: 52.128 – 87.872] for T1D. This indicates a difference between the 2 subgroups of 
ratios was 24 years in males, 5 years in females, and 11 years in T1D. There was minimal 
difference between males and females and the relationship between the various subgroups was 
statistically significant (p-value < 0.001). This is shown by the survival curve Figure 4.46. 
4.9.16. Low-Density Lipoprotein LDL: HDL ratio and survival times 
A similar trend of reducing median survival times with increasing ratios was observed with 
LDL: HDL ratios. Figure 4.47 indicates the curve of T1D population according to their LDL: 
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HDL ratios. This trend indicates an inverse relationship; as higher values were associated with 
poorer survival in the various subgroups. 
                         
Figure 4.47: Survival curve according to the LDL: HDL ratio in people with T1D in the 
Wirral 
The difference between the various subgroups was statistically significant (p-value <0.001). 
The difference between those with ratios ≤ 1.5 and ≥ 3.7 was 21 years for males, 4 years for 
females and 17 years for T1D. Males had higher median survival than females of a minimum 
difference of 3 years for those with ratios 1.6-3.6 and a maximum difference of 13 years in 
those with ratios of ≥ 3.7. 
4.10 Hazard Ratios 
The hazard ratio (HR) is defined as a measure of the likelihood of mortality at a specified time 
value of the predictors or risk. Following modelling, one potential benefit is to ascertain which 
of the predictors or combination of predictors influence the median survival. This also creates 
a platform to ascertain prognosis of the disease condition. Figure 4.48 illustrates the survival 
curve for people with T1D with gender differentiation. 
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Figure 4. 48: Survival curve for people with T1D, in the Wirral between years 2000 and 
2012, according to gender. 
Females had better survival than men during the period under consideration (-2 log likelihood 
statistics = 2202.60; X2=.004; p-value 0.949). The multivariate analysis of the predicting 
variables and their corresponding HR, 95%CI and p-values as illustrated in Table 4.23. Gender, 
BMI (kg/m2), index of multiple deprivations, High-density lipoproteins HDL (mmol/l), 
TC/HDL ratio, LDL/HDL ratio, Age at diagnosis, Duration of diagnosis were not effective in 
the ascertaining the probability of mortality in T1D. 
Table 4.21: Predicting factors and hazard ratios with their corresponding 95% CI 
Predicting factors Hazard ratios [95 % CI] p-values 
Gender 0.962 [0.231 – 2.070] 0.692 
Systolic BP (mmHg) 1.666 [0.669- 4.149] 0.273 
Diastolic BP (mmHg) 1.105 [0.414- 2.953] 0.842 
Smoking status 1.241 [0.606- 2.540] 0.556 
Serum creatinine (µmol/l) 1.964 [1.088- 3.545] 0.025 
HbA1c (%) 1.101 [0.812- 1.493] 0.534 
BMI (kg/m2) 0.923 [0.486 - 1.752] 0.806 
IMD quintiles 0.722 [0.474- 1.100] 0.129 
Total Cholesterol (mmol/l) 1.829 [0.712 - 4.700] 0.210 
High-density lipoproteins (mmol/l) 0.319 [0.066- 1.543] 0.156 
Low-density lipoproteins (mmol/l) 1.346 [0.426- 4.254] 0.613 
Triglycerides (mmol/l) 1.286 [0.545- 3.036] 0.566 
TC/HDL ratio 0.496 [0.094- 2.622] 0.409 
LDL/HDL ratio 0.595 [0.123- 2.888] 0.520 
Age at diagnosis 0.799 [0.868 - 0.939] 0.326 
Duration of diagnosis 0.964 [0.510- 1.250] 0.559 
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In contrast, the following predicting factors were linked with greater risk of mortality in T1D; 
SBP (mmHg), DBP (mmHg), smoking status, serum creatinine (µmol/l), HbA1c (%), Total 
Cholesterol (mmol/l), Low-density lipoproteins LDL (mmol/l), and Triglycerides TG (mmol/l). 
However, all the predicting variables considered were statistically insignificant but clinically 
significant (p-value >0.05).  
 
Computation was done to adjust for predictors that did not cross the 1.0 value line to determine 
the significant variable on which the Cox model was based; there was no alteration to those 
shown in table 4.24. Values of the coefficients for the predictor variables of gender, BMI 
(kg/m2), IMD quintiles, HDL (mmol/l), TC/HDL ratio, LDL/HDL ratio, Age at diagnosis, and 
duration of diabetes (years) were computed to evaluate if the Cox model was dependent any of 
them. Table 4.22 shows the results elaborating on their HR and 95% CI. 
 
Table 4.22: Explanatory factors which the Cox model did not depend on after adjustments. 
Predicting factors Hazard ratios [95 % CI] p-values 
Gender 0.784 [0.356 - 1.727] 0.546 
BMI (kg/m2) 1.135 [0.779 - 1.653] 0.509 
IMD quintiles 0.872 [0.450 - 2.186] 0.283 
High-density lipoproteins (mmol/l) 0.992 [0.450 - 2.186] 0.983 
TC/HDL ratio 1.615 [0.643 - 4.053] 0.308 
LDL/HDL ratio 1.465 [0.598 - 3.591] 0.403 
Age at diagnosis 0.816 [0.623 - 1.068] 0.139 
Duration of diagnosis 0.782 [0.462 - 1.324] 0.361 
 
Following adjustments, BMI (kg/m2), TC/HDL ratio and LDL/HDL ratio were found to be 
clinically significant but statistically insignificant, having HR of 1.135 [95% CI: 0.779 - 1.653], 
1.615 [95% CI: 0.643 - 4.053], and 1.465 [95% CI: 0.598 - 3.591] respectively. 
Using bivariate analysis for correlation between the predicting factors, the analysis showed the 
strongest correlation was between gender and BMI (kg/m2) with Pearson correlation of 0.219, 
p-value 0.001. The following predicting factors had poor and positive correlations with gender; 
smoking status, SBP (mmHg), Total Cholesterol (mmol/l), Low-density lipoproteins LDL 
(mmol/l), and TSH levels. Negative and poor correlations were observed in predicting variables 
of age group at diagnosis, Creatinine levels, HbA1c (%), DBP (mmHg), TG, TC: HDL, LDL: 
HDL, Duration of diabetes, and index of multiple deprivations. 
The categorisation of the predicting variables and a further application of the Cox regression 
model yielded results as displayed in Table 4.25. The predictive risk of mortality for females 
was slightly lower than males’ but not statistically significant. 
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Table 4.23: Cox proportional hazard model of predicting factors and hazard ratio, with their 
corresponding 95% CI and p-values in T1D 
Predicting factor Hazard ratio [95%CI] p-
value 
Females 0.930 [0.164- 5.287] 0.935 
Males 1.000 [reference]  
Age of diagnosis (years)   
0 – 4 1.000 [reference] - 
5 – 9   0.666 [0.00007- 29.200] 0.945 
10 – 14 1.919 [0.027- 13.788] 0.764 
15 – 19 1.153 [0.042- 31.457] 0.933 
20 – 24 1.419 [0.042- 48.490] 0.846 
25 – 29 1.508 [0.086- 26.401] 0.779 
30 – 34 0.864 [0.055- 13.598] 0.917 
35 – 39 1.012 [0.094- 10.949] 0.992 
Index of Multiple Deprivation   
Quintile 1(most deprived) 1.000 [reference]] - 
Quintile 2(above average) 2.123 [0.162- 27.768] 0.566 
Quintile 3(average) 1.350 [0.063- 29.046] 0.848 
Quintile 4(below average) 1.304 [0.056- 30.183] 0.868 
Quintile 5(least deprived) 1.888 [0.117- 30.544] 0.654 
Smoking status   
Never smoked 1.000 [reference] 0.898 
Current smoker 1.065 [0.132- 8.602] 0.953 
Ex-smoker 1.556 [0.205- 11.800] 0.669 
BMI (kg/m2)   
≤ 18.4 1.000 [reference] 0.999 
18.5 - 24.9 0.548 [0..00008 - 36.76] 0.915 
25.0 - 29.9 1.045 [0.010- 108.709] 0.985 
30.0 - 34.9 0.883 [0.008- 93.630] 0.958 
35.0 - 39.9 1.479 [0.013- 162.753] 0.870 
≥ 40 1.352 [0.004- 437.779 ] 0.919 
HbA1c (%)   
≤ 5.9 (41) 1.000 [reference] - 
6.0-6.4(42-46) 0.665 [0.0001- 30.911] 0.941 
6.5-6.9(48-52) 0 .803 [0.004- 156.436] 0.935 
7.0-7.4(53-57) 1.095 [0.031- 38.889] 0.960 
7.5-8.0(58-64) 0.739 [0.043- 12.789] 0.835 
8.1-8.4(65-68) 0.882 [0.029- 27.227] 0.943 
8.5-9.0(69-75) 0.652 [0.039- 10.975] 0.766 
9.1-9.4(76-79) 0.719 [0.018- 28.867] 0.861 
9.5-10(80-86) 0.586 [0.305 – 12.126] 0.998 
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≥ 10.1 0.599 [0.027- 13.493 ] 0.747 
Serum creatinine (µmol/l)   
≤ 61 1.000 [reference] 0.057 
62-106 0.250 [0.066- 40.594] 0.322 
107-129 0.072 [0.005- 1.080] 0.057 
130-149 0.082 [0.003- 1.926] 0.120 
≥ 150 0.047 [0.00043- 53.035] 0.395 
Low density lipoprotein [LDL] 
(mmol/l) 
  
≤ 2.5 1.000 [reference] 0.985 
2.6 - 3.3 4.037 [0.0002- 62505.661] 0.777 
3.4 - 4.1 5.441 [0.0004- 59515.447] 0.721 
4.2 - 4.9 6.390 [0.002- 25278.350] 0.661 
≥ 5.0 1.430 [0.0004- 4266.892] 0.930 
High density lipoproteins [HDL] 
(mmol/l) 
  
0.4-0.7 1.000 [reference] 0.484 
0.8-1.1 1.149 [0.024- 141.13] 0.963 
1.2-1.5 1.156 [0.788 - 1.694] 0.343 
≥ 1.6 1.160 [0.764 - 1.784] 0.473 
Triglycerides [TG] (mmol/l)   
≤ 1.6 1.000 [reference] 0.484 
1.7-2.2 0.959 [0 .053 - 17.295]  0.977 
≥ 2.3 2.826 [0.144- 55.376] 0.494 
Total Cholesterol (mmol/l)   
≤3.9 1.000 [reference] 0.987 
4.0-4.5 0.252 [0.001- 62.932] 0.625 
4.6-5.2 0.360 [0.002- 53.117] 0.688 
5.3-6.1 0.333 [0.004- 27.619] 0.625 
≥6.2 0.347 [0.007- 16.864] 0.593 
Total Cholesterol: HDL ratio   
≤ 3.5 1.000 [reference] 0.916 
3.6-5.0 0.554 [0.006- 52.541] 0.799 
≥ 5.1 0.421 [0.005- 37.904] 0.706 
Low-Density Lipoproteins: HDL 
ratio 
  
≤ 1.5 1.000 [reference] 0.917 
1.6-3.6 0.294 [0.0001- 518.112] 0. 748 
≥ 3.7 0.254 [0.0002-280.442 ] 0.702 
Duration of Diabetes   
1-10 1.000 [reference] 0.688 
11-20 0.177 [0.0003- 101.740] 0.827 
21-30 5.816 [0.220- 153.507] 0.292 
31-40 1.422 [0.080- 25.174] 0.810 
41-50 0.744 [0.085- 6.501] 0.789 
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The HRs according to age group at diagnosis reflects a sinusoidal pattern with the highest HR 
recorded for the age group 10-14 years. 
 
                      
 Figure 4.49: Survival curve for females with T1D according to their age at diagnosis (years) 
 
                    
 Figure 4.50: Survival curve for males with T1D according to their age at diagnosis (years) 
Values for all the subgroups were not statistically significant. Excluding the age groups 5-9, 
30-34, other age groups of 10-14, 15-19, 20-24, 25-29, and 35-39 had higher HRs as compared 
to the reference group of 0-4 years. Figures 4.49 and 4.50 illustrate the survival curves for 
females and males respectively according to their age at diagnosis with minimal differentiation. 
The index of multiple deprivations had extrapolated HRs for the various subgroups that were 
not statistically significant. Using the most deprived group as the reference group, the least 
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deprived quintile had a slightly increased predictive risk of mortality with HR 1.888 ([95% CI: 
0.117- 30.544). Figures 4.51 and 4.52 show the survival curves for females and males 
respectively according to IMD. 
                   
Figure 4.51: Survival curve for females with T1D in the Wirral according to their IMD 
quintile 
                
Figure 4.52: Survival curve for males with T1D in the Wirral according to their IMD quintile 
According to smoking status, current smokers had a higher predictive risk of mortality as 
compared to non-smokers. Using non-smokers as the reference group, the HRs for current 
smokers and Ex-smokers were 1.065 [95%CI: 0.132 – 8.602], and 1.556 [95%CI: 0.205 – 
11.800] respectively. 
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Figure 4.53: Survival curve for females with T1D, in the Wirral according to their smoking 
status 
                       
Figure 4.54: Survival curve for males with T1D, in the Wirral according to their smoking 
status 
The HRs for those who never smoked and current smokers were not statistically significant. 
Figures 4.53 and 4.54 show the survival curves for females and males according to their 
smoking status. For BMI (kg/m2), using the group with BMI ≤ 18.4 kg/m2 as the reference 
group, the group having the lowest risk of death were those with BMI 18.5 - 24.9 having HR 
of 0.0548 [95%CI: 0.00008 – 36.76. The highest risk of death was in those BMI 35.0 - 39.9 
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(kg/m2). Figures 4.55 and 4.56 illustrate the survival curves with gender differentiation 
according to BMI category. 
                     
Figure 4.55: Survival curve for females with T1D in the Wirral, according to their BMI 
(kg/m2) 
                       
Figure 4.56: Survival curve for males with T1D in the Wirral, according to their BMI (kg/m2) 
There was no indication that HbA1c (%) was a factor in ascertaining the probability of the 
occurrence of death. The overall trend followed a sinusoidal pattern Figures 4.57 and 4.58 show 
the survival curves for females and males according to their HbA1c (%) levels. 
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Figure 4.57: Survival curve for females with T1D in the Wirral according to their HbA1c (%) 
                      
Figure 4.58: Survival curve for males with T1D in the Wirral according to their HbA1c (%) 
Values for HRs were not statistically significant. Values for serum creatinine were not effective 
in predicting the probability that mortality had occurred. Those with levels of 107-129 and 130-
149 (µmol/l) had HRs of 0.072 [95%CI: 0.005 – 1.080], and 0.082 [95%CI: 0.003 - 1.926] 
respectively. Figures 4.59 and 4.60 reflect survival curves for females and males according to 
their serum creatinine levels. 
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Figure 4.59: Survival curve for females with T1D in the Wirral, according to their serum 
creatinine levels (µmol/l) 
                      
Figure 4.60: Survival curve for males with T1D in the Wirral, according to their serum 
creatinine levels (µmol/l) 
There was an increase in mortality risk as LDL levels increased, this is shown by those having 
LDL levels in the subcategories 2.6 - 3.3, 3.4 - 4.1, and 4.2 - 4.9 (mmol/l) having HRs of 4.037 
[95%CI: 0.0002 – 62505.6], 5.441 [95%CI: 0.0004 – 59515.45], and 6.390 [95%CI: 0.002 – 
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25278.35] respectively. Figures 4.61 and 4.62 show the survival curves for females and males 
according to their LDL levels. 
                   
Figure 4.61: Survival curve for females with T1D in the Wirral, according to their serum 
LDL level (mmol/l) 
                      
Figure 4.62: Survival curve for males with T1D in the Wirral, according to their serum LDL 
level (mmol/l) 
Values for levels of HDL indicate that HDL was a predictive risk factor for the probability of 
mortality but not statistically significant. HDL levels 0.8-1.1, and 1.2-1.5, and ≥ 1.6 (mmol/l) 
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had HRs of 1.149 [95%CI: 0.024 – 141.13], 1.156 [95%CI: 0.788 - 1.94], and 1.160 [95%CI: 
0.764 - 1.784] respectively. Figures 4.63 and 4.64 show the survival curves for females and 
males according to their HDL levels. 
                       
Figure 4.63: Survival curve for females with T1D in the Wirral, according to their serum 
HDL level (mmol/l) 
                       
Figure 4.64: Survival curve for males with T1D in the Wirral, according to their serum HDL 
level (mmol/l) 
Triglycerides [TG] (mmol/l) was not effective in predicting if the probability of mortality 
occurring. Values of between 1.7-2.2mmol/l had HR of 0.959 [95%CI: 0.538 – 17.295] but nor 
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statistically significant. Figures 4.65 and 4.66 show the survival curves for females and males 
according to their TG levels. 
                                 
Figure 4.65: Survival curve for males with T1D in the Wirral, according to their serum TG 
levels (mmol/l) 
                               
Figure 4.66: Survival curve for males with T1D in the Wirral, according to their serum TG 
levels (mmol/l) 
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For total cholesterol, the highest predictive risk of mortality was recorded in those with levels 
of 4.6 – 5.2 mmol/l having HR of 0.360 [95% CI: 0.002- 53.117]. Figures 4.67 and 4.68 show 
the survival curves for females and males relating to their cholesterol levels. 
                       
Figure 4.67: Survival curve for females with T1D in the Wirral, according to their serum total 
Cholesterol levels (mmol/l) 
                 
Figure 4.68: Survival curve for males with T1D in the Wirral, according to their serum total 
Cholesterol levels (mmol/l) 
TC: HDL and LDL: HDL was not predictive of the probability of death, they were not 
statistically significant. Figures 4.69, 4.70, 4.71, and 4.72 show survival curves for females and 
males according to their TC: HDL and LDL: HDL ratios.  
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Figure 4.69: Survival curve for females with T1D in the Wirral, according to their TC: HDL 
ratio 
                    
Figure 4.70: Survival curve for males with T1D in the Wirral, according to their TC: HDL 
ratio             
                      
Figure 4.71: Survival curve for males with T1D in the Wirral, according to their HDL: LDL 
ratio 
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Figure 4.72: Survival curve for males with T1D in the Wirral, according to their HDL: LDL 
ratio 
4.11 Life expectancy  
Using life table analysis to estimate survival, the life expectancy for those with T1D in the 
Wirral, from birth was 51.17 years and 36.12 years for females and males respectively in the 
year 2011. Table 4.26 shows the breakdown of life expectancy extrapolated from life tables in 
males and females. Computation of life expectancy followed a sinusoidal pattern in life 
expectancy as the age of diagnosis increased. This is reflected in Figure 4.73 
Table 4.24: Life expectancy (years) by age and sex in people with T1D in the Wirral 2000-
2012 
Age at diagnosis (years) Life expectancy in people with T1D in the Wirral (years) 
 Females Males 
1 51.17 36.12 
2 48.16 51.17 
3 45.15 64.72 
4 63.21 51.17 
5 57.19 59.70 
6 63.21 66.22 
7 66.22 76.76 
8 51.17 57.19 
9 63.21 75.25 
10 69.23 57.19 
11 76.04 64.58 
12 64.56 60.20 
13 75.25 75.25 
14 54.18 62.61 
15 81.27 66.22 
16 76.00 72.24 
17 69.23 75.68 
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18 66.22 78.26 
19 66.22 63.21 
20 66.22 79.52 
21 72.24 81.27 
22 75.25 76.64 
23 73.40 75.25 
24 75.64 66.22 
25 72.24 77.48 
26 70.02 75.25 
27 80.77 63.21 
28 72.24 81.27 
29 71.94 75.25 
30 81.27 81.27 
31 63.21 81.27 
32 63.21 80.73 
33 60.20 72.24 
34 69.23 56.76 
35 70.73 72.02 
36 64.72 81.27 
37 80.87 63.21 
38 73.75 77.21 
39 81.27 81.27 
40 66.22 78.26 
 
                       
Figure 4.73: Comparative analysis of life expectancy between females and males with T1D. 
Diagnosis at 5 years of age showed slightly higher life expectancy for males than females with 
a median survival of 59.70 years and 57.19 years respectively. A female diagnosed at the age 
of 10 years was expected to 12 years more than her male counterpart diagnosed at the same 
age.  
During the teenage years, females had higher life expectancy except in the following years 14, 
17, and 18. Life expectancy was equal in males and females at the age of 30 years. However, 
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by age 40, males diagnosed were expected to live more than females by 12 years. By 
comparison, to the Wirral standard population, for 2009-2011, life expectancy at birth was 77.5 
years and 81.5 years for males and females respectively. This showed a difference of 30 years 
and 41 years for females and males respectively.  
4.12 Years of potential life lost (YPLL) 
Years of potential life lost (YPLL) which is a measure of premature mortality shows that males 
and females had 1797 years and 1553 years respectively in potential years lost. Further 
differentiation into YPLL rates, showed that the overall rate for T1D population was 4.8 per 
1000, 4.7 per 1000 in males and 2.3 per 1000 in females. As such, males had a greater burden 
of almost 54% as compared to 46% in females. 
Table 4.25: Sex differentiation of YPLL, YPLL (%), YPLL rate and AYPLL in T1D. 
Sex YPLL (%) YPLL rate (per 1000) AYPLL 
Males 1797(53.6) 4.7 21.1 
Females 1553(46.4) 2.3 20.2 
Total 3350(100) 4.8 20.7 
 
AYPLL, which is a weighted average to determine the magnitude of premature mortality, 
highlighted that males died on average 21.1 years as compared to 20.2 years in females and 
20.7 years in the total T1D population. 
4.13 Assessment of retinopathy 
As a measure of the development of microvascular complications, retinopathy was assessed. 
1224 participants were assessed for retinopathy, below is a distribution of retinopathy in T1D.   
                  
     Figure 4.74: Distribution of retinopathy among T1D in the Wirral 
14%
68%
18%
No retinopathy Non-proliferative retinopathy Proliferative retinopathy
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Chapter 5: Discussion 
This study investigated the predictive factors for mortality in a cohort of T1D patients in the 
Wirral Peninsular identified by the diabetes mellitus register between 1st of January, 2000 and 
31st December, 2012. It provides an insight into factors that predict mortality in T1D. The 
design and analysis involved in this study’s approach enabled the influx of causal associations 
related to mortality, predictors of mortality, survival and life expectancy in T1D. This allowed 
for current information with regards to certain competing risk/predictive factors such as: the 
age at diagnosis, gender, duration of diabetes, biochemical parameters (serum creatinine, 
glycaemic levels estimated from HbA1c, TSH levels, and lipid levels), smoking, blood 
pressure, BMI, IMD, retinopathy and cause of mortality in the cohort with T1D. The theoretical 
basis of this study employed the use of multiple regression analysis to identify significant 
predictors of mortality in this cohort.  
The literature review identified that T1D accounts for between 5 – 10% of the total number of 
people with diabetes, with variations in the incidence and prevalence of this condition. The 
estimates for incidence of T1D in the UK was high at 22.8 per 100,000, this study found lower 
values for the incidence of T1D in the Wirral with values ranging from 2.18 – 15 per 100, 000 
over the follow up period. Prevalence estimates obtained from the Wirral for T1D was between 
10.9 – 116 per 100,000, these values were lower but comparable to the value obtained for the 
UK of 187.7 per 100,000 (JDRF, 2017). For the incidence rate, while the observed rate for this 
study followed a fluctuating pattern but gradual reduction at the tail end of the study, this differs 
from what was obtained in the UK which was a consistent yearly rise (4%) in the incidence of 
T1D. However, a steady rise was noted in the prevalence over the study follow up period. A 
similar trend is observed by the steady increase in the prevalence of T1D from other studies 
(Diabetes UK, 2016). For this study, the peak age at diagnosis was 10 – 14 years which does 
not differ from estimates obtained for the UK (Diabetes UK, 2014; Diabetes UK, 2017). This 
study highlighted that the growing burden of T1D is mainly due the prevalence of T1D, the 
reason for this trend is not fully understood however several authors point to a poor 
understanding of the complex interplay of genetic and environmental factors. There is need for 
more research to get a better understanding of the genetic and environmental triggers of the 
onset of T1D (Rewers & Ludvigsson, 2016; Snouffer, 2017; Mayer-Davis et al. 2017). 
This study identified malignancy-related deaths (21.6%) as the major contributor to mortality 
in this cohort. This is in contrast to findings from other studies which attribute the major cause 
of death in T1D to cardiovascular diseases (Tu et al. 2008; Huxley et al. 2015; Lind et al. 2015). 
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However, in this cohort, cardiovascular diseases still account for a high proportion of mortality 
(16.2%). In this study cerebrovascular disease has been allocated a separate group however, in 
various other studies it has been included as one of the cardiovascular diseases (Lind et al. 
2011; Miki et al. 2013); following this principle, cardiovascular complications will account for 
approximately 30% of deaths making it to account for the most amounts of deaths in this cohort 
(Huxley et al. 2015).  
In this study, significant predictors of mortality in this cohort (p-value <0.05) were the age at 
diagnosis, duration of diagnosis, HbA1c, SBP, DBP, and triglyceride (TG) levels. The findings 
from this study agree with some of the risk factors identified from previous studies (Soedamah-
Muthu et al. 2008, 2014; Olson et al. 2002; Weis et al. 2001; Mühlhauser et al., 2000).  
These findings support the argument that to limit the impact of T1D on premature mortality, 
measures should be focussed on limiting the effects of cardiovascular complications by 
enhancing measures that reduce modifiable cardiovascular complications (Mameli et al. 2015). 
As such one of the cardinal measures for the prevention of cardiovascular complications in 
T1D is optimal glycaemic control. This is observed by the concept of “Metabolic Memory” 
which entails the introduction of early aggressive treatment with the aim of establishing normal 
metabolic control at an early stage of the condition which helps to limit cardiovascular 
complications (Misra, & Bloomgarden, 2018; Testa et al. 2017). This concept was supported 
by the DCC/EDIC trial which established that those in the intensive therapy group had reduced 
rates of retinopathy, nephropathy and CVD (Lachin et al. 2014; Lachin et al. 2016). However, 
there is a need to further explore certain scenarios in the management of T1D such as whether 
variations in glycaemic levels affect the concept of metabolic memory and at what point during 
the life cycle of the T1D is there optimum effect of intensive care in management either at the 
early stages or the later stages of control (Misra, & Bloomgarden, 2018). This study also 
identified hypoglycaemia as posing significant mortality risk; this is evident through repeated 
hypoglycaemic episodes and with increasing duration of T1D, there is an increased chance of 
reduced hypoglycaemic awareness which is a predictor of mortality (Rewers et al. 2002). 
Additionally, repeated hypoglycaemic episodes have been considered as possible initiating 
factor in the development of preclinical atherosclerosis, the mechanism of which remains 
poorly understood (Giménez et al. 2011). The quality statement provided by NICE Quality 
standard [QS125] is focussed on providing CSII with CGMs to individuals with T1D prone to 
repeated severe hypoglycaemic episodes and reduced hypoglycaemic awareness. The use of 
CGMs and CSII, if applied properly have been found to enhance better glycaemic control while 
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reducing hypoglycaemic episodes and mitigating long term CVD complications (Sherr et al. 
2018; Lung et al. 2014; Boland et al. 1999).  In the future, with further technology advancement 
and reduce cost of production, there may be a need for cost benefit analysis to introduce these 
technologies as standard measures of care. 
This study identified triglycerides as a significant predictor of mortality in T1D, elevated TG 
has been found to closely correlate with microalbuminuria and the progress of chronic renal 
failure in patients with long term T1D (Mäkinen et al. 2012). Research has also established 
dyslipidaemia as increasing the risk of developing CVD, a potent risk factor for all-cause 
mortality in T1D (Collier et al. 2018). Dyslipidaemia is identified as presenting increased risk 
of poorer glycaemic control, nephropathy and hypertension (Zabeen et al. 2018; Vergès, 2009). 
In T1D, it is characterised by both quantitative and qualitative changes in lipid levels (Ganjali 
et al. 2017), this implies that to achieve optimal control in T1D, a multipronged approach is 
required to tackle the multifactorial risk factors in T1D. One approach is the use of statin 
therapy for lowering lipids which has been found to be beneficial for improved outcomes (Hero 
et al. 2016), but the NICE guidelines advocates its use in T1D for patients over the age of 40 
years, established nephropathy and T1D duration > 10 years (NG17, NICE, 2015a). In this 
study, it could be inferred that CYPs are also prone to abnormal lipid levels at an early stage 
and thus prone to early onset of CVDs. As such, this finding supports the argument by some 
authors that further research is needed to explore the beneficial use of statins in lowering 
abnormal lipids starting from adolescent age (Marcovecchio et al. 2017; Canas et al. 2015). 
Similarly, the use of use of ACE-I which has beneficial effects in reducing the incidence of 
microalbuminuria and hence improving outcomes is not advocated in CYPs, further research 
is needed to explore their efficacy and safety in the young with T1D (Marcovecchio et al. 2017; 
Donaghue et al. 2014). This study also found blood pressure to be significant predictor of 
mortality, because the use of medications is not encouraged by the NICE in CYPs, this implies 
that further emphasis should be placed on lifestyle measures to improve outcomes. One of such 
measures advocated by the NICE guidelines is the use of screening methods to identify and 
follow up micro-and macrovascular complications. The guidelines advice the start of screening 
for nephropathy and retinopathy from the age of 12 years, this is to identify at an early stage 
those at risk of early complications (NG18, NICE 2015b). During the teenage age years and 
early in the diagnosis of diabetes, further emphasis should be placed on structured education 
and lifestyle modification such as diet and exercise. Structured education applied at an early 
stage is found to enable the individual diagnosed with T1D to better understand their condition. 
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The acquired knowledge enhances patient empowerment by providing them with the necessary 
skills and motivation to better manage T1D. Hence an empowered individual is more likely to 
experience better medical, social and behavioural outcomes. This results in cost effective use 
of available health resources (Chatterjee et al 2017). Recent evidence support the hypothesis 
that exercise significantly reduces the risk of premature mortality in T1D (Tikkanen-Dolenc et 
al. 2017), research also highlighted that exercise has the beneficial effect of increasing insulin 
sensitivity, with a further effect of better glycaemic control (Bernardini et al. 2004). 
In this study, the peak age of diagnosis was 10-14 years; this implies that this age group is very 
important for targeted intervention. In gleaning from the studies conducted by Mabhala et al. 
(2017, 2018) which argues that maladjusted individuals with negatively altered life course are 
usually influenced in early life possibly from teenage years into early adulthood and is familial 
and societal context specific. This view is further supported by Worthman, Tomlinson, & 
Rotheram-Borus, (2016), who suggested that the maximal influence of parenting on any child 
occurred during the adolescent years (10 – 15 years [median 12 years]). They argued that this 
is the period where the child is most at risk of several influences (familial and societal) that 
threaten their educational, health, and social attainment, a derailment of which may have 
enduring consequences for lifetime well-being. Additionally, the pubertal period raises its own 
risk of physical, psychological and behavioural (peer pressure) influences that could either 
enhance resilience or deviate one’s life course (Blakemore & Mills, 2014). As argued by 
Spencer et al. (2012), the key to successful outcomes in the management of T1D are strong 
family cohesion and societal support. This is supported by Ashraff, Siddiqui, & Carline, (2013), 
who argue that management of T1D in a child impacts on family life and young people who 
reported optimal control were more likely to be from family units that supported independence 
and had strong family cohesion and less conflicts. There is need to explore interventions that 
target family relationships with the aim of enhancing communication, improving conflict 
resolution, and enhancing resilience to create a balanced family atmosphere which has the 
potential to improve adherence to treatment regimens and self-care (Hauser et al. 1990; 
Wysocki et al. 2006, 2007). One of such intervention is the Behavioural family systems therapy 
(BFST-D) on diabetes implemented in the US that found significant adherence to treatment 
regimens and improvement to family cohesion (Wysocki et al. 2007). There is need for further 
research to replicate this intervention or similar variants in cohorts of T1D in the UK (Funnell, 
2006). The teenage years are also noted as a period of social influence from friends and peers; 
they are noted to be part of the support networks that are important in the management of T1D. 
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Few studies have noted that support from friends and family create an atmosphere of resilience 
(Ashraff, Siddiqui, & Carline, 2013). However, there is need for further research to explore the 
influence of peers and how these can be integrated into models of care for T1D (Akhter, 
Turnbull, & Simmon, 2018; Kazemi et al. 2016; Palladino, & Helgeson, 2012).Additionally, 
the benefits of the influence of support networks can be further enhanced by structured 
education, this is evidenced by the impact of several educational programmes in T1D (Plank 
et al. 2004; Davies et al. 2008; Deakin et al. 2006, 2011; Diabetes UK, 2015, X-PERT, 2017; 
NICE, 2016a).  
This study noted adverse mortality outcomes for those in the lower socioeconomic groups, 
although this finding should be viewed with caution and requires further research, it infers that 
social and economic conditions in which these patients resides can impact on their (both 
patients and caregivers) ability to adequately manage T1D to achieve optimum control 
(Mabhala et al. 2017, 2018; Worthman et al. 2016; De Bellis, & Zisk, 2014). This translates to 
imply that for policy enactment and implementation, there is need to enact policies which 
support families (care givers) and patients with T1D especially during their teenage years. 
These policies should focus on identifying those most vulnerable to the impacts of adverse 
societal and environmental factors with the aim of ensuring equitable resource availability and 
building resilience that positively impacts on treatment adherence and glycaemic control in 
T1D (Neckerman et al. 2016; Worthman et al. 2016). 
This study revealed the absolute risk of mortality varied according to the predictor variable 
being examined. The evaluation of these predictor variables is found to reveal that the exact 
contribution of a predictor variable to mortality risk fall within a continuum. It is important to 
interpret these findings based on a balanced view of the impact of these variables. Several 
studies on T1D highlight the influence several predictor variables on mortality risk at varying 
points of exposure status to the condition (Distiller, 2014; Schoenaker et al. 2014; Grau et al. 
2016; Lachin et al. 2016). This study highlight that these multiple risk factors do not only 
present as singular risk factors to mortality but are also cumulative in complex interactive 
processes (Distiller, 2014). Research suggests that while some of the predictive risk factors can 
be prevented or potentially reversible other are irrevocable. In this study, some of the 
irrevocable risk factors are age and gender; some potentially revocable risk factors were blood 
pressure, lipid profiles, and glycaemic control.    
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This study has highlighted differential increased potential risk of mortality according to gender. 
This study showed that females were 4 times at increased risk of mortality when compared to 
their males’ counterparts. This finding is in agreement with the study carried out by Huxley 
and colleagues who reported similar results (rSMR 1·37 [95% CI 1·21–1·56] p<0·0001) and 
also Lung et al. (2014) who reported that males had a RR of 3.25 (95% CI 2.82–3.73) as 
compared to females with RR of 4.54 (95% CI 3.79–5.45). Although the reason behind this 
trend remains uncertain, a possible explanation for this observation is explained by Huxley, 
Barzi, & Woodward, (2006). They suggest that effects from vascular dysfunction of this 
condition such as coronary artery calcification and endothelial damage are more pronounced 
in females than males. One other reason suggested is that women, in general, have a higher life 
expectancy that than men, hence they are prone to the longer exposure of the cumulative effect 
of glycaemic variations that is hypo and hyper-glycaemia (Huxley, Barzi, & Woodward, 2006). 
Several other authors have suggested other reasons for this trend; they suggest that women due 
to their physiological attributes may influence the effect of insulin sensitivity leading to the 
observed trend. Some of these factors include inputs from the endocrine pathways 
(hypothalamus-pituitary-ovarian axis), and hormonal factors associated with the effects of 
puberty and menopause (Kim, Elimi, Henderson, Cogen, & Kaplowitz, 2012; Kaplowitz, 2012; 
Paris et al., 2009; Amiel et al., 1986; Huxley, Peters, Mishra & Woodward, 2015). This trend 
is also noted due to significant excess risk of mortality identified in females secondary to 
cardiovascular disease hence increasing the cumulative effect of several risk factors in women 
(Rawshani et al. 2018).  The absolute risk of mortality within the study period revolved around 
a narrow range of 3% to 5%.  The maximal risk of mortality in the study was in 2005 with a 
maximal risk of 5%; this could be attributed to coincide with the early transition period that 
indicated the implementation of the National service framework (NSF) for diabetes (Diabetes 
UK, 2008). The overall risk of mortality during the study period fell to 2%; this reflects 
developments in the better management approaches of several risk factors of T1D.  
This study found out that the age of diagnosis, and increasing duration of diabetes, was 
significantly associated with increased risk of mortality. Although this study identified 
relatively reduced mortality risk before the age of 18 years, the relative risk of mortality 
significant increases after the age of 18 years. The reasons for this observed trend may be due 
indirectly to the cumulative impact of the effects of metabolic syndrome. A study by Chillarón 
et al. (2010) identified the incidence of metabolic syndrome in 31.9% of their cohort diagnosed 
after the age of 18 years. They also found out that age at diagnosis was a significant and 
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independent risk for the development of metabolic syndrome. They also suggested an increased 
association of metabolic syndrome with the early onset of microvascular complications. A 
further study by Chillarón et al. (2014) argued that between 8 – 40 % of individuals diagnosed 
with T1D after the age of 18 years meet the criteria for metabolic syndrome. Metabolic 
syndrome was linked to the early onset of cardiovascular diseases which was identified as one 
of the leading causes of mortality in T1D (Chillarón et al. 2015). Another possible reason to 
explain this trend may be the resultant effect of reduced β-cell mass with increasing age as 
observed by reduced detectable levels of IAA with increasing age and dysfunctional 
mitochondrial function with increasing age (Chen et al. 2017; Bluestone, Herold, & Eisenbarth, 
2010; Akirav, Kushner, & Herold, 2008; Matveyenko, & Butler, 2008). Hence the link between 
increasing age of diagnosis with increased mortality may be as a result of complex interactions 
of multifactorial factors. 
This study outcome reflects a significant increase in mortality risk with increasing duration of 
T1D. This highlighted a positive correlation with increasing duration of this condition which 
showed proportional linearity. This finding is supported by findings from the study conducted 
by Rawshani and colleagues in 2018 which found an increased risk of developing 
cardiovascular disease conditions with those diagnosed at the younger age group (1 – 10 years), 
with the early development of cardiovascular disease they were at an increased risk of 
mortality. As the duration of T1D progressed, there was an increase in the cumulative 
metabolic effects from cardiovascular diseases leading to excess premature mortality. This 
trend was further highlighted when the duration of diabetes was greater than 20 years. This 
study confers with findings from other studies (Akata, Mabhala, Bowen-Jones, & Cooper, 
2016; Orchard, Costacou, Kretowski, & Nesto, 2006; Lung et al. 2014; Huxley, Peters, Gita, 
& Woodward, 2015).    
For this study glycaemic control is shown to carry a significant risk of mortality. This study 
showed that the maximum risk of mortality was observed in those with average HbA1c levels 
at ≤ 5.9% (41mmol/mol) at 25%. This study highlighted nonlinearity similar to a U-shaped 
pattern with spline knot points at HbA1c levels (7.5%, 8.5%, 9.5% and 10.1%). The least risk 
of mortality was found in those with HbA1c levels of 6.0-6.4% (42-46mmol/mol). Above 
HbA1c levels of 6.5%, mortality risk followed a varied sinusoidal pattern (figure 4.3f). This 
study concurs with findings for Schoenaker et al. (2014) who observed a similar trend with 
glycaemic control and mortality. Alternative a study by Lind et al. (2014) identified a 
monotonic linear rise in the risk of mortality with a corresponding increase in average HbA1c 
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levels. The possible reasons that explain the observed trend in this study remain uncertain. 
However some authors argue that individuals with lower HbA1c levels are at an increased risk 
of hypoglycaemic coma hence increased risk of mortality. This is especially evident with 
increasing duration of T1D when there is an increased loss of hypoglycaemic awareness 
(Lachin et al. 2016). There may also be a significant contribution to higher mortality risk from 
death in bed syndrome which is very difficult to evaluate (Secrest et al. 2011). Several other 
contributing factors are noted to have contributions to increased hypoglycaemic levels such as 
the presence of concurrent clinical conditions such as anaemia or conditions with increased 
haemoglobin turnover, hypokalaemia, QT syndrome, renal failure, poor compliance with 
treatment regimens, psychiatric disorders, poor cognitive impairment, and social problems 
(Lind et al. 2016; Tsujimoto et al. 2014; Riddle et al. 2010; Gallagher, Le Roith, & 
Bloomgarden, 2009).  
Smoking is acknowledged to be one of the principal risk factors for the cardiovascular disease, 
coronary heart disease, peripheral arterial disease, heart failure and all-cause mortality (Pan et 
al. 2015; Weis et al. 2001). The findings from this study show that the absolute risk of mortality 
was 7%, 8%, and 14% in non-smokers, smokers, and ex-smokers respectively. Smoking had a 
HR of 1.241 [95% CI 0.606- 2.540] and p-value 0.556. These results agree with findings from 
Pan et al. 2015). Factors that may influence higher mortality risk in ex-smokers than current 
smoker include the number of years, quantity smoked and time of quitting which were not 
explored for this study. 
This study noted the increased relative risk of mortality in quintile 1 (most deprived), and 
quintile 4 (below average). This indicates that the construct of IMD increases the risk of 
mortality in T1D. However the results were not statistically significant. Findings from this 
study confer with findings from several other studies (Scott et al. 2017; Saydah, Imperatore, & 
Beckles, 2013; Forssas et al. 2012; Secrest et al. 2011). 
This study showed an increased risk of mortality with BMI 35.0 - 39.9 Kg/m2 and ≥ 40 kg/m2 
having respective HR of 1.479 [95% CI: 0.013- 162.753] and 1.352 [95% CI: 0.004- 437.779] 
although not statistically significant. The absolute risk for these 2 groups were 19% and 20% 
respectively. The findings from this study reveal almost a J shaped pattern of mortality, a 
phenomenon similarly identified from other studies termed the obesity paradox (Carnethon, 
Rasmussen-Torvik, & Palaniappan, 2018; Qin, Liu, & Wan, 2017; Conway et al. 2009). 
Although some studies do not record any significant relationship of BMI with mortality in T1D, 
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obesity is noted to be a risk factor in the development of cardiovascular disease hence an 
indirect risk to increase mortality in T1D (Vestberg et al. 2018). 
This study highlighted that worsen levels of serum creatinine significantly increased the risk 
of mortality. This pattern reflected a linear proportionality to mortality risk with absolute risk 
for 107-129µmol/l, 130-149µmol/l, and ≥ 150µmol/l, of 18%, 40%, and 40% with a relative 
risk of 3.0, 6.7, and 6.7 respectively. This study highlights that nephropathy and its progression 
to chronic kidney disease and end-stage renal failure still present a significant risk of mortality 
in T1D. Nephropathy is also noted to be strongly associated with the onset of cardiovascular 
disease through its cumulative but varied mechanisms which enhance vascular damage (de 
Ferranti et al. 2014). The study agrees with similar findings from several other studies and 
emphasises the need for reno-protective measures to mitigate the long term impact of 
nephropathy (H. de Boer, & Bakris, 2018; Gagnum et al. 2017; Lind et al. 2014; Bentata et al. 
2013). 
5.1.The relationship between various predicting risk factors and mortality in T1D 
This study found a linear rise in the risk of mortality with increasing systolic blood pressure 
(SBP). The absolute risk of mortality was highest (35%) in those who had SBP ≥160mmHg. 
The relative risk also revealed a similar pattern to absolute risk as those with SBP ≥160mmHg 
had a relative risk of 11.6. Values of 140 – 159mmHg also showed an increased risk of 
mortality of 23%. The HR documented for all-cause mortality as it relates to SBP was 1.666 
[95% CI: 0.669 – 4.149], p-value 0.273. The findings in this study are consistent with findings 
from other studies as the advent of raised blood pressure is shown to precipitate and exacerbate 
the clinical course of micro - and macrovascular complications (Collier et al. 2018; Perkins et 
al.2003; Orchard et al. 2001; Weiss et al. 2001). This study showed that the risk of mortality 
was prevalent at the two extremes of diastolic blood pressure. This reflected a U-shaped pattern 
with those having blood pressures ≤59 mmHg and ≥100mmHg having absolute mortality of 
38% and 35% respectively. The HR documented for all-cause mortality as it relates to DBP 
was 1.105 [95% CI: 0.414 – 2.953], p-value 0.842.  This result was in agreement with 
observations from other studies (Collier et al. 2018; Perkins et al.2003; Orchard et al. 2001; 
Weiss et al. 2001). 
Abnormal lipid profiles remain potent predictors of the advent of cardiovascular disease and 
total mortality in T1D (Weiss et al. 2001; Orchard et al. 2001). For total cholesterol (TC) levels, 
this study found an increase in the risk of mortality with increasing levels of TC. This was 
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particularly evident with levels of ≥6.2mmol/l which had a mortality risk of 24%, findings from 
this study are consistent to findings from other studies (Schofield et al. 2016; Maahs et al. 2010; 
Pietri et al. 1983). 
This study also found an inverse V-shaped relationship in mortality risk with the rise in total 
triglyceride levels (TG). The maximal risk of mortality was found in those with TG levels 1.7-
2.2mmol/l with 12% absolute risk of mortality. Although the risk mortality in those with TG 
levels of ≥2.3mmol/l was marginally increased with 10% absolute risk of mortality, this finding 
was significant, with HR for all-cause mortality was 1.286 [95% CI: 0.545- 3.036], P-value 
0.566. The findings from this study contrast with findings from other studies which show a 
direct linear rise in the risk of mortality with rising TG levels (Gylling et al. 2004). 
This study highlighted a proportionate increase in mortality risk with increasing LDL levels. 
The highest risk of mortality was found in those with LDL levels ≥ 5.0mmol/l with an absolute 
risk of 27% and relative risk of 5.4. These findings agree with findings from other studies 
(Olesen et al. 2017; Schofield et al. 2016; Di Angelantonio et al. 2009). 
In this study, an increase in HDL levels was associated with an increase in the risk of mortality; 
those with HDL levels of ≥ 1.6mmol/l had the highest risk of mortality of 8%. However, this 
observation contrasts with findings from other studies. (Hewing, Moore, & Fisher, 2012; 
Voight et al. 2012; Emerging Risk Factors Collaboration et al. 2009). Early and later studies 
such as the Framingham study that examined the relationship between lipid profiles and 
cardiovascular risk suggest that higher levels of HDL confer protection against the advent and 
progression of cardiovascular diseases. This is achieved through its antiatherogenic effects on 
vascular function (Ganjali et al. 2017; Arca et al. 2007; Gordon et al. 1977). The study by Bain 
et al. (2003) suggests elevated HDL levels may confer some level of protection in T1D patients, 
which is enhanced by genetic predisposition. However, findings in this study do not reflect 
this; a possible reason for this observation is put forward by a recent study by Femlak and 
colleagues in 2017. They suggest that although in the general population, raised HDL levels 
independently confers risk reduction to alter the progress of cardiovascular disease; this is no 
present in the pathological state of T1D. In T1D, these functions of HDL become dysfunctional. 
They suggest that possible reason for this is an alteration of the HDL proteome, which then 
becomes a proinflammatory protein, following oxidative insults to enzymatic activities 
associated with the functions of HDL. This subsequently leads to a deficiency in the ability of 
HDL to suppress inflammatory signals in T1D. Another mechanism that explains the findings 
171 
 
of this study may be due to genetic alteration to the HDL molecule which impacts on its quality. 
This, therefore, means that raised quantity of plasma HDL-C does not necessarily confer 
protection from cardiovascular disease (Eren, Yilmaz, & Aydin, 2012 Costacou, Evans, & 
Orchard, 2011: Vergès, 2009). 
For TC/HDL ratio and LDL: HDL ratio, this study identified trends where increased levels of 
cholesterol ratios reflected an increased risk of mortality. For TC/HDL ratio, values ≥ 3.7 had 
an absolute risk of 19% and relative risk of 2.7, TC/HDL ratio with values ≥ 5.1 had an absolute 
risk of 13% and relative risk of 2.2. The HRs for TC/HDL and LDL/HDL ratios were 1.615 
[95% CI: 0.643 - 4.053], p-value 0.308 and 1.465 [95% CI: 0.598 - 3.591], p-value 0.403. 
Findings from this study are consistent with findings from other studies (Guy et al. 2009; 
Gylling et al. 2004).  
Research has highlighted an increased risk of thyroid dysfunction with T1D (Umpierrez et al. 
2003), with a stronger correlation for hypothyroidism. The study revealed a U-shaped pattern 
in mortality risk with T1D according to TSH levels. The mortality risk was more prominent 
with TSH levels of ≤0.4 mU/L, having an absolute mortality risk of 15% as compared with 
TSH levels ≥4.0 mU/L, having an absolute mortality risk of 12%. The findings from this study 
should be interpreted with caution as there is paucity of research that links thyroid disorder 
with mortality risk in T1D. Also findings from this study are based on a small number of 
participants inferring reduced statistical power to ascertain such causality and effect.  However 
research findings only correlate the increased incidence of hypothyroidism to T1D and 
increased severity of T1D in those having hypothyroidism, there is need for further research to 
identify any correlations between mortality and thyroid disorders in T1D (Jonsdottir et al. 2017; 
Fatourechi et al. 2017). 
5.2.Evaluation of mortality rates and standardised mortality rates 
Limited research has been done to evaluate the cause of mortality, trends in mortality, survival 
in a population cohort of participants with T1D in the Wirral, UK. This elaborates specific 
estimates on these trends. 
This study provides precise estimates of age – and sex-specific mortality rates, and absolute 
mortality. In the study, revealed varied patterns mortality with age and sex specific (adjusted 
and standardised) rates. The age – and sex-specific mortality rates found higher specific 
mortality rates in males for age groups 0-4, 15-19, and 30-34; females had higher specific 
mortality rates in age groups 5-9, 10-14, 20-24, 25-29, and 35-39 years. The difference in 
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specific mortality rates was marked in the age group 35-39 where there was a fourfold 
difference in rates between females and males. These patterns are reflected in the age-adjusted 
and standardised age-adjusted mortality rates. However, in contrast to Laing et al. (2003) who 
found similar mortality rates for age groups in males and females below the age of 40 years. 
The mortality rate difference estimates obtained from this cohort reveal negative values which 
show that age-adjusted mortality rates for this cohort were higher than those obtained from the 
standard Wirral population. This reflects excess mortality in this cohort as compared to the 
standard population. The findings from this study agree with the trends observed in the study 
by Laing and colleagues in 2003.  
The specific mortality rates according to calendar year were higher in females than males 
reflecting similar trends in adjusted and standardized adjusted mortality rates. These findings 
reflect similar findings in other studies (Soedamah-Muthu at al. 2006; Skrivarhaug et al. 2006; 
Morrish et al. 2001). 
This study found a sinusoidal pattern of standardised mortality ratio (SMR) according to age 
groups, the highest SMR was recorded in the age group 5-9 years with SMR 8.05 [95% CI: 
2.07 -14.03]. The lowest SMR was recorded in the age group 35-39 years with SMR 6.73 [95% 
CI: 3.2 – 10.26]. Across all age groups, this study found almost similar SMRs in both males 
and female participants. This result agrees with several other studies (Gagnum et al. 2015; 
Nishimura et al. 2001). However, several other studies show higher SMRs for females than 
males. A study by Laing et al. (1999), found SMRs of 2.7 (95% CI 2.5–2.9) and 4.0 (95% CI 
3.6–4.4), in males and females. Harjutsalo, Forsblom, & Groop, (2011) estimated higher SMRs 
for females than males in their population cohorts with values of 5.5 for females as compared 
to 3.0 in males for the early onset cohort, and 3.6 for females as compared to 2.6 in males for 
the late onset cohort. These differences may be attributed to the population characteristics of 
the comparative cohorts. 
5.3.Predictor variables and their influence on T1D with survival, life expectancy and 
potential years lost. 
Previous studies have established reduced life expectancy with T1D with the expected 
reduction in years ranging from 12 to 17 years (Livingstone et al. 2015; Brown, Scott, & Moir, 
2001). The reduction in life expectancy is attributed to the impact of microvascular and 
cardiovascular complications n T1D (Liang et al. 2001). 
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Using life table analysis, this study found reduced life expectancy from birth with having a 
diagnosis of T1D. Analysis of this cohort showed that females from birth were expected to live 
to the age of 51 years while males from birth were expected to live to the age of 36 years. With 
life expectancy from birth in the Wirral for males and females being 78 and 82 years 
respectively, this reflected a reduction of 31 years for females and 42 years in males. At age 40 
years, females and males were expected to live to ages 66 and 78 years respectively. This study 
reflects similar patterns observed from previous studies (Livingstone et al. 2015; Brown, Scott, 
& Moir, 2001).  
This study found no significant relationship between gender and survival, the survival period 
for males and females were 77.185 years [95% CI: 75.191 – 79.179] and 76.011 years [95% 
CI: 73.169 – 78.000] respectively. The real impact of the burden of T1D is reflected in the 
burden of premature mortality as evidenced by the YPLL, for males and females having 1169 
and 1005 potential lost years respectively. Cardiovascular risk factors are identified as 
contributory to lost years (Livingstone et al. 2015; Brown, Scott, & Moir, 2001).  
This study found that age at diagnosis was an important determinant of survival, although not 
statistically significant, this study found a mild increase with survival times as age of diagnosis 
increased, however, the absolute risk of mortality increased with increasing age of diagnosis. 
The results from this study are comparable to results from other studies (Rawshani et al. 2018) 
This study found the increasing risk of mortality with increasing duration of diabetes. However, 
survival with T1D followed a sinusoidal but linear rising pattern with increasing duration of 
diabetes. Significantly, those with duration of diabetes less than 10 years had median survival 
for males and females of 48.416 years [95% CI: 47.625 – 49.207] and 45.527 years [95% CI: 
42.961 – 48.094] respectively. This indicates that there was better survival with longer duration 
of diabetes. This correlates with findings from the study by Elsamahy, Elhenawy, & Altayeb, 
(2017) who argue that a shorter duration of diabetes may predict poor long-term outcome. 
This study identified a significant relationship between glycaemic control and survival for T1D. 
Although survival followed a sinusoidal pattern, those with HbA1c ≤ 5.9 (41mmol/mol) had 
worsened survival times of 59.415 years [95% CI: 44.180 - 79.649], 58.286 years [95% CI: 
45.040 - 93.531], 59.101 years [95% CI: 45.607 – 72.595] respectively for males, females and 
the total cohort respectively. This correlates closely with the finding that those with lower 
values for HbA1c [≤ 5.9 (41mmol/mol)] has the greatest risk of mortality (Schoenaker et al. 
2014). 
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This study identified a U-shaped pattern with survival times according to serum creatinine 
levels. The values obtained for this cohort were significant; this indicates that increasing 
creatinine levels which correlates closely with worsening renal function and advancement of 
diabetic nephropathy relates to reduces survival in T1D. Findings from this study correlate with 
findings from other studies (H. de Boer, & Bakris, 2018; Gagnum et al. 2017; Lind et al. 2014; 
Bentata et al. 2013)  
For systolic blood pressure (SBP), although this study identified a linear increase in the risk of 
mortality with increasing SBP, this pattern is not reflected in the survival times. Survival times 
increase with the rise in SBP. The reason for this observation remains unclear. However, this 
finding is not statistically significant.  
Diastolic blood pressure (DBP) reflected an increased risk of mortality at the two extremes of 
blood pressure; however, observations from survival time show significantly, that higher 
values for DBP (≥100mmHg) resulted in reduced survival times. This observation is consistent 
with findings from other studies (Collier et al. 2018; Perkins et al.2003; Orchard et al. 2001; 
Weiss et al. 2001). Plausible explanations for the observed pattern is that hyperglycaemia 
contributes to the vascular dysfunction which aids in the cascade of events that result in the 
formation of atherogenic plaques implicated in arterial stiffness and its precipitant effect on 
increased cardiovascular risk (de Boer et al. 2008). 
This study identified that increased levels of HDL, TG, LDL, LDL/HDL and TC/HDL ratios 
were associated with increased mortality risk. These findings agree with findings from other 
studies (Schofield et al. 2016; Maahs et al. 2010; Pietri et al. 1983).  
With regards to survival, the trend observed with total cholesterol which was statistically 
significant reflected fluctuations but reducing survival with increasing levels of total 
cholesterol. HDL levels did not reveal any particular trend, but those with HDL levels of ≥ 
1.6mmol/l had survival times of 69.000 years [95% CI: 62.195 - 75.805] and 67.000 years 
[95% CI: 63.675 - 70.325] in males and females respectively. A linear trend was observed with 
TG levels were increase in TG levels lead to a reduction in survival times for this cohort. The 
least survival times were observed in males and females with TG levels of ≥ 2.3mmol/l having 
a median survival of 70 years [95% CI: 60.933 – 79.067] and 72 years [95% CI: 62.015 – 
81.985] respectively. Similarly, the least survival times for LDL levels was observed in males 
and females with LDL levels ≥ 5.0 mmol/l having a median survival of 45 years [95% CI: 
37.031 – 52.969] and 46.8 years [95% CI: 45.512 – 96.088] respectively. There was a 
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proportionate fall in median survival with rising levels of LDL. Survival relating to TC: HDL 
levels revealed an observed trend that reflected reduced median survival with rising ratios. The 
least median survival of 58 years [95% CI: 49.826 – 66.174] and 73 years [95% CI: 61.078 – 
75.783] as observed for males and females respectively was found with TC: HDL ratios ≥ 
5.1mmol/l. However, for LDL: HDL ratios, a similar trend was observed for females but not 
for males. These findings further add to the results of other research (Olesen et al. 2017; 
Schofield et al. 2016; Di Angelantonio et al. 2009; Ganjali et al. 2017; Arca et al. 2007; Gordon 
et al. 1977).  
These observations lend credence to the argument that dyslipidaemia is one of the main factor 
responsible for the development of cardiovascular disease which contributes to excess 
mortality in T1D. There is the need to continue the mortality risk reduction measures such as 
the use of physical exercise, the use of statins and ACE inhibitors (Kearney et al. 2008). 
Furthermore, the combination of abnormal lipid profiles and increased blood pressures further 
increase the risk of diabetes vascular complications. (Krentz, Clough, & Byrne, 2009)  
For this study, current smokers had the least survival times as compared to non-smokers and 
ex-smokers. The median survivals for current smokers were 75.338 years [95% CI: 71.689 – 
78.987] and 69.159 years [95% CI: 62.732 – 75.589] for males and females respectively. The 
link between smoking and reduce survival in T1D is attributed to a range of factors. Smoking 
confers its harmful effect T1D through its independent risk to the development of 
cardiovascular disease and its effect on the increase in all-cause and excess mortality in T1D 
(Haire-Joshu, Glasgow, & Tibbs, 1999; Haire-Joshu, Glasgow, & Tibbs, 2004). Smoking is 
seen to potentiate the risk of development and progression of macrovascular and microvascular 
complications; this is achieved through several mechanisms (Chaturvedi, Stephenson, & 
Fuller, 1995). Biochemically, smoking significantly potentiates elevated levels of abnormal 
lipids and increases dysfunctional levels of HDL cholesterol; it also contributes to the advent 
and progression of insulin resistance and poorer glycaemic control (Solberg et al. 2004; Al-
Delaimy et al. 2001; Facchini et al. 1992). In T1D, smoking increases the risk of worsening 
microvascular complications of neuropathy, retinopathy and nephropathy hence contributing 
to reduced survival times and worsening mortality risk (Clair et al. 2015; Biesenbach, & 
Zazgornik, 1996). 
This study results revealed increased mortality risk with increasing BMI. Survival trend with 
BMI found a decreasing trend with increasing BMI. The least survival times were recorded in 
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males and females with BMIs 35.0 - 39.9 kg/m2 (Minges, Whittemore, & Grey, 2013; Conway 
et al. 2009), they were 40 years [95% CI: 22.396 - 57.604] and 61 years [95% CI: 48.998 - 
73.002] respectively. These findings are consistent with results from other studies (Conway et 
al. 2009). 
This study found no significant trend in survival according to IMDs assigned, however, 
mortality risk revealed J shaped pattern of mortality, these findings agree with results from 
other studies (Carnethon, Rasmussen-Torvik, & Palaniappan, 2018; Qin, Liu, & Wan, 2017; 
Conway et al. 2009). 
This study found a total of 86% of T1D patients had some level of retinopathy. These findings 
agree with findings from other studies (Esteves et al. 2009; Roy et al. 2004; Fong et al. 2004).  
5.4.Study strengths and limitations 
5.4.1. Strengths 
The management of T1D is principally carried out in the secondary care, with support from the 
primary care systems. The use of the Wirral diabetes register, which had linkages between 
primary, secondary and other allied services allowed for accurate ascertainment of patients 
with T1D in the Wirral. The use of the register allowed for accurate information to be garnered 
that aided in the process of disease surveillance, aiding in the estimation of accurate estimates 
concerning T1D in Wirral which has contributed to existing knowledge, and quality 
improvements.  
The retrospective cohort study design was best fit to establish estimates for time to event 
analysis; it provided accurate indices for life expectancy, standardised mortality rates, hazard 
ratios, relative and absolute mortality.  This is one of the studies of its kind that has established 
the impact of several competing risk factors on mortality in T1D. It has highlighted the role 
and input of several factors such as the age of diagnosis, duration of diabetes, biochemical 
profiles, and socioeconomic factors such as smoking, and IMD on the survival of individuals 
with T1D. 
One other strength to this study is the use of a large of a number of participants (sample size) 
who were selected by applying some strict selection criteria; allowing for estimation of precise 
estimates that allowed drawing inference from predictor variables and mortality. It also aided 
the exploration of competing risks and their outcome variables in T1D. The systematic review 
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and meta-analysis on mortality established current trends in mortality and established research 
gaps which formed the basis for the research questions for this study was conducted.  
5.4.2. Limitations of the study 
This study had inclusion criteria of T1D diagnosed before the age of 40 years. A potential 
limitation may have been the inclusion of a small number of participants that may have had the 
actual diagnosis of T2D. This may have minimally impacted on the precise estimates for 
relative and absolute mortality.  
The inherent design of this study infers that the potential limitations of non-randomisation of 
participants in this cohort may be present. These include biases such as selection bias, loss to 
follow-up and confounding. Strict adherence to the inclusion criteria and the use of appropriate 
statistical techniques were introduced to correct for biases. Additionally the retrospective study 
design ensured that selection bias was absent. 
One major limitation of this study is its inability to access for the causes of death in study 
participants owing to the inability to acquire the data due to restrictions from the law, the 
destruction of mortality data after 8 years after death meant that information on the cause of 
death was no longer available for analysis. 
In using internal comparison cohorts for this study ensured that the groups had similar 
characteristics. However, this allowed for increased probability of type 1 error. This was 
catered for by using the Bonferroni method, which corrected P-values to ensure statistical 
significance.  
One other limitation of this study is the impact of missing data for the variables used in analyses 
for the study. The may have potentially reduced the precision of estimates for analysis of the 
various competing risk on mortality in T1D in the Wirral. However, because the missing values 
were missing at random, the decisions to include them in the analysis lead to convergence in 
statistical models analysis. Owing to the sample size, and statistical significance (p-0.05), the 
impact of the variability of confounding was reduced. 
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Chapter 6: Conclusion and Recommendations 
This study set out to establish the following; current trends in mortality, analysis of the key 
policies set out during the study period their achievements and recent evidence, establish the 
competing risk contributing to mortality in T1D within the Wirral, and establish how predictor  
factors (age at diagnosis, body mass index (BMI), socioeconomic status, age, sex, and duration 
of T1D, biochemical profiles that include glycaemic control and lipid profiles, and 
complications) influenced mortality in T1D in the Wirral. 
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6.1. Contributions from the literature review and systematic reviews 
The literature review chapter established the important role of bio-physiological processes 
leading to the diagnosis of T1D, highlighting complex interactions between genetic and 
environmental factors involved in the mechanisms that trigger the onset of T1D these 
mechanisms. Studies that generated evidence as it relates to T1D were mostly derived from 
epidemiological studies; they identified that the morbidity and mortality that results from the 
diagnosis of T1D involves an interplay of predictor and competing risk factors that are not 
necessarily additive but evolve through complex interplays. The systematic review of mortality 
established recent trends in mortality in T1D.  
6.2. Contributions of the findings of this study 
In this study, while the incidence of T1D in the Wirral remained relatively stable with a minor 
decline at the end of the study, there was a steady increase in the prevalence of T1D. This infers 
that the prevalence of T1D is largely due to improved survival primarily relating to improved 
management of this condition further evidenced by improving life expectancy from T1D. 
Several predictive and competing risk factors in this study are contributory to proportionate 
levels of mortality in T1D. The complex interplays of these factors majorly contributed to the 
reduced life expectancy and the negative impacts on survival from T1D. For instance, for 
absolute and relative risk, gender, age at diagnosis, duration of T1D, BMI, serum creatinine 
levels, SBP, total cholesterol, LDL, HDL, TC\HDL, and LDL\HDL showed a linear increase 
in mortality risk. The IMD and DBP followed a U-shaped relationship with relative and 
absolute mortality, while glycaemic levels reveal a sinusoidal pattern with the highest risk of 
mortality at the levels ≤ 5.9mmol/mol (41%). This study reveals that independently, singular 
predictor risk factors contribute to relative and absolute mortality in T1D, however when two 
or more of these predictors risk are combined, the emergent risk of mortality is greatly 
exaggerated, this risk of mortality is not always linearly exaggerated but mostly follow 
uncertain and arbitrary outcomes. For example, the combination of smoking, hypertension and 
lipid abnormalities increases and accelerates the risk of vascular damage resulting in increased 
risk of macrovascular complication and mortality from cardiovascular conditions (Collier et al. 
2018; Schofield et al. 2016; Pan et al. 2015; Weis et al. 2001).   
The study found a strong influence of age of diagnosis and duration of T1D on mortality in 
T1D. It also highlighted that in this cohort, the age-specific relative, absolute and excess 
mortality in this cohort was higher than the resident comparative population. These findings 
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reflect that T1D in the Wirral encroach on resources accrued to public health and constitute a 
significant burden to health resources in the Wirral. 
This study established the influence of predictor and competing risk on life expectancy in T1D. 
This study noted reduced life expectancy in individuals with T1D as compared to those without 
T1D. At age 40 years, females and males with T1D were expected to live to ages 66 and 78 
years respectively as compared to 82 and 78 years for those without T1D in the Wirral. This 
noted a marked reduction in females as compared to males.  
6.3. Contributions to knowledge and implications for practice 
This study found the increasing prevalence of T1D puts a burden on the available health 
resources. Despite, this study has noted significant advancement in the management of T1D 
over the last 3 decades. This finding translates to infer that advancement in the management of 
this condition may lead to better management of health resources in the future (Henshaw, 2006; 
Peckham et al. 2011; Dinesh, 2013). 
 This study identified significant risk to mortality in those with persistent hypoglycaemic 
episodes; this risk of mortality was highest in those with average HbA1c levels ≤ 5.9% 
(41mmol/mol).  This emphasises the need for healthcare providers to better identify at an early 
stage and monitor those at risk of recurrent hypoglycaemic episodes with the aim of mitigating 
the effects of hypoglycaemia (Lachin et al. 2016). This subset of people with increased risk of 
hypoglycaemic episodes should consider the use of appropriate technology as stipulated by the 
NICE guidelines. However, the before the institution of these devices are commenced, there is 
need to establish that the individuals are adequately prepared both physically and 
psychologically to benefit maximally from the use of CSIIs and CGMs (Lawton et al. 2016). 
For this study, the mean ± SD and median ± IQR HbA1c for this cohort were 9.29 ± 20.12 and 
8.62 ± 2.00. The mean ± SD and median ± IQR age at diagnosis were 18.37 ± 10.12 and 17.00 
± 15.00. The mean ± SD and median ± IQR duration of T1D were 24.15 ± 15.27and 21.00 ± 
22.00 respectively. For this study, the least risk of mortality was for those with HbA1c levels 
of 6.0-6.4% (42-46mmol/mol). According to targets levels (48 mmol/mol [6.5%]) set by the 
NICE guidelines, treatment targets should aim for these values. However, it is noted in this 
study that a significant proportion of participants and extrapolated further that a significant 
proportion of individuals with T1D still do not attain the recommended target levels set by the 
NICE guidelines. This supports the argument for an approach of specified individualised 
approach to care and management to attain target levels as set by the NICE guidelines (Diabetes 
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UK, 2106). With the mean age of diagnosis being as early as 8 years, there is a need to ensure 
commencement of individualised care plan at a very early stage of diagnosis after adequate 
cost-benefit-risk analysis. However, this study acknowledges the availability of limited 
resources in providing these services. 
In this study, a significant proportion of participants had developed some levels of retinopathy, 
considering the average age of diagnosis for this cohort, it infers that the development of 
microvascular complications such as retinopathy and nephropathy occur very on early in T1D. 
Screening services that detect the early onset of these microvascular complications can mitigate 
further worsening of complications hence improving life expectancy. As such, the 
recommended process of regular eye examination and the early intervention by laser therapy 
treatment has significantly reduced the risk of blindness from diabetic retinopathy (Keech et 
al. 2007; Ciulla, Amador, & Zinman, 2003; Frederick, 1993). This enhances survival and 
reduces mortality (Jansson, Hufthammer, & Krohn, 2018).  
Regardless of the effects that age, gender and muscle mass have on creatinine levels, worsening 
creatinine levels which translates to worsening GFR leading to diabetic nephropathy remain an 
early predictor of mortality in T1D. However, the institution of early reno-protective measures 
such as the use of ACE inhibitors has proven to mitigate the progression of diabetic retinopathy 
that leads to end-stage renal failure. Similarly, the use of statins has been noted to mitigate the 
effects of dyslipidaemia leading to the onset and progression of cardiovascular complications 
(Marcovecchio et al. 2017). However, there remains ongoing argument on how early to 
institute these measures in T1D soon after diagnosis (Rawshani et al. 2018). Further research 
is needed on the cost-benefit-risk analysis in beginning these therapies at pre-pubertal or 
adolescent age in those with T1D. 
In this study, while SBP followed a linear relationship with mortality, DBP followed a U-
shaped pattern with mortality. This indicates that abnormal high values for SBP and the two 
extremes of DBP contribute significantly to mortality, this indicates that regular monitoring 
and control of blood pressures to ensure that within the approved limits as recommended by 
the NICE guidelines will further reduce the risk of mortality. 
This study identified the need for early risk assessments to identify patients who require 
immediate and ongoing psychological support and institute the appropriate referrals. Also, 
appropriate support for caregivers (especially parents) through referrals to support groups is 
essential. 
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Education stills remain one of the cornerstones to patient empowerment; effort should be made 
to continue to improve enrolment and participation of patients the approved courses. This 
would improve better understanding of the management of the condition, hence contributing 
to the appropriate use of health resources.  
6.4. Future research  
This study utilised a central database register (WDR), to access data to gather evidence as it 
relates to mortality indices, including the effects of predictor and competing risk in T1D. 
However, post-2012 the use of centralised registers have now been decentralised to various 
subunits. Hence, research that presents a similar picture to this study requires significant effort 
to gather relevant information. This new system is plagued with different coding systems, and 
information varies with location. Hence new audit processes are dependent on the response of 
the individual units which possess the required information. Research is required to estimate 
the cost-benefit analysis of the two different methods of data storage and access. This research 
can be explored further by utilising the available ongoing databases such as the Clinical 
Practice Research Datalink (CPRD), the Health Improvement Network database (THIN),  
QResearch, and ResearchOne. 
Future research is needed to assess factors that affect gender variations that increase the risk of 
mortality in T1D. Recent advancement in the field of genetics has helped enhance the 
knowledge of genetic and antibody test that aids in the prevention of T1D or the preservation 
of insulin function post-diagnosis in T1D. However, this requires further research to scale up 
these treatment measures. This study has identified that a significant number of patients still 
do not meet the recommended target levels for HbA1c, future research is needed to explore 
individualised factors that assist individuals to attain target levels of HbA1c. Further research 
is needed to assess the advantages of introducing CGMs with insulin pump systems on the 
management of T1D. 
In conclusion, this study has highlighted significant progress in survival and life expectancy 
over the last 25 years. However, life expectancy from T1D remains sub-optimum as compared 
to the general population. Mortality risk in T1D is dependent on the several predictors and 
competing risk; gender variation still exist regarding mortality in T1D.There is need for further 
understanding of the processes that enhance the complex interplay of the predictor risk factors 
and the emergent outcomes of T1D. 
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APPENDICES 
Appendix I 
Retrospective cohort study of Type 1 Diabetes Mellitus (T1DMM) in the Wirral 
Peninsula 
Background 
It is estimated that over 350 million people have been diagnosed with an estimated rise to over 
500 million cases in the year 2035 (International Diabetes Federation (IDF), 2014).  
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Diabetes (DM) is known to be of great public health concern in the United Kingdom (Diabetes 
UK, 2010). Research indicates that there is an increasing number of people being diagnosed 
with diabetes has increased from 1.6 million in 1996 to 3.2 million in 2014 (Diabetes UK, 
2014). A future of this trend postulates that the number of people that would suffer from this 
condition in 2025 would be almost 5 million people, at the moment an estimate of about 
630,000 people remain undiagnosed (Diabetes UK, 2014; IDF, 2014).  The UK currently 
spends approximately 10% of its annual NHS expenditure which equates to almost 9 billion 
pounds per year in tackling Diabetes (Diabetes UK, 2014). 
Type 1 diabetes (T1DM) a major contributor to the overall prevalence of DM is estimated to 
be increasing by almost 3% yearly having a total number of approximately 330, 000 cases in 
the UK (Diabetes UK, 2010). Type 1 Diabetes (T1DM) is considered to be a condition of great 
health concern as it results in chronicity that is carried on through life for any individual 
affected. Majority of the cases are attributed to autoimmune in origin, resulting in the 
destruction of B-cells of the Langerhans islets. Although some cases are also non-autoimmune 
forms (maturity-onset diabetes of youth- MODY).  It is also known that Type 1 Diabetes 
(T1DM) can considerably reduce the life expectancy of an individual by as much as 20 years 
(Diabetes UK, 2014). 
Critical analysis of the existing literature  
T1DM is known to correlate closely with significant risk of acquiring cardiovascular disease 
(CVD) and increased risk of all-cause mortality (Aanstoot et al. 2007). Cardiovascular disease 
(CVD) contributes to 44% of fatality in people with type 1 DM (Diabetes UK, 2014). Previous 
studies demonstrate that good glycaemic control is paramount to potentially reduce the 
occurrence of CVD and other related DM complications (Orchard et.al. 2006; Liingstone et al. 
2012). However, the impact of tight glycaemic control on the relative risk of CVD and 
mortality in the UK remains uncertain (Soedamah-Muthu et al. 2006). Whilst several studies 
report CVD incidence among those with T1DM, there are few studies that have directly 
compared CVD incidence in T1DM with the general population (Soedamah-Muthu et al. 
2006). 
Contribution to knowledge 
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There is a need therefore to obtain a comprehensive picture of relative CVD and other 
morbidity rates (e.g. stroke, amputation, nephropathy, neuropathy, carcinoma) and mortality 
rates associated with T1DMM.   
Method 
The method employed for use in this study will be a retrospective (historical) cohort study 
design using data (2000-2012) from the Wirral Diabetes Register. The retrospective cohort 
study has the merit of investigating multiple outcomes of a single risk (type 1 DM), it also 
allows for ease of subgroup analysis within cohorts. This method is appropriate for T1DM due 
to the temporal sequence between diagnoses and the manifestation of complications. There 
would also be a comparison with the National UK data in the general population (Nwaneri, 
Bowen Jones, & Cooper, 2013). The comparison would be set in context using a narrative 
review of diabetes service provision within the set period. 
Rationale and aims 
1. To obtain a comprehensive picture of relative CVD and other morbidity rates (e.g. 
stroke, amputation, nephropathy, neuropathy, carcinoma) and mortality rates associated 
with T1DM.   
2. To obtain a comprehensive picture of service provision (policy documents) between 
2000-2014 in England and its application in the Wirral peninsula. 
3. Provide information that will impact service utilisation and practice, creating avenues 
for further research 
Methodology 
The Wirral Diabetes Register provides data for a cohort of 16,000 people (2012 figures) living 
with T1DM from 1997 to 2012. It ensures that all patients (≥18 years) are reported yearly based 
on annual patient visits in primary or secondary care. The data therefore captures a clear 
temporal sequence of exposure to T1DM, including changes in treatment and service 
modalities, alongside multiple outcomes related to T1DM. Data are quality assured annually 
and these data (alongside pre-existing notes) are stored for 8 years following patient mortality. 
The magnitude, depth and quality of information held on the register offers the prospect of 
conducting a large retrospective cohort study of T1DM (Appendix 1 for sample of diabetes 
register form).  
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Wirral Diabetes Register: summary of data available  
Demographic factors  
Diabetes duration  
Attendance rates to clinic  
Treatment (and therefore co-morbidities based on treatment 
profiles)  
Blood pressure  
Biochemical profiles: HbA1c, micro-albuminuria, urea, 
electrolytes.  
Lipid values  
Fundoscopy screening for retinopathy  
Foot screening for neuropathy  
Complication rates  
Referrals to Allied Health Professionals e.g. dietician, 
chiropodists, psychologists  
Table 1: Summary of available data 
The study will be divided into five phases:  
1. Narrative qualitative analysis of T1DM service provision between 2000-2012 in 
England and its application in the Wirral peninsula. This would be done using a realist 
review which brings into focus the practical realities and evidence on health care 
policies in relation to diabetes care (Pawson, Greenhalgh, Harvey & Walshe, 2005).  
2. Current evidence based on quantitative systematic reviews of factors related to 
T1DM, such as mortality rates; rates of micro- and macro-vascular complications and 
carcinoma; and sub-group analysis to explore mortality and morbidity in relation to 
socio-economic factors, age, gender and life style.   
3. Statistical analysis of the T1DM Wirral Diabetes Register data including: mortality 
rates; rates of micro- and macro-vascular complications and carcinoma; and sub-group 
analysis to explore mortality and morbidity in relation to socio-economic factors, age, 
gender and life style.   
4. Comparison with UK National mortality statistics for the general population. 
5. Synthesis and interpretation of the data sets using theory. 
6. Application to clinical practice 
Analyses of data will potentially provide evidence that would inform service delivery, track 
any variations in diseases pattern over the years, and provide evidence for future research. 
Conduct of the research would be done in three stages;  
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First stage:  This will involve critical and detailed qualitative and quantitative reviews of 
service provisions which would help identify research questions that need to be answered. It 
would help in the research design.  
Second stage: This stage involves data collection and analysis. Data collection will primarily 
be obtained from the diabetes register. Data will be collected for the specified period (year 
2000 forward). Sample selection will include patients who have been diagnosed with type 1 
diabetes and sample size will be gotten based on power calculations and inputs from the 
statistical advisor. The statistical tools will be used to analyse data is the Statistical Package for 
Social Sciences (SPSS).  Analysis of data will be made in relation to the set objectives of the 
study. The initial process will involve validating data gotten. Various statistical comparisons 
will be done using test such as; Mann-Whitney U test (unpaired data to test for differences 
between comparison groups); Wilcoxon signed-rank test (comparing sets of observations on a 
single sample); chi-squared test (comparing proportions or percentages in categorical data 
between groups); Spearman, Kendall rank (determining correlations between groups). 
Statistical significance will be held at p values of <0.05. 
Third Stage: This will involve writing up and dissemination of findings using set procedures 
as provided by the University of Chester PhD guidelines.  
Theory 
Complexity Theory will be used to provide a guide to the interpretation of findings. Complexity 
does justice to the dynamics through which the numerous determinants of diabetes outcomes 
are inter-related. Previous research into diabetes provided insight into the inadequacy of 
traditional scientific frameworks, demonstrating the need for one that appreciates T1DM as a 
complex adaptive system (Cooper, & Geyer, 2008). This novel theoretical approach, alongside 
the study of a large cohort of people with T1DM, comparison with National statistics and the 
mapping exercise, represent the original contributions made by this research study. Findings 
will provide data to inform the development/advancement of current knowledge and 
recommendations for future research. 
ETHICAL CONSIDERATIONS AND RESEARCH GOVERNANCE 
In conducting research, it is important to ensure that ethical principles governing the process 
of research are adhered to (Weingarten, Paul & Leibovici, 2004; The Research Ethics 
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Guidebook, 2013). In the course of this review, it will be ensured that the work of existing trials 
will be treated accurately and fairly (The Research Ethics Guidebook, 2013). 
Ethical approval may not be explicitly required for this review as it does not directly involve 
human participation, however the findings of included studies carried out become raw data for 
analysis and interpretation, it is ethical practice to consider how it can best build on work that 
has already been done (The Research Ethics Guidebook, 2013; Weingarten, Paul & Leibovici, 
2004). 
Ethical responsibilities will be taken seriously such as thoroughness in searching, checking of 
all details and following up on different results, inaccuracies, questionable publication ethics 
and conflicts of interest (O’Mathuma, 2008). Ethical principles that will be followed during 
the course of this review are: 
Avoidance of harm and distress: 
“First, do no harm” is the bedrock of medical ethics, and causing harm should be avoided in 
any research. The doctrine of “double effect” where an intention for good unintentionally 
causes harm (Runzheimer & Larsen, 2013) should be kept in mind, as this assist in making 
difficult decisions about whether actions with double effects can be undertaken. The 
participants should be made to understand the risk and benefits and which outweighs the other. 
Avoidance of psychological harm should be avoided when getting information from 
participants in research; ways should be devised to make participants talk about sensitive issues 
without making them uncomfortable. Confidential records should be stored securely and 
specification on how data will be shared should be discussed and specified (Smith, 2003). 
However, this review involves already published data and these issues do not evolve. 
 
Potential benefits:  
Healthcare providers endeavour to improve health, strive to do the most good in every situation 
or promote good (O’Mathuma, 2008). It involves taking actions to serve the best interest of the 
subject. Each situation should be considered individually because what is good for one 
participant may not be for another (Runzheimer & Larsen, 2013). This study is expected to 
provide stronger precision of estimates, hence provide stronger evidence for public health 
practice. 
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Health and Safety issues for researchers: 
Responsibility will be taken to work safely and efficiently and not change research protocols 
for the health and safety of researcher, to ensure that the results of the review are not 
compromised (Institute of Occupational Safety and Health, 2012). This will be enhanced by 
following guidelines (Social Research Association, 2013) and scheduled timeline created, 
feeding and resting adequately to prevent breakdown in health. 
Fidelity: 
This means experimental manipulations will be conducted as planned or interventions are 
delivered as designed (Horner, Rew & Torres, 2006) but since there will not be direct contact 
with participants but results in this review, It will be demonstrated that the review is carried 
out as planned and each of the outcome components is delivered in a comparable manner to all 
participants and is true to the theory and goals underlying the research (Dumas, Lynch, 
Laughlin, Philips & Prinz, 2001).  
Justice: 
This demands a researcher attempt to be fair as possible when administering the intervention 
and this action should be justified (Runzheimer & Larsen, 2013). It also involves fair 
distribution of limited resources (O’Mathuna, 2008). This principle will be adhered to in this 
review. 
Veracity: 
In general, truthfulness, accuracy, conveying and perceiving the truth will be done during the 
course of this review and the report will be conveyed as the study reveals. 
 
Confidentiality and Respect for persons: 
This will be adhered strictly to. Identities and research records of participants will be kept 
confidential whether or not an explicit pledge has been given. The right to remain anonymous 
and private will be respected and it will be the responsibility of the researcher to protect the 
confidentiality of participant’s data (Social Research Association, 2013). 
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This study does not require any consent to be gotten, however if need is required to contact 
anyone this will be gotten and confidentiality kept. 
Management of Data: 
The Data Protection Act (1998) will be adhered to. The researcher will be accountable to the 
law; therefore, the use of personal data is bound to comply with this law. These data will be 
processed fairly and lawfully, efforts will be made to inform participants about any new 
purposes of data processing or by secondary use by other participants, data only necessary and 
adequate for the research will be collected and this will be accurate, how long the data will be 
kept before it is destroyed will be stated and honoured, where necessary data processed will be 
made available to participants but as long as data do not capture participant’s identity this will 
not be done, steps will be taken to secure personal data and how this will be done will be 
conveyed to participants, consent will be obtained for any transfer of data; Sensitive data will 
be processed as duly required (Social Research Association, 2013). 
Autonomy: 
Participants will have the right to control what happens to them (Runzheimer & Larsen, 2013) 
or they have the right to decide (O’Mathuna, 2008) and this right of individuals to self-
determination will be respected. Furthermore, this review will not involve the participation of 
vulnerable persons who are persons without the adequate capability to protect them. 
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Figure 1: University of Chester Ethical Approval 
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Figure 2: Ethical Approval from Wirral University Teaching Hospital 
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Appendix IV 
 Decision table on The Appropriate Statistical Test (adapted from Intuitive Biostatistics 
a Nonmathematical Guide to Statistical Thinking Motulsky, 2010). 
Goal 
Type or level of Data 
Measurement 
(from Gaussian 
Population) 
Rank, Score, or 
Measurement 
(from Non- 
Gaussian 
Population) 
Binomial 
(Two Possible 
Outcomes) 
Survival Time 
Describe one 
group 
Mean, SD 
Median, 
interquartile range 
Proportion 
Kaplan Meier 
survival curve 
Compare one 
group to a 
hypothetical 
value 
One-sample t-test Wilcoxon test 
Chi-square 
or 
Binomial test ** 
 
Compare two 
unpaired groups 
Unpaired t-test 
Mann-Whitney 
test 
Fisher's test 
(chi-square for 
large samples) 
Log-rank test or 
Mantel-Haenszel* 
Compare two 
paired groups 
Paired t-test Wilcoxon test McNemar's test 
Conditional 
proportional 
hazards 
regression* 
Compare three 
or more 
unmatched 
groups 
One-way 
ANOVA 
Kruskal-Wallis 
test 
Chi-square test 
Cox proportional 
hazard 
regression** 
Quantify 
association 
between two 
variables 
Pearson 
correlation 
Spearman 
correlation 
Contingency 
coefficients* 
 
Predict value 
from another 
measured 
variable 
Simple linear 
regression 
Or Nonlinear 
regression 
 
Nonparametric 
regression* 
Simple logistic 
regression* 
Cox proportional 
hazard 
regression* 
Predict value 
from several 
measured or 
binomial 
variables 
Multiple linear 
regression* 
Or Multiple 
nonlinear 
regression* 
 
Multiple logistic 
regression* 
Cox proportional 
hazard 
regression* 
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Appendix V 
 
Figure 3: Poster Presentation Diabetes United Kingdom Conference 2017 
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Appendix VI 
Table 3. 3: CASP Checklist 
S/N Author 1 2 3 4 5 6 7 8 9 10 11 12 CASP Score Follow up period 
1 
Asao et al. 
2003 
Y Y Y Y Y Y Y 
standardized mortality ratios were 12.9 (10.8–
15.3) and 3.7 (3.3–4.1) 
N/a Y Y Y 10 25 years. 
2 
Alleman 
2009 
Y Y Y Y Y Y Y 
Diabetic patients had increased all-cause 
mortality compared with the general population 
(SMR [95% CI] 3.8 [3.5–4.3]). 
N/a Y Y Y 10 18.8 years 
3 Barcelo 2006 Y Y Y Y Y Y Y 
Mortality rates higher in HA(14%in males and 
females, respectively) was higher than in AC 
(7% in males and 9%in females) for both 
genders (males, p = 0.0005; females, p = 
0.0491) 
N/a Y Y Y 10 26 years 
4 
Bosnyak et 
al. 2005 
Y Y Y Y Y Y Y 
Black participants had a significantly higher 
mortality rate compared with White 
participants for acute complications (hazard 
ratio = 4.9, 95%confidence intervals: 2.0, 
11.6), but not for any other cause 
N/a Y Y Y 10 15.8 years 
5 
Bruno et al. 
2008 
Y Y Y Y Y Y Y 
The all-cause mortality rate of 1.19/1000 
person-years (95% CI 0.76-1.87) and an SMR 
of 1.96 (1.25-3.08). hazard ratio (HR) 
(HR=3.90, 95% CI 1.14-13.39) 
N/a Y Y Y 10 7.75 years 
6 
Burnet et al. 
2007 
Y Y Y Y Y Y Y 
Age 17 years (13.36/1,000 person-years), early 
adolescence (ages 10–13 years) 
(3.49/1,000person-years), 10 years (0.89/1,000 
person-years)or at ages 14–16 years 
(0.81/1,000 person-years). 
N/a Y Y Y 10 17.5 years 
7 
Collado-
Mesa et al. 
1997 
Y Y Y Y Y Y Y 
Overall the cohort experienced 8.5 times all-
cause mortality compared to the general 
populace. Female SMR 10.0 (95% CI 6.9-14.6) 
higher than Males SMR 7.5 (95% CI 5.3-10.3) 
N/a Y Y Y 10 25.6 years 
8 
Conway 
2012 
Y Y Y Y Y Y N 
HRs (CI) for all-cause mortality was 4.3 (3.4–
5.6), 4.2 (2.8–6.3), and 2.0 (1.4–2.8) in groups 
A, B, and C, respectively. 
N/a Y Y Y 9 20 years 
9 Cooper 2014 Y Y Y Y Y Y Y 
Standardized mortality ratio for all-cause 
mortality was 1.7 (95% CI 0.7–3.3) for male 
N/a Y Y Y 10 6 years 
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and 10.1 (95% CI 5.2–17.7) for female subjects 
with Type 1 diabetes (median age at the end of 
study 25.6 years). 
10 
Dahlquist 
2005 
Y Y Y Y Y CT Y 
Mean age- and sex-SMR was 2.15 (95% CI 
1.70 –2.68) and tended to be higher among 
females (2.65 vs 1.93, P  0.045). Mean age at 
death was 15.2 years (range 1.2–27.3) and 
mean duration of 8.2 years (0 –20.7). 
N/a Y Y Y 10 15 years 
11 
Dawson 
2008 
Y Y Y Y Y CT Y 
SMRs were slightly higher for females than 
males in almost all age-at-onset groups, being 
2.48 (95% CI: 2.18–2.78) for females and 2.17 
(95% CI: 1.91–2.43) for males overall, but 
reaching a peak in the <30 age at onset group 
for both females and males being 4.25 (3.07–
5.44) and 3.26 (2.494.03), respectively. 
N/a Y Y Y 10 21.4 years 
12 Edge 1999 Y Y Y Y Y Y Y 
The standardised mortality ratio was 2.3 (95% 
CI, 1.9 -2.9), being highest in the age group 1–
4 years, at 9.2 (95% CI, 5.4 -14.7). 
N/a Y Y Y 10 30 years 
13 
Florkowski 
2002 
Y Y Y Y Y Y Y 
Standardized mortality ratio (SMR) of 2.0 
(95% CI 1.8-2.2). Relative mortality was 
greatest for the group aged 0-29 years (SMR 
3.0 (95% CI 2.4-3.7) 
N/a Y Y Y 10 10 years 
14 
Harjutsalo 
2011 
Y Y Y Y Y Y Y 
The all-cause mortality rate of 361 (95% 
confidence interval 342 to 382) per 100 000 
person-years. Standardised mortality ratio was 
3.6 (95% confidence interval 3.3 to 3.9) in the 
early onset cohort and 2.8 (2.6 to 3.0) in the 
late onset cohort. 
N/a Y Y Y 10 37 years 
15 Laing 1998 Y Y Y Y Y Y Y 
Relative risk of death (standardized mortality 
ratio, SMR), was higher for females than males 
at all ages, being 4.0 (95% CI 3.6-4.4) for 
females and 2.7 (2.5-2.9) for males overall, but 
reaching a peak of 5.7 (4.7-7.0) in females aged 
20-29, and of 4.0 (3.1-5.0) in males aged 40-
49. 
N/a Y Y Y 10 25 years 
16 
Laing(a) 
2003 
Y Y Y Y Y Y Y 
The standardised mortality ratios were higher 
in women than men at all ages, and in women 
N/a Y Y Y 9 19 years 
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were 44.8 (95%CI 20.5–85.0) at ages 20–29 
and 41.6 (26.7–61.9) at ages 30–39. 
17 
Laing(b) 
2003 
Y Y Y Y Y Y Y 
1437 deaths during the follow-up, 80 due to 
cerebrovascular disease. Overall, the 
cerebrovascular mortality rates in the cohort 
were higher than the corresponding rates in the 
general population, and the SMRs were 3.1 
(95% CI, 2.2 to 4.3) for men and 4.4 (95% CI, 
3.1 to 6.0) for women. 
N/a Y Y Y 10 20 years 
18 
Laron-Kenet 
2001 
Y Y Y Y Y Y Y 
There was significant excess mortality in the 
patients with Type 1 Diabetes, SMRs being 
three times higher than that of the general 
population 
N/a Y Y Y 10 31 years 
19 Lin  2014 Y Y Y Y Y Y Y 
SMR from all-causes were significantly 
increased at 3.00 (95% Confidence Interval 
(CI) 2.83–3.16) in patients with T1D. The sex-
specific SMR was 2.66 (95% CI 2.46–2.85) 
and 3.58 (95% CI 3.28–3.87) for male and 
female patients, respectively 
N/a Y Y Y 10 11 years 
20 Lind 2014 Y Y Y Y Y Y Y 
Corresponding hazard ratios for death from 
cardiovascular causes were 2.92 (95% CI, 2.07 
to 4.13), 3.39 (95% CI, 2.49 to 4.61), 4.44 
(95% CI, 3.32 to 5.96), 5.35 (95% CI, 3.94 to 
7.26), and 10.46 (95% CI, 7.62 to 14.37). 
N/a Y Y Y 10 13 years 
21 
Moss et al. 
1991 
Y Y Y Y Y CT Y 
The SMR for heart disease was 9.1, with the 
excess being greater in females (10.3) than in 
males (8.7). 
N/a Y Y Y 10 12 years 
22 
Morimoto 
2013 
Y Y Y Y Y Y Y 
Mortality rate at the 35-year follow-up (per 
100,000 person-years) was 659.3, and the 
standardised mortality ratio (SMR) was 10.7. 
The SMR at the 25-year follow-up markedly 
declined from 19.3 in the 1965–1969 diagnosis 
group to 6.6 in the 1975–1979 diagnosis group. 
N/a Y Y Y 10 35 years 
23 
Nishimura 
2001 
Y Y Y Y Y Y Y 
Crude mortality rate was 627 per 100,000 
person-years (95% CI 532–728), and 
standardized mortality ratio was 519 (440–
602). 
N/a Y Y 
Y 
 
 
10 34 years 
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24 Otani 2014 Y Y Y Y Y Y Y 
mortality rate (95%CI) and age and sex-
adjusted SMR (95%CI) were 457 (288–627) 
and 3.0 (1.9–4.2) in Group A, 265 (143–387) 
and 2.2 (1.2–3.2) in Group B, and 144 (29–
259) and 1.6 (0.3–2.9) in Group C, respectively 
N/a Y Y Y 10 20 years 
25 
Pambiano 
2006 
Y Y Y Y Y Y Y Incidence density per 100 person-years. N/a Y Y Y 10 50 years 
26 
Patterson 
2007 
Y Y Y Y Y Y Y 
Standardised mortality ratio (SMR) of 2.0 
(95% CI 1.7–2.4). 
N/a Y Y Y 10 16 years 
27 Podar 2000 Y Y Y Y Y Y Y 
The SMR for the Estonian cohort was 4.35 
(95% CI 2.25–7.61), the highest for the 
Lithuanian cohort was 7.55 (4.89–11.15), and 
the lowest for the Finnish cohort was 1.62 
(1.10–2.28). 
N/a Y Y Y 10 10 years 
28 
Raymond 
1995 
Y Y Y Y Y Y Y 
Male and female SMRs were significantly 
raised for the age groups 45-64, 65-74, and 75-
84 years. Cerebrovascular disease accounted 
for 38 (10%) deaths and the SMR for women 
was significantly raised. 
N/a Y Y Y 10 9 years 
29 Riley 1995 Y Y Y Y Y Y Y 
Overall SMR of 2.2 (95% CI 2.0-2.4) 
compared to the Tasmanian population. 
N/a Y Y Y 10 9 years 
30 
Roberts et 
al., 2004 
Y Y Y Y Y Y Y 
58 deaths during the three years follow up 
period (standardised mortality ratio of 8.5; 95% 
confidence 
interval 6.5 to 10.8), 
N/a Y Y Y 10 31 years 
31 
Schober 
1997 
Y Y Y Y Y Y Y 
Overall SMR from all causes was 1.53 (95% CI 
0.68–3.46) for both sexes and 2.56 (95% CI 
0.81–8.12) for females and 1.05 (95% CI 0.33–
3.33) for males. 
N/a Y Y Y 10 11 years 
32 
Swerdlow 
2003 
Y Y Y Y Y Y Y 
The SMRs for South Asian patients diagnosed 
under age 30 years were 3.9 (95%CI 2.0–6.9) 
in men and 10.1 (5.6–16.6) in women, and in 
the corresponding non, South Asians were 2.7 
(2.6–2.9) and 4.0 (3.6–4.3), respectively. 
N/a Y Y Y 10 28 years 
33 
Skrivarhaug 
2005 
Y Y Y Y Y Y Y 
The mortality rate was 2.2/1000 person-years. 
The overall SMR was 4.0 (95% CI 3.2–4.8) 
and was similar for males and females. 
N/a Y Y Y 10 20 years 
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34 
Warner et 
al., 1998 
Y Y Y Y Y Y Y 
Standardised mortality ratio (SMR) of 247 
(95% confidence interval (CI) 163 to 362). 
N/a Y Y Y 10 17 years 
35 
Washington 
et al., 2012 
Y Y Y Y Y Y Y 
Overall Mortality rate was 1170 per 100,000 
person-years (95% CI: 727, 1883). 
 
N/a Y Y Y 10 40 years 
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